DANIEL J. WALLACE, M.D., F.A.C.P., F.A.C.R.
Curriculum Vitae - Up to date as of January 1, 2014
Personal:
Address:8737 Beverly Blvd, Suite 302
West Hollywood, CA 90048
Phone:(310) 652-0920
FAX:(310) 360-4812
E mail:drdanielwallace@gmail.com

Education:
University of Southern California, 2/67-6/70, BA Medicine, 1971.
University of Southern California, 9/70-6/74, M.D.
Postgraduate Training:
7/74-6/75 Medical Intern, Rhode Island (Brown University) Hospital, Providence, RI.
7/75-6/77 Medical Resident, Cedars-Sinai Medical Center, Los Angeles, CA.
7/77-6/79 Rheumatology Fellow, UCLA School of Medicine, Los Angeles, CA.
Medical Boards and Licensure:
Diplomate, National Board of Medical Examiners, 1975.
Board Certified, American Board of Internal Medicine, 1978.
Board Certified, Rheumatology subspecialty, 1982. California License: #G-30533.
Present Appointments:
Medical Director, Wallace Rheumatic Study Center, 8737 Beverly Blvd, Suite 301 and 302; 1996-
Attending Physician, Cedars-Sinai Medical Center, Los Angeles, 1979-
Clinical Professor of Medicine, David Geffen School of Medicine at UCLA, 1995-
Professor of Medicine, Cedars-Sinai Medical Center, 2012-
Expert Reviewer, Medical Board of California, 2007-
Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, 2010-
Honorary Appointments:
Fellow, American College of Physicians (FACP)
Fellow, American College of Rheumatology (FACR)
Member, Royal College of Physicians (London)
Hospital Appointments:
Cedars Sinai: Clinical Chief of Rheumatology, 1991-1996
Chairman, Medical Peer Review 1985-1987, Member 1982-1989
Intern Selection Committee, 1979-1993
Medical Advisory Committee, 1985-1988, 1991-1996
Performance Improvement Committee, 1991-1996
Hospital Peer Review Committee, 1986-1989, 1992-1994
Division of Rheumatology Reappointment/Peer Review, 1988-present
Pharmacy gamma globulin committee, 2002-present
Chairman of Department of Medicine Search Committee 2011-
Clinical Academic Promtions and Appointments Council 2011-
Division of Rheumatology Reappointment/Peer Review, 1988-present
Pharmacy gamma globulin committee, 2002-present
Century City Doctor’s Hospital: Consulting Physician, 1979-present
Chief of Rheumatology, 1982-1984
City of Hope Medical Center, Duarte, CA: Chief Rheumatology Consultant, 1980-1988
UCLA Center for the Health Sciences : Attending Physician, 1981-
Prior Academic Appointments:
Associate Clinical Professor, UCLA School of Medicine 1988-1995
Assistant Clinical Professor, UCLA School of Medicine, 1981-1988
Assistant Clinical Professor, USC School of Medicine 1979-1981
Books
1. Wallace, DJ and Dubois EL, eds., Dubois' Lupus Erythematosus, 3rd Edition, Lea and Febiger, Philadelphia, PA, 1987, 775 pp.
2. Wallace, DJ and Hahn, BH, eds, Dubois' Lupus Erythematosus, 4th Edition, Lea and Febiger, Philadelphia,PA, 1993, 953 pp.
3. Wallace DJ, The Lupus Book, Oxford University Press, NY/London, 1995, 258 pp.
4. Wallace DJ, Hahn BH, Eds., Dubois' Lupus Erythematosus, 5th Edition, Williams and Wilkins, Baltimore, MD, 1997, 1289 pp.
5. Wallace DJ, Wallace JB, Making sense of fibromyalgia, Oxford University Press, NY/London, 1999, 242pp.
6. Wallace DJ, The Lupus Book, New and Revised, Oxford University Press, NY/ London, 2000, 271 pp.
7. Lane NE, Wallace DJ, All About Osteoarthritis, Oxford University Press, NY/London, 2001, 258 pp.
8. Wallace DJ, Hahn BH, Eds, Dubois’ Lupus Erythematosus, 6th Edition, Lippincott Williams & Wilkins, Philadelphia, PA, 2002, 1348 pp.
9. Wallace DJ, Wallace JB, All About Fibromyalgia, Oxford University Press, NY/London, 2002, 258 pp
10. Wallace DJ, Wallace JB, Fibromyalgia: An essential guide for patients and their families, Oxford University Press, NY/London, 2003, 196 pp.
11. Wallace DJ, Editor, The New Sjogren’s Syndrome Handbook, Oxford University Press, NY/London, Revised and Expanded 3rd Edition, 2005, 265 pp.
12. Wallace DJ, Clauw DJ, Fibromyalgia and other central pain syndromes, Lippincott Williams & Wilkins, Philadelphia, PA, 421 pages, 2005, 10 pp.
13. Wallace DJ, The Lupus Book: A Guide for Patients and their Families, Oxford U Press, NY/London, 2005, 291 pp.
14. Wallace DJ, Hahn BH Eds, Dubois’ Lupus Erythematosus, 7th Edition, Lippincott Williams & Wilkins, 2007, Philadelphia, PA, 1441 pp.
15. Wallace DJ, Lupus: The Essential Clinician’s Guide, Oxford American Rheumatology Library, Oxford University Press, New York, 2008, 115 pp.
16. Clauw DJ, Wallace DJ, Fibromyalgia: The Essential Clinician’s Guide, Oxford American Rheumatology Library, Oxford University Press, New York, 2009.
17. Wallace DJ, Editor, The Sjogren’s Book: Sjogren Syndrome Foundation, Fourth Edition, Oxford University Press, New York 2012, 395 pages.
18. Rheumatoid Arthritis, Michael Weisman, Oxford American Rheumatology Library, Daniel J Wallace, Series Editor, 90 pages, 2011.
19. Wallace DJ, Hahn BH, Dubois’ Lupus Erythematosus and Related Syndromes, 8th edition, Elsevier Saunders, Philadelphia, PA, 694 pages, 2013.
20. Wallace DJ, The Lupus Book: A Guide for patients and their families, Oxford U Press, NY/Oxford, 2013.
Organizations and Positions Held:
Lupus Foundation of America
Co-chairman, 1999-2000
Member, Board of Directors 1991-1998, Vice President 1999-2000
National Medical Advisory Board, 1988-
Los Angeles Chapter Medical Advisory Board, Co-Chair 1989-1999
Member, Los Angeles County Medical Association
Member, California Medical Association
Member, American Medical Association
Member, Southern California Rheumatism Society
Member, Gerontology Society
Member, Arthritis Foundation
LA. Metro Committee Chairman, 1989-1994
Community Services Committee, 1989-1994
Medical and Scientific Committee, 1989-1994
Institutional Grants Committee, 1989-1994
Fibromyalgia Subcommittee, 1988-; Chairman 1990-1995
Representative, National House of Delegates, 1987, 1990
Board of Directors, Southern California, 1994-2006
Member, American College of Rheumatology
Research and Education Foundation, National Advisory Council Meeting, 2011-
Committee on Rheumatologic Practice, 1982-1985
Lupus Council, 1986-; Chairman 1990-1991
Nominations Committee 1991-1994
Research & Education Foundation Board of Directors, 1993-1999; Chairman 1995-1999
Nominating Committee, 2005-
Lupus Abstract Selection Committee 2010-
The American Lupus Society (merged with Lupus Foundation of America, 1996)
National Medical Advisory Board, 1988-1996
Los Angeles Chapter Medical Advisory Board, 1980-1996
Los Angeles Chapter Chief Medical Advisor, San Fernando Valley Medical Advisory Board
Member, American Society for Apheresis
Medical Executive Committee, 1987-1989
Editor, ASFA Newsletter, 1987-1989
United Scleroderma Foundation Board of Directors, 1990-1997
Scleroderma Foundation, Southern California, Board of Directors, 2001-2004
American Fibromyalgia Syndrome Association, Medical Advisory Board, 1994-
Board of Directors, Lupus Research Institute, 2000-
Founder, Lupus LA - 2000
Co-Chairman, Industrial Relations Council
Sjogren's Syndrome Foundation Medical Advisory Board, 1997-
Medical Advisory Board, Maryland Lupus Foundation, 2001-2004
Examination writer, American Board of Internal Medicine, for Internal Medicine Boards, 1994, 1995
Member, SLICC (Systemic Lupus International Coordinating Committee), 2003-
NIH Lupus Biomarkers Committee, 2004-
Member, Lupus Clinical Trials Consortium (LCTC), 2005-2010
Lupus Abstract Selection Committee 2010-
Laboratory Experience:
Therapeutic apheresis project, Cedars-Sinai Medical Center, 1977-1997
Cedars-Sinai Lupus Research Laboratory 1990-
Summer research fellow, Cedars-Sinai Medical Center, 1968-1970, under Dr. Leon Morgenstern,
Chairman, Department of Surgery, dealing with wound healing of intestinal anastamoses and synthesizing trypsin inhibitor.
USC Cancer Virology Laboratory, Dr. Murray Gardner and J. Earle Officer, PhD,1972-1974, retroviruses and aging.
Publication Review Experience:
Editorial Board, Journal of Clinical Apheresis, 1982 -2004
Editorial Board, Lupus, 1997-
Editorial Board, Bulletin on the Rheumatic Diseases, 1998-2004
Editorial Board, Arthritis & Rheumatism, 1998- 2003
Editorial Board, Journal of Musculoskeletal Pain, 1999-
Editorial Board, Journal of Rheumatology, 1999-
Editorial Board, Journal of Clinical Rheumatology, 2003-
Editorial Board, Future Rheumatology, 2006-
Editor, Current Opinion in Rheumatology, Lupus issues, 1994- 2000
Editor-in-Chief, Current Rheumatology Reviews, 2005-
Reviewer for over 50 medical journals
Honors
Globus Award, Best Medical Paper, 1984-5, Mt. Sinai J Medicine
Humanitarian Award, Lupus Foundation of America, 1989 and 1991
Best Doctors in the United States, Town and Country Magazine, October, 1989
The American Lupus Society, Lupus Hall of Fame, 1989
"The Best Doctors in America," Woodward/White, Aiken, SC, 1994
Best Doctors in Los Angeles, Los Angeles Magazine, 1996
Jane Wyman Humanitarian Award, Arthritis Foundation, 1996
Expert Consultant, Medical Board of California, 1995-
Lupus Foundation of America, Outstanding Service Award, 1997
“Spirit of Hope” Award, Southern California Scleroderma Foundation, 2001
Achievement Award, SLE Foundation, 2002
James R Klinenberg Achievement Award, Arthritis Foundation Southern California Chapter, 2004
Founder’s Award, Lupus LA, SLE Foundation, 2008
Medical Achievement Award, SLE Foundation 2011
Syndrome Foundation, Healthcare Professional Leadership Award, 2012
Personal Research Grants:
BSRG Cedars-Sinai Research Grant, $10,000, 1978-1979,
Apheresis in rheumatoid arthritis
Haemonetics Research Institute Grant, $25,000, 1980-1981,
Double-blind controlled trial of apheresis in rheumatoid arthritis
Kroc Foundation Grant, $59,000, 1981-1982,
Apheresis in systemic lupus erythematosus
Haemonetics Research Institute Grant, $25,000, 1982,
The immunology of apheresis
Parker Foundation Grant, $76,250, 1983-1985,
Selective immunoadsorption in rheumatoid arthritis
Winthrop Pharmaceuticals Grant, $5,000, 1989-199,
The role of hydroxychloroquine on lipids
The American Lupus Society Grant, $28,000, 1990-1992,
An index of lupus literature
Winthrop Pharmaceuticals Grant $7,500, 1991-1993,
Cytokines and their influence on hydroxychloroquine
Co-Investigator with Dr. Mariana Linker-Israeli, 3 year NIH grant for $350,000 "Interleukin-6 genetic polymorphisms", 1994-1996
Co-Investigator with Dr. Mariana Linker-Israeli, NIH grant for $442,670,
"Abnormal IL-6 Production in SLE," Agency Award #2RolAR4252-04, 1997-1999
American Fibromyalgia Syndrome Association, $24,600, 1998-1999,
The role of the Th-1/Th-2 axis in fibromyalgia
Food and Drug Administration, RF 412-3324A, $24,000, 2000-2002
Comparison of IV cyclophosphamide to mycophenolate mofetil for induction therapy of active Class III-IV nephritis in systemic lupus erythematosus. Co-investigator with M Weisman for Cedars effort
Co-investigator with Dr. Michelle Petri, NIH Grant, Brain Conections: Cognitive function in SLE, National Institute of Arthritis, Musculoskeletal and Skin disorders, 2003-, Grant number: R01AR4912501, 2004-
AROSE: Revising ACR diagnostic/classification criteria for lupus, Lupus Foundation of America, NIH-NIAMS ARO051871-013, 2004-
The role of mycophenolate mofetil in patients with extra-renal lupus, Aspreva, $62,500, 2006-
A study to investigate pro-inflammatory HDL cholesterol as an indication of risk for atherosclerosis in subjects with systemic lupus erythematosus, Alliance for Lupus Researach, $72,500, 2006-
Co-investigator, Rituxan in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (NIH Grant # N01-AR-4-2273), 2007-
Co-investigator, The use of abatacept in lupus nephritis (NIH Grant # N01A115416), 2008-
Improving the Recognition, Diagnosis, and Referral Patterns of Patients with Systemic Lupus Erythematosus Through Enhanced Care Coordination and Practice Efficiencies – A QI/PI CME Demonstration Project for the Cedars-Sinai Medical Group, France Foundation, 2012- , $150,000
Past and Ongoing Drug Study Collaborative Protocols:
Eli Lilly, Benoxaprofen, 1977-1979 in RA
Syntex, Naproxen, 1980-1982 in RA
CIBA-Geigy, Diclofenac, 1985-1987 in RA
Winthrop, Hydroxychloroquine-methotrexate, 1988-1992 in RA
Rorer, Calcitonin in Fibromyalgia, 1989
Sandoz, Sandostatin in Fibromyalgia, 1990-1991
Smith-Kline, Namebutone for Osteoarthritis, 1991-1992
Genelabs, Dehydroepiandrosterone (DHEA) for Lupus, 1994-1997, an open label and double blind trial
La Jolla Pharmaceuticals, LJP 394 for Lupus Nephritis, 1996-1999, Double-blind trial
Immunex, Double-blind trial of TNF-alpha (Enbrel) for Rheumatoid Arthritis, 1997-1999
Boehringer-Ingelheim, Meloxicam for Rheumatoid Arthritis, 1998-1999
Boehringer-Ingleheim, Meloxicam for Osteoarthritis, 1998-1999
Merck, MK-0966 for Rheumatoid Arthritis, 1998
Immunex, Open-label trial of TNA-alpha (Enbrel) for Rheumatoid Arthritis, 1997-
Biogen, Anti-CD40L therapy for lupus nephritis, 1998-1999
Smith Kline, SB 217969/Clenolixib for Rheumatoid Arthritis, 1998-1999
La Jolla Pharmaceuticals/Abbott, LJP 394 for Lupus nephritis, open label #90-11, 1998-2000
Merck, MK-0966 for osteoarthritis, 1998-1999
Smith Kline, SB 217969/Clenolixib (Open Label), for rheumatoid arthritis1998-1999
Roche, Randomized, double-blind trial of Ro32-3555 (Trocade) for rheumatoid arthritis, 1998-2000
Amgen, A randomized, placebo controlled double-blind, multicenter, dose-finding study to evaluate the safety and efficacy of weekly administration of PEGlycated recombinant methionyl human soluble tumor necrosis factor receptor Type I (PEGsTNF-RI) in pattients with rheumatoid arthritis, 1999-2000
Merck, An active comparitor and placebo controlled, parallel group, double-blind 52 week study to assess safety and efficacy of MK-0966 in rheumatoid arthritis patients, 1999-2000
Merck, Randomized, double-blind multicenter study to evaluate tolerability and effectiveness of rofecoxib (MK-0966) 25 mg/d vs naproxen 500 mg bid in patients with osteoarthritis, 1999-2000
Zeneca, Randomized, double blind placebo controlled, parallel group multicenter trial to assess the analgesic efficacy and tolerability of treatment with multiple doses of 1600 mg ZD6416 bid compared with treatment with placebo in patients with osteoarthritis of the hip or knee, 1999
Biogen C99-1021, An open label, multiple dose study to evaluate the efficacy, safety and pharmokinetics of BG 9588 (anti CD40 antibody) in subjects with proliferative lupus glomerulonephritis, 1999-2001
Anergen, A phase I double blind, randomized placebo controlled, dose escalation study to evaluate the safety, tolerability and biological activity of a 2 week induction course and 1 maintenance cycle of AG 4263 in subjects with rheumatoid arthritis, 1999
IDEC, Phase II randomized, double blind, placebo-controlled, multiple center, mutiple dose, dose finding safety, tolerance and efficacy study of IDEC-131 in patients with active SLE, 1999-2000
Centocor, An open-label trial of anti-TNF chimeric monoclonal antibody Infliximab in patients with active rheumatoid arthritis, 1999-2000
Merck, A randomized, placebo-controlled, parallel group, double-blind study to evaluate the safety and efficacy of rofecoxib 25 mg and celeboxib 200 mg in patients with osteoarthritis of the knee or hip, 2000
Cypress, A post approval, market preference, unblinded general experience study to gather additional information about the Prosorba column in general rheumatology practice settings, 1999-2000
Searle, Clinical protocol to evaluate the long term safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis, 1999-2001
Searle, Clinical protocol of a multicenter, double-blind, placebo-controlled randomized, comparison study of the efficacy and safety of 3 valdecoxib doses and naproxen in treating the symptoms and signs of rheumatoid arthritis, 1999-2001
Knoll, A multicenter randomized placebo-controlled Phase II study of the human anti-TNF D2E7 administered as subcutaneous injections in rheumatoid arthritis patients treated with methotrexate, 1999-2001
Knoll, A multicenter Phase II study of the human anti-TNF antibody D2E7 administered as subcutaneous injections in rheumatoid arthritis patients treated with methotrexate, 2000-2001
Amgen, A double-blind extension study to provide treatment with PEGylated recombinant human methionyl soluble tumor necrosis factor Type I (PEG sTNF-R1) to subjects completing trials TNF 980246 and TNF 990136, 2000
Fujisawa, An open-label, long-term study to evaluate the safety of Prograf (tacrilimus) for the treatment of rheumatoid arthritis, 2000-2002
Fujisawa, a randomized double-blind placebo controlled study to assess the efficacy and safety of prograf (tacrilimus) in the treatment of rheumatoid arthritis in patients who have failed one or more disease modifying antirheumatic drugs, 2000-2002
Knoll DE031: A multicenter randomized double-blind placebo-controlled study of the safety of human anti-TNF monoclonal antidoby D2E7 in patients with active rheumatoid arthritis, 2000-
Knoll, Study of New Onset Rheumatoid Arthritis (SONORA), 2000-
Knoll DE013, A prospective multicenter randomized double-blind active comparator-controlled parallel-groups study comparing the fully human monoclonal antibody TNF alpha antibody D2E7 every second week with methotrexate given weekly and the combination of D2E7 and methotrexate administered over 2 years in patients with early rheumatoid arthritis, 2000-
La Jolla Pharmaceuticals, LJP 394-90-09, A randomized, double-blind, placebo-controlled, multicenter safety and efficacy trial of LJP 394 in systemic lupus erythematosus (SLE) patients with a history of renal disease, 2000-2002
Centocor, MEDIII Pso-A-1, A multicenter placebo, controlled, double blind, randomized study of anti-TNF chimeric monoclonal antibody (cA2, infliximab) in patients with active psoriatic arthritis, 2000-2002
Bristol-Myers Squibb, IM 101-101, A multicenter, randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of intravenous infusions of BMS-188667 given monthly in combination with sub-cutaneous injections of etanercept given twice weekly to subjects with active rheumatoid arthritis, 2001-
Amgen, 2000223, A multicenter double-blind study to evaluate the safety and efficacy of anakinra (r0metHul IL-ra) and entanercept in subjects with rheumatoid arthritis using methotrexate, 2001-
Allergan, 192371-011-01, A multicenter, double masked, randomized, vehicle controlled parallel group study of the safety and efficacy of cyclosporin opthalmic emulation used twice daily for 6 months in patients with moderate to severe keratoconjunctivitis, 2001-2002
Vertex, VX00-745-102, A 12 week, randomized, double-blind, placebo-controlled, dose-ranging study of VX-745 in patients with rheumatoid arthritis, 2001-2002
Hoffman-LaRoche, WA15541c, A double-blind, randomized, placebo controlled study to evaluate the safety and efficacy of Ro32-3555 (Trocade) as adjunct to background antirheumatoid therapy, in preventing structural damage in rheumatoid arthritis, 2000-2002
Knoll, DE020, A multicenter 2 year continuation study of the human anti-TNF antibody D2E7 administered as a subcutaneous injection in patients with rheumatoid arthritis, 2001-
Proctor and Gamble, The effect of testosterone patch on activity of systemic lupus erythematosus, 2001-
Pharmacia, 872-IFL-0513-004, Clinical protocol for a double-blind, placebo-controlled, randomized six week comparison study for the efficacy of valdecoxib 20 mg q d and rofecoxib 25 mg q d in relieving the signs and symptoms of osteoarthritis of the knee, 2001-2002
Optime Therapeutics, LEDA.C.001, A phase II study of the safety and efficacy of topical liposome-encapsulated diclofenac analgesic (LEDA) in patients with osteoarthritis of the knee, 2001-2002
Centocor, START Protocol CO1168T41, A randomized, double-blind trial of the safety of TNF-alpha chimeric monoclonal antibody (Infliximab) in combination with methotrexate compared to methotrexate alone in patients with rheumatoid arthritis on standard disease modifying anti-rheumatic background therapy, 2001-2003.
XOMA, HURA 501.02, A Phase II, Double-blind, Placebo-controlled Study to Determine the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Efalizumab in Subjects with Moderate to Severe Rheumatoic Arthritis on a Stable Dose of Methotrexate, 2002-2004
Cypress Bioscience, Inc., FMS-021, A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Milnacipran for Treatment of Fibromyalgia, 2002-2003.
Immunex Corporation, 016.0034, Rheumatoid Arthritis DMARD Intervention and Utilization Study (RADIUS 1), 2001-2003.
Immunex Corporation, 016.0036, Phase 3 Randomized, Double-Blind, Placebo-controlled Study of 50mg Etanercept (EnbrelÒ) Administered SC Once Weekly in Patients with Active Rheumatoid Arthritis, 2002-2003
Immunex Corporation, 016.0037, Multicenter, Double-blind, Pacebo-Controlled, Randomized Phase 3 Study of Etanercept in the Treatment of patients with Ankylosing Spondylitis, 2002-2003
Amgen, Inc., 20020103 KONTROL, Psychometric Assessment of the Cedars-Sinai Health Related Quality of Life (CSHQ-RA) Instrument in Rheumatoid Arthritis Subjects Receiving KineretÔ (Anakinra) Therapy, 2002-2003.
Isis Pharmaceuticals, Inc., ISIS 104838-CS7, A Double-blind, placebo-controlled, randomized trial of the safety, efficacy, and pharmacokinetic profile of ISIS 104838 (TNF-a antisense oligonucleotide) subcutaneous injections in active rheumatoid arthritis patients, 2002-2004
Scios, Inc., 782.344, A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of SCIO-469 in Patients with Active Rheumatoid Arthritis Receiving Methotrexate, 2002-2004.
Janssen Parmaceutica Products, L.P., CIS-USA-154, Limited access protocol for the use of oral cisapride in the treatment of refractory gastroesophageal reflux disease and other gastrointestinal motility disorders, 2002-2005
Abbott, A multicenter study of the safety of human anti-TNF monoclonal antibody D2E7 in subjects with active rheumatoid arthritis, 2002-
Amgen, Rheumatoid arthritis DMARD intervention and utilization study (RADIUS 2), 2002-2005
Genelabs, The use of GL701 in the prevention of osteoporosis in patients on corticosteroids with lupus erythematosus, 2003-
Cipher Canada, A double-blind, randomized, placebo-controlled, multi-dose, Phase III, paraller group study of Tramadol ER in the relief of signs and symptoms of osteoartahritis of the hip and knee, 2003-2005
Centocor, A multicenter, double-blind trial of anti TNF alpha chimeric monoclonal antibody (Infliximab) for the treatment of subjects with psoriatic arthritis, 2003-2005
Centocor OPPOSITE, Open label, Pilot Protocol of Patients with Rheumatoid Arthritis who switch to Infliximab after incomplete response to etanercept, 2003-2005
Amgen MRI, The use of MRI to Describe and Identify the Early Findings Leading to Foot Erosions in High Risk Subjects with Rheumatoid Arthritis, 2003-
Glaxo Smith Kline, CXA20006, A Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Phase 2, Parallel Group, dose-ranging Finding studyTo assess the Safety and efficacy of GW406381 Administered For 42 days to Subjects with Rheumatoid Arthritis, 2003-2005
IDEC, 102-20/WAI17042, A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination with MTX in Subjects with Active Rheumatoid Arthritis Who have had an inadequate Response to MTX and Anti-TNFalpha Therapies 2003-.
Novartis,CCOX189A2335, A 13-Week, multicenter, international, randomized, double-blind, placebo-controlled, parallel-group study of COX189 200mg in patients with rheumatoid arthritis using naproxen 500mg b.i.d. as comparator, 2003-2004
Prometheus, 03-MTX-02, Measurement of Methotrexate and Folate Polyglutamate Levels and MTHFR Polymorphisms in a Cross-Section of Rheumatoid Arthritis Patients to Assess Correlations of Toxicity and Efficacy, 2003-2006
Human Genome Science, LBRA01, A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to evaluate the safety, tolerability and Efficacy of LymphoStat-B™ (LSB) in subjects with RA, 2004-2005
Abbott,M02-537, A Multicenter continuation trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients with Moderate to Severly Active Psoriatic Arthritis, 2003-2006
Biorad, Collection of Prospective Samples for Investigational Studies of Bio-Rad BioPlex 2200 ANA Screen on the BioPlex 2200, 2004-
SLICC (Systemic lupus erythematosus International Coordinating Committee) Registry for Atherosclerosis, 2003-, Regristry for central nervous system lupus, 2003-
Prometheus Imuran SLE: An Open Label Safety and Efficacy Trial of Imuran for Patients with Systemic Lupus Erythematosus, 2004-2006
Wyeth Research: Protocol 3140A1-200-WW: A Double-Blind, Placebo-Controlled, Parallel, Randomized Study to Evaluate the Efficacy and Safety of 3 Oral Dose Levels of TMI-005 in Subjects with Active Rheumatoid Arthritis on a Background of Methotrexate, 2004-2005.
LJP: Protocol 394-90-14: A Randomized, Double-Blind, Placebo-Controlled, Four-Arm Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 100mg and 300mg of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients with a History of Renal Disease, 2004-2007.
Scios: Protocol B007: A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy of Oral SCIO-469 in Subjects with Active Rheumatoid Arthritis Who are not Receiving DMARDS Other than Hydroxychloroquine, 2004-2006
Orphan Medical, Inc.: Protocol OMC-SXB-26: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (sodium oxybate) with Placebo for the Treatment of Fibromyalgia, 2004-2005
Amgen B cell: An exploratory study to characterize the variability in circulating B cell populations in subjects with systemic lupus erythematosus (SLE), 2004-2006
A Phase IIB MultiCenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Glucocorticosteroids in the Treatment of Active SLE and the Prevention of Subsequent Lupus Flares, BMS, 2005-
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects with Moderate to Severe SLE, Genentech, 2005-
A Multi national, Multi center, randomized, double blind, placebo controlled, multiple dose, four arm study to assess the efficacy, tolerability and safety, of three different doses of Edratide (TV-4710) Subcutaneous injections in SLE patients, TEVA 2005-2007
A phase III, Randomized, Double blind, Placebo controlled, multi center study of Epratuzumab in patients with acute severe SLE Flares Excluding the Renal or Neurologic Systems, Immunomedics, 2005-2006
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects with Systemic Lupus Erythematosus (SLE), Human Genome Sciences, 2005-2007
A Phase Ib, multi-centre, double-blind, placebo-controlled, dose-escalating, single dose study to assess the safety, pharmacokinetics and pharmacodynamcs of TACI-Fc5 when administered subcutaneously to patients with SLE, Serono, 2005-2006
A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 623 following multidose administration in subjects with SLE, Amgen , 2005-2006
A Phase 2 study to evaluate the safety, tolerability and activity of fontolizumab (HuZaf) in patients with active rheumatoid arthritis, Protocol ZAF-711, sponsored by Protein Design Labs, Inc (PDL), 2006-2007
Phase 1 Single Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of TRU-015 Administered Intravenously in Subjects with Rheumatoid Arthritis. Protocol 15001, Trubion 2004-
A double-blind, randomised, placebo controlled, dose escalating, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthritis who have previously failed one or more disease modifying anti-rheumatic drugs. Protocol Hx-CD20-403 Genmab, 2005-
A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of Ocrelizumab compared to placebo in patients with active Rheumatoid Arthritis continuing Methotrexate treatment. Protocol WA20494/ACT3985g, Genetech, 2005- 2007
A Phase III, Multicenter, Open-Label, Continuation Trial of LymphoStat-B Antibody (Monoclonal Anti-BLys Antibody) in Subjects with Rheumatoid Arthritis (RA) who Completed the Phase II LBRA 01. Protocol LBRA99, Human Genome Sciences, 2006-
An Exploratory study to characterize biomarker assays in healthy subjects and in subjects with Rheumatoid Arthritis. Protocol 92005637, Amgen 2006-2007
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate Safety and Tolerability of a Single IV Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Patients Who Have Mild System Lupus Erythematosus (SLE) With Cutaneous Involvement. Protocol MI-CP126, MedImmune, 2006-2008
“A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RITUXIMAB IN SUBJECTS WITH ISN/RPS CLASS III OR IV LUPUS NEPHRITIS” PROTOCOL LUNAR, GENENTECH, 2006-
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER STUDY OF EPRATUZUMAB IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS. PROTOCOL IMMU-103-03 IMMUNOMEDICS, 2005-2006
A MULTI CENTER, OPEN LABEL, CONTINUATION TRIAL OF LYMPHOSTAT B ANTIBODY (MONOCLONAL ANTI-BLYS ANTIBODY) IN SUBJECT WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WHO COMPLETED THE PHASE 2 PROTOCOL LBSL02. PROTOCOL LBSL9, HUMAN GENOME SCIENCES, 2006-
Genentech IFN 3958g, A Phase I, Randomized, Double-blind, Placebo-controlled, escalating single and multiple dose study of the safety, tolerability, and Pharmacokinetics of rhuMAb IFNalpha In adults with mildly active SLE, 2007-.
UCB SL0006, An Open-Label Re-treatment Trial for Patients Previously Randomized into the SL0003 and SL0004, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studies of Epratuzumab in patients with SLE, 2007-.
UCB SL0007, A Phase Iib, Randomized, Double Blind, Placebo controlled, dose and dose regimen-ranging study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus erythematosus patients with Active Disease
Medimmune MPI-CP152, A Phase IB, Multicenter, Randomized, Double-blind, Placebo-controlled, dose escalation study with an open label extension to evaluate the safety and tolerability of multiple intravenous doses of MEDI-545, a fully human Anti-Interferon-Alpha Monoclonal Antibody , in patients with Systemic Lupus Erythematosus 2007-.
Human Genome Sciences C1056, A Phase 3, Multi-Center, Randomized, Double-Blind, placebo-controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-Blys Antibody, in Subjects with SLE, 2007-.
Genentech WA 20499/ACT4071g Ocrelizumab, A Randomized, double blind, placebo controlled, parallel group, multi-center study to evaluate the efficacy and safety of two doses of Ocrelizumab in patients with active SLE, 2007-.
Genentech WA 20500, A Randomized, double blind, placebo controlled, parallel group, multi-center study to evaluate the efficacy and safety of two doses of Ocrelizumab in patients with WHO or ISN Class III or IV Nephritis due to SLE, 2007-.
Wyeth, A Randomized, two arm, parallel group study of the safety, pharmacokinetics, and pharmacodynamics of TRU-015 added to standard therapy in subjects with Membranous Nephropathy secondary to Systemic Lupus Erythematosus
BMS Lupus Nephritis IM 101-075, A sequential adaptive phase II/III multi-center, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Abatecept versus Placebo on a background of Mycophenolate Mofetil and Glucocorticoids in subjects with active Proliferative Glomerulonephritis due to Systemic Lupus Erythematosus (SLE), 2007-
The systemic lupus erythematosus (SLE) activity gene expression (SAGE) sudy, XDx protocol SL 105, 2007-
Regerneron, Phase I: A Randomized, double blind, placebo controlled, single ascending dose study of the safety and tolerability of REGN88 (IL6R-m-Ab) in subjects with Rheumatoid Arthritis receiving concomitant Methotrexate, 2008-
BMS IM 101-167, A Phase IIIb, Multicenter, Randomized, Withdrawal study to evaluate the Immunogenicity and safety of Subcutaneously Administered Abatacept in Adults with Active Rheumatoid Arthritis, 2008-.
Boehringer Ingelheim Pramipexole Trial 248.637, Pramipexole ER in Fibromyalgia, 2008-
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 in the United States, 2008 –
A Phase IIb, Multi-center, Open-label, Follow-up Study to Assess the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease Who Participated in Study SL0007. Protocol UCB SL0008, 2008-
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Systemic Lupus Erythematosus patients with Active Disease. Rigel C-935788-015
A Randomized, Parallel, Double-blind, Placebo-controlled dose regimen finding study to evaluate the safety and efficacy of TRU-015 in Subjects with Active Seropositive Rheumatoid Arthritis on a stable background of Methotrexate, protocol 3206K1-2203-WW, 2008-
A Phase IIIB, multi-centre study with a 12 week double-blind, placebo-controlled, randomized period, followed by an open-label extension phase to evaluate the safety and efficacy of certolizumab pegol administered to patients with active rheumatoid arthritis, Protocol UCB C87094. 2008-
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate Safety Of Multiple-Dose, Intravenously Administered Medi-545, A Fully Human Anti-Interferon-Alpha Monoclonal Antibody, In Adult Patients With Dermatomyositis Or Polymyositis, Protocol MI-CP151. 2008- Medimmune MPI-CP152, A Phase IB, Multicenter, Randomized, Double-blind, Placebo-controlled, dose escalation study with an open label extension to evaluate the safety and tolerability of multiple intravenous doses of MEDI-545, a fully human Anti-Interferon-Alpha Monoclonal Antibody , in patients with Systemic Lupus Erythematosus 2007-2010
Human Genome Sciences C1056, A Phase 3, Multi-Center, Randomized, Double-Blind, placebo-controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-Blys Antibody, in Subjects with SLE, 2007-2010.
Human Genome Sciences C1066, A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 in the United States. 2008-
BMS Lupus Nephritis IM 101-075, A sequential adaptive phase II/III multi-center, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Abatecept versus Placebo on a background of Mycophenolate Mofetil and Glucocorticoids in subjects with active Proliferative Glomerulonephritis due to Systemic Lupus Erythematosus (SLE), 2007-
The systemic lupus erythematosus (SLE) activity gene expression (SAGE) sudy, XDx protocol SL 105, 2007-2009
BMS IM 101-167, A Phase IIIb, Multicenter, Randomized, Withdrawal study to evaluate the Immunogenicity and safety of Subcutaneously Administered Abatacept in Adults with Active Rheumatoid Arthritis, 2008-
Novo Nordisk NN8360-3559, A randomized, double-blind, placebo-controlled, single dose-escalation and multiple dose extension trial of NNC 0152-0000-0001 administered i.v. or s.c. in subjects with Systemic Lupus Erythematosus, 2009
Genentech IFN4575g, A phase II, Randomized, Double-blind, placebo-controlled study to evaluate the efficacy and safety of Rontalizumab (rhuMAb IFNalpha) in patients with moderately to severely active Systemic Lupus Erythematosus, 2009-
Amgen (AMG 827) 20070264, A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects with Rheumatoid Arthritis, 2009- 2010
Crescendo Bioscience, Inc. CR10, Index for Rheumatoid Arthritis Measurement (InFoRM) Study, 2009-
Immune Tolerance Network: Protocol ITN034AI, A randomized, double-blind, controlled, phase II Multicenter trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs Cyclophosphamide Alone in the Treatment of Lupus Nephritis, 2009-2010
Array BioPharma Inc. 797-201, A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study To Investigate The Safety, Efficacy, Pharmacokinetics and Pharmacodynamics Of 12 Weeks Of Treatment With ARRY-371797 In Patients With Active Ankylosing Spondylitis And Inadequate Response To Conventional Therapy, 2009-2009
UCB C87094, A Phase IIIB, multi-centre study with a 12 week double-blind, placebo-controlled, randomized period, followed by an open-label extension phase to evaluate the safety and efficacy of certolizumab pegol administered to patients with active rheumatoid arthritis, 2008-2010
Roche Laboratories Inc. ML22533/A, An open-label, randomized study to evaluate the safety, tolerability and efficacy of tocilizumab (TCZ) monotherapy or TCZ in combination with non-biologic disease modifying antirheumatic drugs (DMARDs) in patients with active rheumatoid arthritis who have an inadequate response to current non-biologic or biologic DMARDs, 2009-
SLICC, Lymphoma Risk in SLE: A Consequence of Immune Suppression or Stimulation? 2009-
Lupus Clinical Trials Consortium, Inc., LCTC Lupus Data Registry, 2009-
Cedars Sinai Medical Center, Cross Cultural Spanish Validation of Lupus Pro: A Patient Reported Outcome Measure for Lupus, 2009-
TEVA Pharma - A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Systemic Lupus Erythematosus Patients with Active Lupus Arthritis. PROTOCOL LA-LAQ-202, 2010 - , NCT01085084
Cephalon, Inc. - A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus. 2010-
Sanofi Aventis US Inc. - A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS). Protocol Number: DRI11073, 2010-
UCB - A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of certolizumab pegol in subjects with active axial spondyloarthritis (AS001), 2010-
UCB. - Phase 3, multicenter, randomized, double‑blind, parallel‑group, placebo‑controlled study to evaluate the efficacy and safety of certolizumab pegol in subjects with adult‑onset active and progressive psoriatic arthritis (PsA), 2010-
Study of Epratuzumab in systemic lupus erythematosus, NCT00383513, 2010-
Duke Autoimmunity Pregnancy Registrsy (DAP Regristry), 2010-
Studies of B cell abnormalities in Systemic Lupus Erythematosus via MiRNA, 2010-
Concurrrent pilot studies in Giant cell arteritis and Takayasu’s arteritis to examine the safety, efficacy, and immunologic effects of abatacept (CTLA4-Ig) in large vessel vasculitis, 2010-
Hp-MMP 9 levels in humans: a pilot study, 2010 -
GlaxoSmithKline - Lupus Impact Tracker: A Longitudinal Validation Study
Protocol GHO-09-1621 2011-
Eli Lilly and Company – A Phase 3, MultiCenter, Randomized, Double-Blind, Placebo Controlled study to evaluate the efficacy and safety of Subcutaneous LY2127399 in patients with Systemic Lupus Erythematosus (SLE), Protocol H9B-MC-BCDS 2011-
Teva Pharmaceutical Industries, LLC - A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo‑Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination with Standard of Care (Mycophenolate Mofetil and Steroids)
Protocol LN-LAQ-201 2011 –
UCB, Inc. - A Phase 3, Randomized, Double blind, placebo controlled, multicenter study of the Efficacy and Safety of Four 12-Week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects with Moderate to Severe Disease (Embody1).
Protocol SL0009 2011-
UCB, Inc. – A Phase 3, Multicenter, open label, extension study to assess the safety and tolerability of Epratuzumab treatment in Systemic Lupus Erythematosus Subjects (Embody 4)
Protocol SL0012 2011 -
Roche - A randomized, double-blind, parallel group study of the safety and effect on clinical outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease modifying anti-rheumatoid arthritis drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis.
Protocol Summacta WA22762 2011 –
Study of Lymphoma in Systemic Lupus Erythematosus, SLICC (Systemic Lupus International Collaborative Clinics), 2009-2011
IRBIS (Internal Registry for Biologics in SLE) Phase I, Retrospective data collection, SLICC (Systemic Lupus International Collaborative Clinics), 2010-
ACR/EULAR Diagnostic and Classification Criteria for Vasculitis, ACR, EULAR, Vasculitis Foundation, Oxford Universitym, 2011-
A study to learn about the safety, effectiveness and effects on the body of abatacept in large vessel vasculitis. Concurrent pilot studies in Giant cell arteritis and Takayasu’s arteritis, Vasculitis Clinical Research Consortium, 2011-
Vasculitis Clinical Research Consortium (VCRC) Genetic Repository DNA Protocol, 2011-
A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo Controlled, 52 week study to evaluate the efficacy and safety of Belimumab (HGS1066) in Adults subjects of Black Race with Systemic Lupus Erythematosus (SLE), Human Genome Sciences, 2012-
A Randomized, Double-Blind, Placebo-controlled, multiple dose, parallel, Multiple dose-level study to evaluate the safety, tolerability and efficacy of AMG 557 in (SLE) subjects with active Lupus Arthritis, Amgen, 2012-
A Double Blind, Randomized, Placebo-controlled, Multicenter, dose ranging study to evaluate the efficacy and safety of PF-04236921 in subjects with Systemic Lupus Erythematosus, Pfizer, 2012.
OMRF Sjogren’s Studies: Gene Expression Profiling in Primary Sjogren’s Syndrome A dose escalation, multi-center study to evaluate the safety, tolerability and proof of mechanism of DV1179 in Subjects with Systemic Lupus Erythematosus, Dynaxax, 2012-
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of subcutaneous LY2127399 in patients with systemic lupus erythematosus (SLE), 2012- , Lilly , 2012- A longitudinal observational study of CXCR5, CXCL13 and other biomarkers in patients with lupus and healthy control subjects , Sanofi, 2012- Protocol WA 27893: Prospective, observational safety study of patients with Granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis treated with rituximab, Genentech 2012- A Study to Evaluate the Efficacy and Safety of R333 6% Ointment Administered Topically to DLE and SLE Patients with Active Cutaneous Discoid Lesions , Rigel, 2012-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis, Biogen, 2012-.
A phase 111, Multicenter, Randomized, Double-blind Placebo-controlled Study to Assess The efficacy and Safety of Tocilizumab in Subjects With Giant Cell Arteritis, Roche, 2013-.
Nodality – Characterization of Immune Alterations in Systemic Lupus Erythematosus (SLE) using Single Cell Network Profiling (SCNP) Protocol 2012087 SLE Landscaping, 2013-.
Ignyta – Molecular Analysis in Biological Specimens from Subjects with Rheumatoid Arthritis (RA) Protocol – IGN-RA104Ignyta – Molecular Analysis in Biological Specimens from Subjects with Systemic Lupus Erythematosus (SLE) and Non-Lupus ControlProtocol – IGN-SLE104, 2013-.
Data Safety and Monitoring Boards
Celecoxib for rheumatoid arthritis, 2006.
Novo Nordisk Anti IL-21 Protocol NN8828-4002, 2012-2013.
Book Chapters
1. Plasma-lymphocytapheresis for the treatment of rheumatoid arthritis, D. Goldfinger, D. Wallace, J. Klinenberg, in Plasma Exchange Therapy, Ed. by H. Borberg, R Reuther, pp. 215-219, GeorgThiemeVerlag,Stuttgart, 1981.
2. The current status of therapeutic apheresis in the management of rheumatoid arthritis, DJ Wallace, D.Goldfinger, J. Klinenberg, in Therapeutic Apheresis and Plasma Perfusion, Ed. by J Tyndall, AR Liss, New York, pp. 27-32, 1982. (Also published as Prog. Clin. Biol. Res. 106:27-32 1982).
3. A controlled study on the use of plasmapheresis in steroid/immunosuppressive resistant systemic lupus erythematosus with nephrotic syndrome, DJ Wallace, D Goldfinger, S. Nichols, D Goodman, M Fichman, M Stewart, JR Klinenberg, in Proceedings of the First International Congress of the World Apheresis Association, Ed. by T Uda, Y Shlokawa, N Inoue, ISAO Press, pp. 91-102, 1987.
4. New and experimental therapeutic modalities, JR Klinenberg and DJ Wallace, in Diagnosis and Management of Rheumatic Diseases, W. Katz, ed, Lippincott, Philadelphia, pp 855-858, 1988.
5. Wallace D, The Treatment of Mild Lupus, in Proceedings of the 2nd Intl Conference on S.L.E., Professional Postgraduate Services, Singapore, 1989, pp. 126-129.
6. Wallace DJ, Peter JB, Bowman RL, Wormsley SB, Silverman S, Fibromyalgia, cytokines, fatigue syndromes, and immune regulation, in Advances in Pain Research and Therapy: Myofascial Pain and Fibromyalgia, Volume 17, JR Fricton and EA Awad, Eds, Raven Press, NY, 1990, pp. 277-287.
7. Wallace D, Metzger AL, The antiphospholipid syndrome, in A Decade of Lupus, H Aladjem editor, Lupus Foundation of America, 1991, Rockville, MD, pp. 126-127.
8. Wallace DJ, Does stress or trauma cause aggravate rheumatic disease?, in Bailliere's Clinical Rheumaology, Exercise and Rheumatic Disease, 8: 149-159, 1994. Richard Panush and Nancy Lane editors, Baillierere Tindall, London.
9. Wallace DJ, Antimalarial agents and lupus. Rheumatic Disease Clinics, in Systemic Lupus Erythematosus, WJ McCune editor, 20: 243-263, 1994, WB Saunders, Philadelphia, PA.
10. Wallace DJ, Metzger AL, Ashman RF, Rheumatic diseases, in Manual of Allergy and Immunology, 3rd edition, G Lawlor, T Fischer, D Adelman, eds, Little, Brown & Company, 1995, pp 303-352.
11. Silverman S, Gluck O, Silver D, Tesser J, Wallace D, Neumann K, Metzger A, Morris R, The prevalence of autoantibodies in symptomatic and asymptomatic patients with breast implants and patients with fibromyalgia, in Immunology of Silicones, M Potter and NR Rose, Eds, Springer-Verlag Berlin, Heidelberg,Germany, pp 317-322, 1996. (Also published as Curr Top Microbiol Immunol 1996; 210:317-322.)
12. Wallace D, Metzger AL, Systemic lupus Erythematosus: Clinical aspects and treatment, in Koopman WJ, editor, Arthritis and Allied Conditions: A Textbook of Rheumatology, 13th Edition, Williams and Wilkins, Baltimore, MD, 1997, pp 1319-1345.
13. Wallace D, Autoimmune Connective Tissue Disorders, Rakel RE, Conn’s Current Therapy 2000, WB Saunders, Philadelphia, PA, pp 774-778.
14. Wallace DJ, Severe lupus, in Rheumatology (3rd Ed), MC Hochberg, AJ Silman, JS Smolen, ME Weinblatt, MH Weisman, Mosby, Edinburgh, 2003, pp. 1419-1426.
15. Shinada S, Wallace DJ, Laboratory features of cutaneous lupus, Cutaneous lupus erythematosus, Springer, Berlin, 2004, p.p. 311-322.
16. Wallace DJ, Fibromyalgia and the neurobiology of sleep, in Sleep and Psychosomatic Medicine, SR Pandi-Perumal, RR Ruoti, M Kramer, Eds, 2007; Informa Healthcare, Abington, United Kingdom, pp. 249-259.
17. Wallace DJ, Systemic lupus erythematosus, Encyclopedia of Stress, 2nd edition, G Fink, editor, Elsevier, 2007, Oxford UK, v 3 pp 708-712.
18. Hallegua DS, Wallace DJ, Sleep and fibromyalgia in the elderly, in Principles and Practice of Geriatric Sleep Medicine, SR Pandi-Perumal, JM Monti and AA Monjan, Eds, Cambridge University Press 2009, pp 160-166.
19. Wallace DJ, Management of nonrenal systemic lupus erythematosus 2, in Targeted Treatment of the Rheumatic Diseases, M Weisman et al Eds, Saunders Elsevier, Philadelphia, PA, 2009, pp 91-107.
20. Goldenberg DM, Wallace DJ, Epratuzumab in SLE, In: Immunotherapeutic agents for SLE. Shoenfeld Y, Meroni PL, Cervera R (Eds). Future Medicine Ltd, London, UK, 56–68 (2012).
21. Editor of Up to Date sections 2011- 2013 for: a) Antimalarial drugs in the treatment of rheumatic diseases, b) Diagnosis and differential diagnosis of systemic lupus erythematosus in adults, c) Musculoskeletal manifestations of systemic lupus erythematosus, d) Overview of therapy of the therapy and prognosis of systemic lupus erythematosus in adults, Lippincott.
22. Wallace DJ, Management of nonrenal and non-central nervous system lupus, in Rheumatology (5th edition), MC Hochberg, AJ Silman, JS Smolen, ME Weinblatt, MH Weisman Eds, Saunders Elsevier, Philadelphia, PA 2013, Chapter 134 pp 1-7.
Articles or Letters to the Editor in Peer Reviewed Publications
1. Wallace D, Aging research: Yesterday and today, Gerontologist, 14: 110-113, 1974.
2. Wallace D, Biology of aging: 1976, An overview, J Am Geriatr Soc, 25: 104-111, 1977.
3. Klinenberg J, Wallace D, Plasmapheresis and Raynaud's Disease, Lancet 1: 1609-1610, 1978.
4. Wallace D, Klinenberg J, Morhaim D, Berlanstein B, Biren P, Callis G, Coexistent gout and rheumatoid arthritis, Arthritis Rheum 22: 81-86, 1979.
5. Wallace D, Klinenberg J, Gatti R, Goldfinger D, Bluestone R, A therapeutic role for pheresis in the management of rheumatoid arthritis, Haemonetics Research Institute Advanced Component Seminar, Boston, 1979.
6. Wallace D, Goldfinger D, Gatti R, Lowe C, Fan P, Bluestone R, Klinenberg J, Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis, Arthritis Rheum 22:703-710, 1979.
7. Somer T, Wallace D, Fan P, Immune complex mediated rheumatic diseases, Rounds, the J of Wadsworth Hospital 19:1-13, 1980.
8. Somer T, Wallace D, Fan P, Immune complex mediated rheumatic diseases, Ann Clin Res, 12:77-86, 1980.
9. Wallace D, Goldfinger D, Thompson-Breton R, Martin V, Lowe C, Bluestone R, Klinenberg J, Advances in the use of therapeutic pheresis for the management of rheumatic diseases, Semin Arthritis Rheum 10: 81-91, 1980.
10. Wallace D, Thomsonians: The people's doctors, Clio Med 14: 169-186, 1980.
11. Wallace D, Podell T, Weiner J, Klinenberg J, Forouzesh S, Dubois E, Systemic Lupus Erythematosus— survival patterns: Experience with 609 patients, JAMA 245: 934-938, 1981.
12. Wallace D, Survival patterns in systemic lupus erythematosus, JAMA 246: 2223, 1981.
13. Wallace D, Brachman M, Klinenberg J, Joint scanning in rheumatoid arthritis: A literature review, Semin Arthritis Rheumatism 11: 172-176, 1981.
14. Wallace DJ, Goldfinger D, Klinenberg J, Current status of therapeutic apheresis in rheumatoid arthritis, Art Organs 5: 297-298, 1981.
15. Wallace DJ, Podell TE, Weiner J, Cox M, Klinenberg J, Forouzesh S, Dubois EL, Lupus nephritis: Expe rience with 230 patients in a private practice from 1950-1980, Am J Med 72: 209-220, 1982.
16. Podell TE, Wallace DJ, Fishbein MC, Bransford K, Klinenberg JR, Levine S, Severe giant cell valvulitis in a patient with Reiter's syndrome, Arthritis Rheum 25:232-234, 1982.
17. Wallace DJ, Goldfinger D, Lower C, Nichols S, Weiner J, Brachman M, Klinenberg J, A double-blind controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis, N Eng J Med 306: 1406-1410, 1982.
18. Wallace D, Goldfinger D, Klinenberg J, Lymphoplasmapheresis in rheumatoid arthritis, N Eng J Med 307: 1271, 1982.
19. Wallace DJ, Bluestone R, Klinenberg JR, The biology of aging and the immune system, Bull Rheum Dis 32: 13-19, 1982.
20. Wallace DJ, Goldfinger D, Bluestone R, Klinenberg JR, Plasmapheresis in lupus nephritis with nephrotic syndrome: A long term follow-up, J Clin Apheresis 1:42-45, 1982.
21. Wallace DJ, Status of therapeutic apheresis in rheumatoid arthritis and systemic lupus erythematosus, Upjohn Monograph, September 1982.
22. Wallace DJ, Hamburger MI, Goldfinger D, Bennett RS, Klinenberg, JR Apheresis perspective for rheumatoid arthritis, Plasma Ther 3: 395-400, 1982.
23. Krakauer RS, Wysenbeek AJ, Wallace DJ, Jones JV, Smith JW, Machesky P, Greenstreet R, Goldfinger D,Klinenberg JR, MacLeod V, Nose Y, Therapeutic trial of cryofiltration in patient. with rheumatoid arthritis, Am J Med 74: 951-955, 1983.
24. Wallace DJ, Klinenberg JR, Goldfinger D, Plasmapheresis for rheumatoid arthritis, N Eng JMed 309: 986-987, 1983.
25. Wallace DJ, Barnett EV, Nichols S, Hancock W, Vibert G, Curd J, Klinenberg JR, Goldfinger D, Immunologic dynamics in cryapheresis for rheumatoid arthritis, J Rheumatol 10:894-900, 1983.
26 Wallace DJ, What to do when the SLE patient is a child, J Musculoskeletal Med 1:11, 1984.
27. Wallace DJ, Fibromyalgia: Unusual historical aspects and new pathogenic insights, Mt. Sinai J Med 51: 124-131, 1984.
28. Wallace DJ, Klinenberg JR, Apheresis, Disease-a-Month 30: 1-45, 1984.
29. Wallace DJ, Medici MA, Nichols MA, Nichols S, Klinenberg JR, Bick M, Gatti R, Goldfinger D,Plasmapheresis versus Iymphoplasmapheresis: Immunologic comparisons and literature review, J Clin Apheresis 2 : 184-189, 1984.
30. Wallace DJ, Metzger AL, White KK, Combination immunosuppressive treatment of steroid resistant polymyositis/dermatomyositis, Arthritis Rheum 28:590-592, 1985.
31. Wallace DJ, Immunonuorescence and fibromyalgia, Arthritis Rheum 28:836, 1985.
32. Wallace DJ, Systemic lupus erythematosus, rheumatology and medical literature: Current trends, JRheumatol 12:913-915, 1985.
33. Wallace DJ, Plasmapheresis in rheumatic diseases, Biomed Pharm 40:284-286, 1986.
34. Wallace DJ, The role of stress and trauma in rheumatoid arthritis and systemic lupus erythematosus, Semin Arthritis Rheum 16: 1253-157, 1987.
35. Adelman DC, Wallace DJ, Klinenberg JR, 34 year delayed-onset lupus nephritis, Arthritis Rheum 30: 479-480, 1987.
36. Wallace DJ, Goldfinger D, Klinenberg JR, Use of autologous pregnancy plasma to treat a flare of juvenile rheumatoid arthritis. Case report and literature review. J Clin Apheresis 3:216218, 1987.
37. Wallace DJ, Does hydroxychloroquine sulfate prevent clot formation in SLE?, Arthritis Rheum 30: 1435-1436. 1987.
38. Wiedmann CE, Wallace DJ, Peter JB, Knight PK, Bear M, Klinenberg JR, Studies of IgG, IgM, IgA antiphospholipid antibody isotypes in systemic lupus erythematosus, J Rheumatol 15:74-79, 1988.
39. Wallace DJ, Comment on the article by Lahita, et al, Arthritis Rheum 31: 150-151, 1988.
40. Wallace DJ, Margolin K, Waller P, Fibromyalgia and interleukin-2 therapy for malignancy, Ann Internal Med 108:909, 1988.
41. Wallace DJ, Dubois' Lupus Erythematosus, Ann Internal Med 109:436-437, 1988.
42. Wallace DJ, Goldfinger D, Goodman D, Fichman M, Klinenberg JR, Predictive value of outcome variables in immunosuppressive resistant lupus nephritis, J Clin Apheresis 4:30-34, 1988.
43. Wigfall DR, Sakai RS, Wallace DJ, Jordan SC, Interleukin-2 receptor expression in peripheral blood lymphocytes from systemic lupus erythematosus patients: relationship to clinical activity, Clin Immunol Immunopath 47:354-362, 1988.
44. Wallace DJ, Comment on article by Studenski et al, Arthritis Rheum 31: 1208, 1988.
45. Wallace DJ, Brachman M, Feldman G, Reichman R, Klinenberg JR, Quantitative computerized joint scanning in rheumatoid arthritis: An accurate reproducible method of quantitating synovitis. A pre liminary report, Mt. Sinai J Med 56: 46-52, 1989.
46. Wallace DJ, The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination, Seminars Arthritis Rheum 18:282-297, 1989.
47. Wallace DJ, Metzger AL, Klinenberg JR, NSAID Usage patterns by rheumatologists in the treatment of systemic lupus erythematosus, J Rheumatology 16:557-560, 1989.
48. Wallace W, Bowman R, Wormsley S, Peter J, Cytokines and immune regulation in the primary fibromyalgia (fibrositis) syndrome, Arthritis Rheum 32: 1334-1335, 1989.
49. Chong PJ, Matzner WL, Wallace DJ, Klinenberg JR, Toyoda M, Jordan SC, 1-25 dihydroxyvitamin-D3 regulation of immunoglobulin production in peripheral blood mononuclear cells in patients with systemic lupus erythematosus, Journal of Autoimmunity, 2:861-867, 1989.
50. Wallace DJ, Genitourinary manifestations of fibrositis: An increased association with the female urethral syndrome, J Rheumatol, 17:238-239, 1990.
51. Wallace DJ, Managing arthritis in the elderly, American Operating Roorm Nurses (AORN) Journal 51: 1074-1080, 1990.
52. Wallace DJ, Metzger AL, Stecher VJ, Tumbull BA, Kern PA, Cholesterol-lowering effect of hydroxy chloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids, Amer J Med 89:322-326, 1990.
53. Wallace DJ, Lupus, acquired immunodeficiency syndrome, and antimalarial agents, Arthritis Rheum 34:373-373, 1991.
54. Clark WF, Dau PC, Euler HH, Guillevin L, Hasford J, Heer AH, Jones JV, Kashgarian M, Knatterud G, Lockwood CM, Pusey CD, Rifle G, Robinson JA, Schroeder JO, Tan EM, Wallace DJ, Weiner SR, Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: Design of the LPSG trial, J Clin Apheresis 6:40-47, 1991.
55. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR, Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis, J Immunol 147:117-123, 1991.
56. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR, Lupus erythematosus in the 1980s: A survey of 570 patients, Seminars Arthritis Rheum 21:55-64, 1991.
57. Wallace DJ, Active idiopathic systemic lupus erythematosus in a 90-year old woman requiring corticosteroid therapy, J Rheumatology 18:1611-1612, 1991.
58. Chong P, Matzner WL, Yamiguchi D, Wallace D, Klinenberg JR, Jordan SC, Inhibition of protein kinase C in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: Effect on spontaneous immunoglobulin production, Autoimmunity 10:227231, 1991.
59. Wallace DJ, Pistiner M, Nessim S, Metzger AL, Klinenberg JR, Cutaneous lupus erythematosus without systemic lupus erythematosus: Clinical and laboratory features, Seminars Arthritis Rheum 21:221-226, 1992.
60. Wallace DJ, Fibromyalgia: Clinical care and disability (Editorial), Journal of Musculoskeletal Medicine 9:3,23:1992 (April).
61. Wallace DJ, Metzger AL, Positive LE Preps and negative ANAs in brothers with SLE: Is there still a role for the LE Cell prep? A literature review, J Rheumatol 19:497, 1992.
62. Wallace DJ, A critique of the NIH lupus nephritis survey, Arthritis Rheum 35:605, 1992.
63. Silverman SS, Wallace DJ, Calcitonin may have some effect in fibromyalgia, J Musculoskeletal Medicine 9: 10, 1992.
64. Wallace DJ, Plasmapheresis for lupus nephritis, N Eng J Med 327: 1029, 1992.
65. Wallace DJ, Linker-Israeli M, Metzger A, Stecher VJ, The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE, Lupus 2:S13-S15, 1993.
66. Wallace DJ, Autologous pregnancy plasma transfusion in RA, Annals of the Rheumatic Diseases, 52:316,1993.
67. Wallace DJ, Is fibromyalgia a legitimate diagnosis?, Journal of Musculoskeletal Medicine 10:13-14 (no. 7),July 1993.
68. Wallace DJ, Plasmapheresis in Lupus (Editorial), Lupus 2:141-143, 1993.
69. Barthels HR, Wallace DJ, False-positive human immunodeficiency virus testing in patients with lupus erythematosus, Seminars in Arthritis and Rheumatism 23: 1-7, 1993.
70. Wallace DJ, Persistent eosinophilia in 2 patients with eosinophilia-myalgia syndrome, Arthritis and Rheumatism 36: 1488, 1993.
71. Wallace DJ, Linker-Israeli M, Hyun S. Klinenberg JR, Stecher V, The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus, Journal of Rheumatology 21: 375-376, 1994.
72. Wallace DJ, Biography: Edmund Lawrence Dubois (1923-1985), Rheumatology Review 3: 49-50, 1994.
73. Linker-Israeli M, Hyun S, Ozeri-Chen T, Wallace DJ, Banks K, Klinenberg JR, Elevated in vivo and in vitro secretion of CD8-a molecules in patients with systemic lupus erythematosus, J Immunol 152:31588-3167, 1994.
74. Wallace DJ, Systemic lupus erythematosus and Sjogren's syndrome, Editorial Overview, Current Opinion in Rheumatology 6:459-460, 1994.
75. Wallace DJ, Schwartz E, Breast implants, N Eng J Med 331:1231-1232, 1994.
76. Wallace DJ, Classifying cutaneous lupus erythematosus, Int J Dermatol 33:524, 1994.
77. Wallace DJ, Lin H-C, Shen GQ, Peter JB, Antibodies to histone (H2A-H2B)-DNA complexes in the absence of antibodies to double-stranded DNA or to (H2A-H2B) complexes are more sensitive and specific for scleroderma-related disorders than for lupus, Arthritis Rheum 37: 1795-1797, 1994.
78. Wallace DJ, Metzger AL, Can an earthquake cause flares of rheumatoid arthritis or lupus nephritis?,Arthritis Rheum 37: 1826-1828, 1994.
79. Harley JB, Sheldon P, Neas B, Murphy S, Wallace DJ, Scofield RH, Shaver TS, Moser KL, Systemic lupus erythematosus—considerations for a genetic approach, J Inves Der 103:S144-S149, 1994.
80. Wallace DJ, Controversy over sclerotherapy for malignant pleural effusions, Ann Int Med 121: 151,1994.
81. Wallace DJ, Successful use of nitrogen mustard for cyclophosphamide resistant diffuse proliferative lupus glomerulonephritis, J Rheumatol 22:801-802, 1995.
82. Wallace DJ, Silverman S, Goldstein J, Hughes D, Use of hyperbaric oxygen in rheumatic diseases; case report and critical analysis, Lupus 4:172-175, 1995.
83. Wallace DJ, Prevalence of fibromyalgia in systemic lupus erythematosus patients: comment on the article by Middleton et al, Arthritis Rheum 38:872, 1995.
84. Barthel HR, Wallace DJ, Klinenberg JR Liver transplantation in patients with systemic lupus erythematosus, Lupus 1995; 4:15-17.
85. Wallace DJ, Schwartz E, Lin H-C, Peter JB, The 'rule-out lupus' rheumatology consultation: Clinical outcomes and perspectives, J Clinical Rheumatol 1995; 1:158-164.
86. Wallace DJ, Clinical applications, J Clinical Apheresis 1995; 10:104-106.
87. Wallace DJ, Lupus erythematosus cell test, Amer J Clinical Pathology 1005; 104: 110-111. 88. Wallace DJ, Book Review: The Fibromyalgia Syndrome: Current research and future directions in epi demiology, pathogenesis and treatment, N Eng J Med 1995; 333:603.
89. Neumann K, Wallace DJ, Azen C, Nessim S, Fichman M, Metzger AL, Klinenberg JR, Lupus in the 1980s: III. Influence of clinical variables, biopsy and treatment on the outcome of 150 patients with lupus nephritis seen at a single center, Seminars Arthritis Rheum 1995: 25:4755.
90. Wallace DJ, Systemic lupus erythematosus and Sjogren's syndrome: Editorial overview, Current Opinion in Rheumatology 1995; 7:369-370.
91. Wallace DJ, Editor, Scientia, Arthritis/Rheumatology, Volume 1, Issues 1-4, 1995, Medical Education Network, New York, NY.
92. Wallace DJ, Quismorio FP Jr, The elusive search for geographic clusters of systemic lupus erythematosus, Arthritis Rheum, 1995, 38: 1564-1567.
93. Wallace DJ, Rheumatology: A wolf at the door, Patient Care, Sep. 15, 1995, pp 148-149.
94. Barthels HR, Wallace DJ, Lupus erythematosus and the liver, Resident &Staff Physician 1996; 42:30-34
95. Wallace DJ, The history of antimalarials, Lupus 1996; 5(supp 1):S2-S3.
96. Wallace DJ, The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review, Lupus 1996; 5(supp 1):S59-S64.
97. Linker-Israeli M, Wallace DJ, Prehn JL, Nand R, Li L, Klinenberg JR, A greater variability of the 3' flanking region of the IL-6 gene in patients with systemic lupus erythematosus, J Autoimmunity, 1996; 23:199-209.
98. Wallace DJ, Basbug E, Schwartz E, Clements P, Metzger AL, Furst DE, Klinenberg JR, A comparison of systemic lupus erythematosus and scleroderma patients with and without silicone breast implants, J Clinical Rheumatology 1996; 2:257-261.
99. Wallace DJ, Editorial overview: Systemic lupus erythematosus and Sjogren's syndrome, Current Opinion in Rheumatology 1996; 8:393-394.
100. Wallace DJ, Quismorio FPQ, Geographic clusters of systemic lupus erythematosus: reply, Arthritis Rheum 1996; 39:1936-1937.
101. Barthel HR, Meier LG, Wallace DJ, Antimalariamittel bei rheumatischen Erkrankenungen, Deutsche Medizinische Wochenschrift 1996; 121:1576-1582.
102. Wallace DJ, Rheumatology Case and Comment Going to extremities, Patient Care 1997; (Jan 15), 31:145.
103. Tsao BP, Cantor RM, Kalunian KC, Chen CJ, Badsha H. Singh R, Wallace DJ, Kitridou RC, Chen SL, Shen N. Song YW, Isenberg DA, Yu CL, Hahn BH, Rotter JI, Evidence for linkage of a candidate chromosome-1 region to human systemic lupus erythematosus, J Clinical Investigation 1997; 99 725-731.
104. Wallace DJ, The fibromyalgia syndrome, Annals of Medicine 1997; 29: 9-21.
105. Wallace DJ, Is hydroxychloroquine destined for a larger role in managing systemic lupus erythe matosus?, J Clin Rheumatol 1997; 3: 1-2.
106. Wallace DJ, Druzin ML, Lahita RG, Clinical rheumatologic applications of reproductive immunology.Facts, fiction, fancy, Arthritis Rheumatol 1997; 40: 209-216.
107. Tsao B. Wallace DJ, Genetics of systemic lupus erythematosus: Commentary, Current Opinion in Rheumatology, 1997; 9: 377-374.
108. Clegg DO, Dietz F. Duffy J, Willkens RF, Hurd E, Germain BF, Wall B. Wallace DJ, Bell CL, Sleckman J, Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine, J Rhetonatol 1997; 24: 1896-1902.
109. Wallace DJ, Chloroquine and cytokines, J Rheumntol 1997; 24: 2051.
110. Wallace DJ, Druzin M, Lahita RG, " 'Expert opinion' versus hard science: comment on the review by Wallace et al: Reply," Arthritis Rheum 1997; 40:1910-1911.
lll. Wallace, D., "Rethinking Somatization, Annals Intern Med 127:1132-l 133, 1997
112. Tsao BP, Cantor RM, Kalunian KC, Wallace DJ, Hahn BH, Rotter JI, The genetic basis of systemic lupus erythematosus, Proc Assoc Amer Physicians 1998; 110: 113-117.
113. Cozen L, Wallace DJ, Risk factors for avascular necrosis in systemic lupus erythematosus, J Rheumatol 1998; 25: 188.
114. Wallace DJ, A reason for the rarity of male lupus, Lupus 1998; 7: 60.
115. Lahita RG, Pisetsky DS, Wallace DJ, Lupus: High-stakes Dx, broad treatment options, Patient Care, February 28, 1998, pp. 105-123.
116. Cozen L, Wallace DJ, Avascular necrosis in systemic lupus erythematosus: Clinical associations and a 47-year perspective, Amer J Orthopedics 1998; 27:352-354.
117. Post S, Wallace DJ, A prevalence survey of lupus in Moorpark, California. Is there any evidence for a lupus cluster, J Clin Rheumatol 1998; 4: 137-140.
118. Wallace DJ, Don't dumb down lupus patient literature!, J Rheumatol 1998: 25:1650.
119. Wallace DJ, Editorial overview: Ten important topics relating to systemic lupus erythematosus and Sjogren's syndrome, Curr Opinion Rheumatol 1998; 10:397-398.
120. Wallace DJ, Goldfinger D, Pepkowitz SH, Fichman M, Metzger AL, Schroeder JO, Euler HH, Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis, J Clinical Apheresis 1998; 13: 163-166
121. Shai R, Quismorio FP Jr, Kwon OJ, Morrison J, Wallace DJ, Neuwelt CM, Brautbar C, Gauderman WJ, Jacob CO, Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families, Hum Mol Genet 1999; 8: 639-644.
122. Wallace DJ, What constitutes a fibromyalgia expert? Arthritis Care and Research 1999; 12: 82-84.
123. Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature, The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes, Arthritis Rheum 1999: 42: 599-608.
124. Linker-Israeli M, Honda M, Nand R, Mandyam R, Mengesha E, Wallace DJ, Metzger A, Beharier B, Klinenberg JR, Exogenous IL-10 and IL-4 down-regulate IL-6 production by SLE-derived PBMC, Clin Immunology 1999; 91: 6-16.
125. Wallace DJ, Lyon I, Pierre Cazenave and the first detailed modern description of lupus erythematosus, Seminars Arthritis Rheum 1999; 28: 305-313.
126. Tsao BP, Cantor RM, Grossman JM, Shen N, Theophilov NT, Wallace DJ, Arnett FC, Hartung K, Goldstein R, Kalunian KC, Hahn BH, Rotter JI, PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus, J Clin Invest 1999; 103: 1135-1140.
127. Wallace DJ, Apheresis for lupus erythematosus, Lupus 1999; 8: 174-180.
128. Wallace DJ, Systemic lupus erythematosus, Science & Medicine 1999; 6: 18-27.
129. Wallace DJ, Linker-Israeli M, It's not the same old lupus or Sjogren's any more: one hundred new insights, approaches and options since 1990, Current Opinion Rheumatol 1999; 11: 321-329.
130. Wallace DJ, Shapiro S, Panush RS, Update of fibromyalgia syndrome, Bulletin Rheum Dis 1999; 48: (no.5)
131. Wallace DJ, Advances in the management of systemic lupus erythematosus (Editorial), Saudi Med J 1999; 20: 489-490.
132. Wallace DJ, Current care for systemic lupus erythematosus, J Musculoskeletal Medicine 1999; 16: 531-539.
133. Gladman DD, Urowitz MB, Esdaile JM, Hahn BH, Klippel JH, Lahita R, Liang MH, Schur P, Petri M, Wallace D, Guidelines for referral and management of systemic lupus erythematosus in adults, Arthritis Rheum 1999; 42:1785-1786.
134. Wallace DJ, Lupus for the Non-Rheumatologist, Bulletin on the Rheumatic Diseases 1999; 48: 1-4 (n o 9)
135. Wallace DJ, What constitutes a mortality study? Comment on the article by Uramoto et al, Arthritis Rheum 1999; 42: 2021-2022.
136. Wallace DJ, Leukocytapheresis and rheumatoid arthritis: Comment on the article by Hidaka et al, Arthritis Rheum 42: 2255-2256, 1999.
137. Pachinian N, Wallace DJ, Klinenberg JR, Mycophenolate mofetil for systemic lupus erythematosus, J Clin Rheumatol 1999; 4: 374-376.
138. Wallace DJ, Weisman M, Should a war criminal be rewarded with eponymous distinction? The double life of Hans Reiter (1881-1969), J Clin Rheumatol 2000; 6: 49-54.
139. Wallace DJ, Is there a role for quinacrine (Atabrine) in the new millennium? (Editorial), Lupus 2000; 9: 81-82.
140. Hallegua DS, Wallace DJ, How accelerated atherosclerosis in SLE has changed our management of the disorder, Lupus 2000; 9: 228-231.
141. Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR, Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature, Lupus 2000; 9: 241-251.
142. Wallace DJ, Salonen E-M, Avaniss-Aghajani E, Morris R, Metzger AL, Pashinian N, Anti-telomere antibodies in systemic lupus erythematosus: a new ELISA test for anti-DNA with potential pathogenetic implications, Lupus 2000; 9:328-332.
143. Wallace DJ, Metzger AL, Neumann K, Osteoporosis--Less than expected in patients with scleroderma, J Rheumatol 2000; 7:1822-1823.
144. Hallegua DS, Wallace DJ, Gastrointestinal manifestations of systemic lupus erythematosus, Current Opinion in Rheumatology 2000; 12:379-385.
145. Linker-Israeli M, Wallace DJ, Prehn J, Michael D, Honda M, Taylor DK, Paullabr M, Fischelg N, Fraser PA, Klinenberg JR, Assocaition of IL-6 gene alleles with systemic lupus erythematosus and elevated IL-6 expression, Genes Immun 1999; 1: 45-52.
146. Tsao BP, Cantor RM, Grossman JM, Shen N, Teophilov NI, Wallace DJ, Arnett FC, Hartung K, Goldstein R, Kalunian KC, Hahn BH, Rotter JI, PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus (Reply to letters), J Clin Invest 2000; 105: 1501-1506.
147. Panush RS, Mihailescu GD, Gornisiewicz MT, Sutaria SH, Wallace DJ, Sex and arthrtis, Bulletin of the Rheumatic Diseases 2000; 49: 1-4 (no. 7).
148. Wallace DJ, Clinical and pharmacological experience with LJP-394, Exp Opin Invst drugs 2001; 10: 111-117.
149. Wallace DJ, Apheresis for lupus erythematosus--state of the art, Lupus 2001; 10: 193-196.
150. Albano SA, Wallace DJ, Managing fatigue in patients with SLE, J Musculoskel Medicine 2001; 18: 149-152.
151. Wallace DJ, Weisman MH, Comments regarding Hans Reiter’s role in Nazi Germany, J Clin Rheumatol 2001; 7: 127-130.
152. Linker-Isareli M, Elstner E, Klinenberg JR, Wallace DJ, Koeffler HP, Vitamin D3 and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC, Clinical Immunology, 99: 82-93, 2001.
153. Wallace DJ, SLE--A prospect for the 21st century: Lessons from the past, The Ryumachi 2001; 41:174.
154. Honda M, Mengesha E, Albano S, Nichols WS, Wallace DJ, Metzger A, Klinenberg JR, Linker-Israeli M, Telomere shortening and decreased replicative potential, contrasted by continued proliferation of telomerase positive CD8+CD28- T-cells in patients with systemic lupus erythematosus, Clin Immunology 20001; 99: 211-221.
155. Wallace DJ, Hallegua DS, Quality-of-life, legal-financial, and disability issues in fibromyalgia, Current Pain and Headache Reports 2001; 5: 313-319.
156. Wallace DJ, Antimalarials--the ‘real’ advance in lupus, Lupus, 2001; 10: 385-387.
157. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH, Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study, Rheumatology (Oxford), 2001; 40: 74-743.
158. Remer CF, Weisman MH, Wallace DJ, Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study, Lupus 2001; 10: 480-483.
159. Pimentel M, Chow EJ, Hallegua D, Wallace D, Lin HC, Small intestinal bacterial overgrowth: A possible association with fibromyalgia, J Musculoskeletal Pain 2001; 9: 107-113.
160. Hallegua DS, Wallace DJ, Silverman S, Bonert V, Mathur JR, Prevalence of fibromyalgia in growth hormone deficient adults, J Musculoskeletal Pain 2001: 35-42.
161. Dequet CR, Wallace DJ, Novel therapies in the treatment of systemic lupus erythematosus, Curr Opinion Invest Drugs 2001; 2: 1045-1053.
162. Wallace DJ, Clinical correlates of avascular necrosis in systemic lupus erythematosus, J Rheumatol 2001; 28: 2365.
163. Wallace DJ, Systemic lupus erythematosus, Drugs of Today 2002; 38: 256-263.
164. Wallace DJ, Management of lupus erythematosus: recent insights, Curr Opinion Rheumatol 2002: 14: 212-219.
165. Solsky MA, Wallace DJ, New therapies in systemic lupus erythematosus, Best Prac Res Clin Immunol 2002; 16: 293-312.
166. Lander SA, Wallace DJ, Weisman MH, Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE, Lupus 2002; 11: 340-347.
167. Silver DS, Wallace DJ, The management of fibromyalgia-associated syndromes, Rhem Dis Clin N Am 2002; 28: 405-417.
168. Wallace DJ, Silicone breast implants do not cause rheumatic diseases, but can they influence them?, Arthritis Rheum 2002; 46: 2545.
169. Tsao BP, Grossman JM, Riemekasten G, Strong N, Kalsi J, Wallace DJ, Chen C-J, Lau CS, Ginzler EM, Goldstein R, Kalunian KC, Harley JB, Arnett FC, Hahn BH, Cantor RM, Familiality and co-occurrence of clinical features of systemic lupus erythematosus, Arthritis Rheum 2002; 46: 2678-2685.
170. WallaceDJ, Weisman MH, The role of environmental factors in rheumatic diseases, Bulletin on the Rheumatic Diseases, 2002; 51: number 10.
171. Tsao BP, Cantor RM, Grossman JM, Kim SK, Strong N, Lau CS, Chen J-J, Shen N, Ginzler EM, Goldstein R, Kalunian KC, Arnett FC, Wallace DJ, Hahn BH, Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosus, Arthritis Rheum 2002; 46: 2928-2936.
172. Wallace DJ, Pyridostigmine for fibromyalgia: comment on the article by Paiva and a historical vignette, Arthritis Rheum 2003; 48: 277-278.
173. Wallace DJ, Weisman MH, The physician Hans Reiter as prisoner of war in Nuremberg: A contextual review of his interrogations (1945-1947), Semin Arthritis Rheum 2003; 32: 208-230.
174. Boumpas DR, Furie R, Manzi S, Ilei GG, Wallace DJ, Balow JE, Vaishnaw A, A short course of BG9588 (anti-CD 40 ligand antibody) imprives serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis, Arthritis Rheum 2003; 48: 719-727.
175. Wallace DJ, Historical Vignette: When thought leaders mislead: “Discoid lupus is not related to SLE”, J Clin Rheumatol 2003; 9:98.
176. Wallace DJ, Historical Vignette: Raynaud’s phenomenon as perceived by musculoskeletal specialists (1862-1957), J Clin Rheumatol 2003; 9:87.
177. Wallace DJ, Guest Editorial: Apheresis for rheumtic and other autoimmune conditions: Where do we stand?, Therapeutic Apheresis and Dialysis 2003; 7: 143-144.
178. Chen LX, Eberhard R, Enzenauer RJ, Horwitz HH, Luk AJ, Menicoff I, Pepmuellar PH, Queen KT, Ramanujam T, Straka PC, Svara C, Travers R, Wallace D, Watanabe W, Weiss T, Schumacher HR, A look at rheumatology in China, J Clin Rheumatol 2003; 9: 228-238.
179. Wallace DJ, Weisman MH, The use of etanercept and other tumor necrosis-alpha blockers in infertility: Its time to get serious, J Rheumatol 2003; 30: 1897-1899.
180. Strand V, Aranow C, Cardiel MH, Alarcon-Segovia A, Furie R, SherrerY, Tumlin J, Wallace DJ, Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo, Lupus 2003; 12: 677-686.
181. Wallace DJ, Advances in the management of systemic lupus erythematosus, Bulletin on the Rheumatic Diseases, 2004; 51: (no 11) 1-7.
182. Pimentel M, Wallace D, Hallegua D, Chow E, Kong Y, Park S, Lin HC, A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing, Ann Rheum Dis 2004; 63: 450-452.
183. Wallace DJ, To fibromyalgia nihilists: Stop pontificating and test your hypothesis (Editorial), J Rheumatol 2004; 31: 632.
184. Wallace DJ, Tumlin JA, LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus, Lupus 2004; 13: 323-327.
185. Horizon A, Wallace D, Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus, Expert Opinion in Drug Safety 2004; 3: 273-278.
186. Wallace DJ, Fever therapy for arthritis, J Clinical Rheumatology 2004; 10:228.
187. Wallace DJ, Hallegua DS, Fibromyalgia: The gastrointestinal link, Curr Pain Headache Rep 2004; 8: 364-368.
188. Wallace DJ, Railway spine, posttraumatic fibromyalgia, and junk science in the courtroom (ca. 1975), J Clinical Rheumatology 2004; 10: 284.
189. Nichol MB, Shi S, Knight TK, Wallace DJ, Weisman MH, Eligibility, utilization and costs in a California Medicaid lupus population, Arthritis Care Res 2004; 51: 996-1003.
190. Wallace DJ, The end of an era: A commentary on the demise of the Bulletin on Rheumatic Diseases (1950-2004), J Clin Rheumatol 2004; 10: 360.
191. Wallace DJ, Whiplash. A case of regretting being responsible for naming a condition, J Clin Rheumatol 2005; 11: 61.
192. Wallace DJ, Rapid prevention of vertebral fractures associated with osteoporosis. Orthopedics. 2005 Mar;28(3):291-8.
193. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J, Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005 ;52:1227-36.
194. Hallegua DS, Wallace DJ, Managing fibromyalgia: A comprehensive approach, J Musculoskeletal Medicine 2005; 22: 382-390.
195. Wu H, Cantor RM, Graham DSC, Lingren CM, Farwell L, de Jager PL, Bottini N, Grossman JN, Wallace DJ, Hahn BH, Julkunen H, Hebert LA, Rovin BH, Birmingham DJ, Rioux JD, Yu CY, Kere J, Vyse TJ, Tsao BP, Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families. Increased T allele frequency in systemic lupus patients with autoimmune thyroid disease, Arthritis Rheum 2005; 52: 2396-2402.
196. Wallace DJ, Clauw DJ, Hallegua DS, Adressing behavioral problems in fibromyalgia, J Musculoskeletal Medicine 2005; 22: 562-579.
197. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB, Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis, N Engl J Med 2005; 353: 2219-2228.
198. Chiou C-F, Weisman M, Sherbourne CD, Reyes C, Dylan M, Ofman J, Wallace DJ, Mizutani W, Suarez-Almazor ME, Measuring preference weights for American College of Rheumatology response criteria for patients with rheumatoid arthritis, Arthritis Rheum 2005; 32: 2326-2329.
199. Lu C-S, Horizon AA, Hwang K-K, FitzGerald J, Lin W-S, Hahn BH, Wallace DJ, Metzger AL, Weisman MH, Chen PP, Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome, Arthritis Rheum 2005; 52: 4018-4027.
200. Vina ER, Fang AJ. Wallace DJ, Weisman MH, Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome, Seminars Arthritis Rheum 205; 35: 175-184.
201. Wallace DJ, Is there a role for cytokine based therapies in fibromyalgia?, Current Pharmaceutical Design 2006; 12: 17-22.
202. Liang MH, Schur PH, Fortin P, St Clair EW, Balow JE, Costenbader K, Crofford L, Pablo PD, Dooley MA, Finckh A, Gordon CP, Lundberg IE, Meyrier A, Nived O, Ponticelli C, Schneider MK, Singh A, Wallace DJ, The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials, Arthritis Rheum 2006; 54: 421-432.
203. Weisman MH, Furst DE, Park GS, Kremer JM, Smith KM, Wallace DJ, Caldwell JR, Dervieux T, Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis, Arthritis Rheum 2006; 54: 607-612.
204. Wallace DJ, Is mycophenolate mofetil a safe and effective treatment for patients with systemic lupus erythematosus?, Nature Clinical Practice Rheumatology 2006; 2:2-3.
205. Wallace DJ, UCTD and unfinished business (Editorial), Current Rheumatology Reviews, 2006; 2: i
206. Wallace DJ, New methods for antinuclear antibody testing: does it cut costs and corners without jeapordizing clinical reliability?, Nature Clinical Practice Rheumatology 2006; 2: 410-411.
207. Mc Mahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, Badsha H, Kalunian K, Charles C, Navab M, Fogelman AM, Hahn BH, Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis, Arthritis Rheum 2006; 54: 2541-2549.
208. Wallace DJ, Scleroderma associated inflammatory arthritis: Common and painful, but ignored by researchers, Current Rheumatology Reviews 2006; 2: 309.
209. Wallace DJ, Antimalarial drugs in the treatment of rheumatic diseases, UpToDate, v14.3, September 11, 2006.
210. Wallace DJ, What’s new in the management of lupus since 2000?, J Clin Rheumatol 2006; 12: 307-31.
211. Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, Isenberg D, Alarcon GS, Clarke A, Bernatsky S, Merrill JT, Petri M, Dooley MA, Gladman D, Fortin PR, Steinsson K, Bruce I, Manzi S, Khamashta M, Zoma A, Aranow C, Ginzler E, Van Vollenhoven R, Font J, Sturfelt G, Nived O, Ramsey-Goldman R, Kalunian K, Douglas J, Thompson K, Farewell V, Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus, Arthritis Rheum 2007; 56: 265-273.
212. Spiegel J, Ishimori ML, Wallace DJ, Weisman MH, The lowest surviving birth weight reported in a systemic lupus erythematosus patient: a review of the literature, Lupus 2007; 16: 52-55.
213. Wallace DJ, Editorial: To immunize or not?, Current Rheumatology Reports 2007; 3:1.
214. Panush RS, Wallace DJ, Dorff EN, Engleman EP, Retraction of the suggestion to use the term “Reiter’s syndrome” sixty-five years later: the legace of Reiter, a war criminal, should not be eponymic honor but rather condemnation, Arthritis Rheum 2007; 56: 693-700.
215. Wu H, Boackle SA, Hanvivadhanaku P, Ulgiati D, Grossman JM, Lee Y, Shen N, Abraham LJ, Mercer TR, Park E, Hebert LA, Rovin BH, Birmingham DJ, Chang D, Chen CJ, McCurdy D, Badsha HM, Thong BYH, Chng HH, Arnett FC, Wallace DJ, Yu CY, Hahn BH, Cantor RM, Tsao BP. Association of a common complement receptor 2 haplotype with increased risk of SLE. Proc. Natl. Acad. Sci 2007; 104: 3961-3966.
216. Wallace DJ, Editorial: At last..A viable biomedical model for fibromyalgia, Current Rheumatology Reviews, 2007; 3: 93
217. Moder KG, Wener MH, Weisman MH, Ishimori ML, Wallace DJ, Buckeridge DL, Homberger HL, Measurement of antinuclear antibodies by multiplex immunoassay: A prospective, multicenter clinical evaluation, J Rheumatol 2007; 34: 978-986.
218. Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Wallace DJ, Crues J, Khanna D, Eckel G, Yeilding N, Callegari P, Visvanathan S, Rojas J, Hegedus R, George L, Mamun K, Gilmer K, Troum O, Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study, Ann Rheum Dis 2007; 66: 893-899.
219. Wallace DJ, Future management of systemic lupus erythematosus, Future Medicine 2007; 2: 229-231. 220. Ishimori M, Pressman BD, Wallace DJ, Weisman MH, Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE?, Lupus 2007; 16: 436-443.
221. Wallace DJ, Why is Current Rheumatology Reviews different than other rheumatology journals? Curr Rheum Reviews 2007; 3:171.
222. Wallace DJ, Biologic and innovative therapies for systemic lupus erythematosus, Rheumatic Disease Clinics Updates; 2007; 2: 2-12.
223. Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Wallace DJ, Crues J, Khana D, Eckel G, Yeilding N, Callegari P, Visvanathan S, Rojas J, Hegedus R, George L, Mamun K, Gilmer K, Troum O, Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: a pilot study, Ann Rheum Dis 2007; 66: 893-899.
224. Urowitz MB, Gladman D, Ibanez D, Fortin P, SanchezGuerrero J, Bae S, Clarke A, Bernatsky S, Gordon C, Hanly J, Wallace D, Isenberg D, Ginzler E, Merrill J, Alarcon G, Steinsson K, Petri M, Dooley MA, Bruce I, Manzi S, Khamashta M, Ramsey-Goldman R, Zoma A, Sturfelt G, Nived O, Maddison P, Font J, van Vollenhoven R, Aranow C, Kalunian K, Stoll T, Buyon J, Clinical manifestations and coronary artery risk factors at diagnosis and systemic lupus erythematosus: data from an international conception group, Lupus 2007; 16: 731-735.
225. Wallace DJ, Neuro-Behcet’s syndrome: Finally, New Insights, Curr Rheumatology Reviews 2007; 3: 242.
226. Horizon AA, Wallace DJ, Lupus case studies shed light on key challenges, J Musculoskeletal Medicine 2007; 24; 454-460.
227. Dall’Era, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D, Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus. Results of a multicenter, Phase Ib, double-blind, placebo-controlled, dose-escalating trial, Arthritis Rheum 2007; 56: 4142-4150.
228. Wallace DJ, Gotto J, Hypothesis: Bipolar illness with complaints of chronic musculoskeletal pain is a form of pseudofibromyalgia, Semin Arthritis Rheum 2008;37: 256-259.
229. Wallace DJ, Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox, Lupus 2008; 17: 91-92.
230. Urowitz MB, Gladman D, Ibanez D, Fortin P, Sanchez-Guererro J, Bae S, Clarke A, Bernatsky S, Gordon C, Hanly J, Wallace D, Isenberg D, Ginzler E, Merrill J, Alarcon GS, Steinsson K, Petri M, Dooley MA, Bruce I, Manzi S, Khamashta M, Ramsey-Goldman R, Zoma A, Sturfelt G, Nived O, Maddison P, Font J, van Vollenhoven R, Aranow C, Kalunian K, Stoll T, Accumulation of coronary artery disease risk factors over three years: Data from an International Inception Cohort, Arthritis Care Research 2008; 59: 176-180. 231. Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC, Isenberg D, Dooley MA, Clarke A, Bernatsky S, Gladman D, Fortin PR, Manzi S, Steinsson K, Bruce IN, Ginzler E, Aranow C, Wallace DJ, Ramsey-Goldman R, van Vollenhoven R, Sturfelt G, Nived O, Sanchez-Guerrero J, Alarcón GS, Petri M, Khamashta M, Zoma A, Font J, Kalunian K, Douglas J, Qi Q, Thompson K, Merrill JT; Systemic Lupus International Collaborating Clinics. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: Results from an international inception cohort study. Arthritis Rheum. 2008 Feb 29;58:843-853 232. Driver CB, Wallace DJ, Lee JC, Forbess CJ, Pourrabbani S, Minoshima S, Waxman AD, Weisman MH. Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2008 Feb 29;59:332-337. 233. Gordon C, Wallace DJ, Shinada S, Kalunian KC, Forbess L, Braunstein GD, Weisman MH, Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.Rheumatology (Oxford). 2008;47:334-8.
234. Venuturupalli RS, Wallace DJ, Lupus Nephritis—An Update, US Renal Disease 2007; Touch Briefings, pp. 63-66, 2008. 235. Hallegua DS, Wallace DJ, Fighting fibromyalgia: Five key issues, J Musculoskeletal Medicine 2008; 25: 172-184.
236. Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, Isenberg D, Alarcon GS, Merrill JT, Clarke A, Bernatsky S, et al, Short term outcome of neuropsychiatric events in systemic lupus upon enrollment into an international inception cohort study, Arthritis Rheum 2008; 59: 721-729.
237. Antoni C, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmeister GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman DD, Manger B, Wassenberg S, Weier R, Walalce DJ, Weisman MH, Kalden JR, Smolen JS, Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: Findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial IMPACT), J Rheumatol 2008; 35: 869-876.
238. M Petri, N Kasitanon, SS Lee, K Link, L Magder, SC Bae, JG Hanly, DA Isenberg, GS, Nived O, Sturfelt, van Vollenhoven R, DJ Wallace, Alarcon, D Adu, CA Casado, SR Bernatsky, IN Bruce, AE Clarke, G Contreras, DM Fine, DD Gladman, C Gordon, KC Kalunian, MP Madaio, BH Rovin, J Sanchez-Guererro, K Steinsson, C Aranow, JE Balow, JP Buyon, EM Ginzler, MA Khamashta, MB Urowitz, MA Dooley, JT Merrill, RR Goldman, J Fnt, J Tumlin, T Stoll, A Zoma, Systemic Lupus International Collaborative Clinics Renal Activity/Response Exercise. Development of a Renal Activity Score and Renal Response Index, Arthritis Rheum 2008; 58: 1784-1788.
239. M Petri, N Kasitanon, SS Lee, K Link, L Magder, SC Bae, JG Hanly, DA Isenberg, GS, Nived O, Sturfelt, van Vollenhoven R, DJ Wallace, Alarcon, D Adu, CA Casado, SR Bernatsky, IN Bruce, AE Clarke, G Contreras, DM Fine, DD Gladman, C Gordon, KC Kalunian, MP Madaio, BH Rovin, J Sanchez-Guererro, K Steinsson, C Aranow, JE Balow, JP Buyon, EM Ginzler, MA Khamashta, MB Urowitz, MA Dooley, JT Merrill, RR Goldman, J Font, J Tumlin, T Stoll, A Zoma, Systemic Lupus International Collaborative Clinics Renal Activity/Response Exercise. Comparison of Agreement in Rating Renal Response, Arthritis Rheum 2008; 58: 1789-1795
240. Wallace DJ, Additional components in measuring fatigue in patients with systemic lupus erythematosus: comment on the article by the Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue, Arthritis Rheum 2008; 59: 1049.
241. Wallace DJ, Are there models for predicting accelerated atherogenesis in systemic lupus erythematosus?, Nature Clinical Practice Rheumatology 2008; 4:
242. Wallace DJ, New European recommendations (European League Against Rheumatism 2008) for the management of lupus erythematosus: American perspective, Polskie Archiwum Medycyny Wewnetrznej 2008.
243. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD, Abetimus sodium for renal flare in systemic lupus erythematosus, Arthritis Rheum 2008; 58: 240-2480.
244. Sanchez-Guerrero J, Fragoso-Loyo HE, Neuwelt M, Wallace DJ, Ginzler EM, Sherrer YRS, Mc Ilwain HH, Freeman PG, Aranow C, Petri MA, Deodhar AA, Blanton E, Manzi S, Kavanaugh A, Lisse JR, Ramsay-goldman R, Mc Kay JD, Kivitz AJ, Mease PJ, Winkler AF, Kal LE, Lee AH, Furie RA, Strand CV, Lou L, Ahmet M, Quarles B, Schwartz KE, Effects of Prasterone on bone mineral densit in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy, J Rheumatol 2008; 35: 1567-1575.
245. Wallace DJ, New European recommendations (European League Against Rheumatism 2008) for the management of lupus erythematosus: American perspective, Polskie Archiwum Medycyny Wewnetrznej, 2008; 118: 402-403.
246. Wallace DJ, Celebrex for lupus, Arthritis Rheum 2008; 58: 2923
247. Wallace DJ, Are there models for predicting accelerated atherogenesis in systemic lupus erythematosus?, Nature Clinical Practice Rheumatology 2008; 4: 450-451.
248. Petri M, Naqibuddin ZM, Carlson KC, Sampedro M, Wallace DJ, Weisman MH, Holliday SL, Padilla PA, Brey RL, Cognitive function in a systemic lupus erythematosus inception cohort, J Rheumatology 2008; 35: 1776-1781.
249. Petri M, Naqibuddin M. Carson KA, Wallace DJ, Weisman MH, Hollilday SL, Sampedro M, Narayana S, Fox PT, Franklin C, Padilla PA, Brey RL, Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus, J Rheumatoloy 2008; 35: 2348-2354.
250. Up to Date (E publication) chapters: Antimalarial drugs in the treatment of rheumatic disease, Differential diagnosis of systemic lupus erythematosus (with Peter Schur) for 2007, 2008 and 2009 editions.
251. Up to Date (E publication) chapters: Antimalarial drugs in the treatment of rheumatic disease, Differential diagnosis of systemic lupus erythematosus (with Peter Schur) for 2007, 2008 and 2009 editions.
252. Askanase AD, Wallace DJ, Weisman MH, Tseng CE, Bernstein L, Belmont M, Seidman E, Ishimori M, Izmirly PM, Buyon JP, Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus, J Rheumatol 2009; 36: 89-95.
253. Wallace DJ, New therapies in systemic lupus erythematosus---trials, troubles and tribulations---working towards a solution: part 2---the politically incorrect version, Lupus 2009; 18: 101-103.
254. Hanly JG, Urowitz MB, Bae SC, Gordon C, Wallace DJ, Clarke A, Bernatsky S, Isenberg D, Anisur A, Alarcon GS, Gladman DD, Fortin PR, Sanchez-Guererro J, RomeroDiaz J, Merrill JT, Ginzler E, Bruce IN, van Vollenhoven R, Nived O, Sturfelt G, Aranow A, Kalunian K, Ramos-Casals M, Zoma A, Douglas J, Thompson K, Farewel V, Prospective analysis of neuropsychiatric events in an international disese inception cohort of SLE patients, Annals Rheum Dis 2009;
255. Posalski JD, Ishimori M, Wallace DJ, Weisman MH, Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years, Lupus 2009; 18:516-521.
256. Mc Mahon M, Grossman J, Skaggs B, FitzGerald J, Sahakian L, Ragavendra N, Charles-Shoeman C, Watson K, Wong WK, Volkman E, chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH, Dysfunctional proinflammatory high-density lipopoteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus, Arthritis Rheum 2009; 60: 2428-2437.
257. Belouski SS, Wallace D, Weisman M, Ishimori M, Hendricks L, Zack D, Vincent M, Rasmussen E, Ferbas J, Chung J, Sample stability and variability of B-cell subsets in blood from healthy subjects and patients with systemic lupus erythematosus, Cytometry Part B: Clinical Cytometry; E Pub Aug 10, 2009; 2009; 00B:
258. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW, Novel evidence-based systemic lupus erythematosus responder index, Arthritis Rheum 2009; 61: 1143-1151.
259. Wallace DJ, Stohl W, Furie RA, Lisse JR, Mc Kay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, Mc Cune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW, A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus, Arthritis Rheum 2009; 61: 1168-1178.
260. Lu LJ, Wallace D, Ishimori M, Scofield R, Weisman M, Male systemic lupus erythematosus: a review of sex disparities in this disease; Lupus 2009; 19: 119-129.
261. Merill JT, Neuwelt CM, Wallace DJ, ShanahanJC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG, Efficacy and safety of rituximab in moderately-to-severaly active systemic lupus erythematosus, Arthritis Rheum 2010; 62: 222-233.
262. Volkmann ER, Grossman JM, Sahakian LJ, Skaggs BJ, FitzGerald J, Ragavendra N, Charles-Schoeman C, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH, Mc Mahon M, Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus, Arthritis Care Research 2010; 62: 258-265.
263. Robinson D Jr, Aguilar D, Schoenwetter M, Dubois R, Russak S, Ramsey-Goldman r, Navarra S, Hus B, Revicki D, Cella D, Rapaport MH, Renahan K, Ress R, Wallace D, Weisman M, Impact of systemic lupus erythematosus on health, family and work: The patient perspective, Arthritis Rheum 2010; 62: 266-273.
264. Lu L-J, Wallace DJ, Navarra SV, Weisman MH, Lupus registries: Evolution and challenges, Seminars Arthritis Rheum 2010: 39: 224-245.
265. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, Clarke A, Bernasky S, Isenberg D, Rahman A, Alarcon GS, Gladman DD, Fortin PR, Sanchez Guererro J, Romero Diaz J, Merrill JT, Ginzler E, Bruce IN, Steinsson K, Khamashta M, Petri M, Manzi S, Dooley MA, Ramsey-Goldman R, van Volenhoven R, Nived O, Sturfelt G, Aranow C, Kalunian K, Ramos-Casals M, Zoma A, Douglas J, Thompson K, Varewell, Prosepective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus, Annals Rheum Dis 2010; 69: 529-535.
266. Belouski SS, Wallace D, Weisman M, Ishimori M, Hendricks L, Zack D, Vincent M, Rasmussen E, Ferbas J, Chung J, Sample stability and variability of B-cell subsets in blood from helthy subjects and patients with systemic lupus erythematosus, Cytometry Part B (Clinical Cytometry) 2010, 788: 49-58.
267. Wallace DJ, Telomere diseases, New Engl J Med 2010; 362:1150.
268. Wallace DJ, Furie RA, Freimuth WW, Reply to letter to the editor, Arthritis Care and Research 2010; 62: 582.
269. Urowitz MB, Gladman D, Ibanez D, Bae SC, Sanchez-guererro, Gordon C, Clarke A, Bernatsky S, Fortin PR, Hanly JG, Wallace DJ, Isenberg D, Rahman A, Alarcon GS, Merrill JT, Ginzler E, Khamashta M, Nived O, Sturfelt G, Bruce IN, Seinsson K, Manzi S, Ramsey Goldman R, Dooley MA, Zoma A, Kalunian K, Ramos M, Van Vollenhoven R, Aranow C, Stoll T, Petri M, Maddison P, Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus, Arthritis Care Res 2010; 62: 881-887.
270. Merrill JT, Burgos-Varagas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Raphupathi K, Peng LT, Kinasczuk M, Nash P, The efficacy and safety of abatacept in patients with non-life-threatening manifestations of SLE: Results of a 12-month exploratory study, Arthritis Rheum 2010; 62: 3077-3087.
271. Osstergaard M, Baslund B, Ribby W, Rojkovich B, Jorgenson C, Dawes PT, Wiell C, Wallace DJ, Tamer SC, Kastberg H, Petersen J, Sierakowski S, Ofatumumab, a human anti CD-20 monoclonal antibody for treatment of rheumatoid arthritis patients with an inadequate response to one or more DMARDs: results of a doub-blind, randomized, placebo-controlled, Phase I/II study, Arthritis Rheum 2010; 62: 2227-2238.
272. Petri M, Naqibuddin M, Carson KA, Wallace DJ, Weisman MH, Holliday SL, Sampedro M, Padilla PA, Brey RL, Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus, J Rheumatol. 2010; 37: 2032-2038.
273. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P, he efficacy and safety of abatacept in patients with non-life-threatening manifestations of SLE: Results of A 12-month exploratory study., Arthritis Rheum. 2010: 62: 3077-3087.
274. Isenberg DA, Allene E, Farewell V, d’Cruz D, Alarson GS, Aranow A, Bruce IN, Dooley MA, Fortin PR, Ginzler EM, Gladman DD, Hanly JG, Inanc M, Kalunian K, Khamashta M, Merrill JT, Nived O, Petri M, Ramsey-Goldman R, Sturfelt G, Urowitz M, Wallace DJ, Gordon C, Rahman A, An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SLEDAI, Annals Rheum Dis 2010;
275. Wallace DJ, Thrombovascular events in systemic lupus erythematosus: comment on the article by Jung et al, Arthritis Rheum 2010; 68: 2823.
276. Hallegua DS, Wallace DJ, Fighting fibromyalgia: Five issues, J Musculoskeletal Medicine, 2010; 27: S3-9.
277. Wallace DJ, Clauw DJ, Hallegua DS, Addressing behavioral abnormalities, J Musculoskeletal Medicine 2010; 27: S21-27.
278. Carr FN, Nicassio PM, Ishimori ML, Moldovan I, Katsaros E, Torralba K, Shinada S, Cooray D, Wallace DJ, Finck S, Jolly M, Wilson AL, Weisman MH, Depression predicts self-reported disease activity in systemic lupus erythematosus (SLE), Lupus 2010;
279. Ostergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, Wiell C, Wallace DJ, Tamer SC, Kastberg H, Petersen J, Sierakowski S, Reduced frequency and severity of infusion-related adverse events after change in ofatumumab infusion regimen—Reply to comment by Abeles, Arthritis Rheum 2010;
280. Rasmussen A, Sevier S, Kelly JA, Glenn SB, Aberle T, Cooney CM, Grether A, James E, Ning J, Tesiram J, Morrisey J, Powe T, Drexel M, Daniel W, Namjou B, Ojwang JO, Nguyen KL, Cavett JW, Te JL, James JA, Scofield RH, Moser K, Gilkeson GS, Kamen DL, Carson CW, Quintero-Del-Rio AI, Ballesteros MD, Punaro MG, Karp DR, Wallace DJ, Weisman M, Merrill JT, Rivera R, Petri MA, Albert DA, Espinoza LR, Utset TO, Shaver TS, Arthur E, Anaya JM, Bruner GR, Harley JB, The Lupus Family Registry and Repository, Rheumatology (Oxford). 2010;
281. Wallace DJ, Advances in drug therapy for systemic lupus erythematosus, BMC Medicine 2010; 8:77, 1-19.
278. Carr FN, Nicassio PM, Ishimori ML, Moldovan I, Katsaros E, Torralba K, Shinada S, Cooray D, Wallace DJ, Finck S, Jolly M, Wilson AL, Weisman MH, Depression predicts self-reported disease activity in systemic lupus erythematosus (SLE), Lupus 2011; 20: 80-84.
279. Ostergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, Wiell C, Wallace DJ, Tamer SC, Kastberg H, Petersen J, Sierakowski S, Reduced frequency and severity of infusion-related adverse events after change in ofatumumab infusion regimen—Reply to comment by Abeles, Arthritis Rheum 2011; 63: 305-310.
280. Rasmussen A, Sevier S, Kelly JA, Glenn SB, Aberle T, Cooney CM, Grether A, James E, Ning J, Tesiram J, Morrisey J, Powe T, Drexel M, Daniel W, Namjou B, Ojwang JO, Nguyen KL, Cavett JW, Te JL, James JA, Scofield RH, Moser K, Gilkeson GS, Kamen DL, Carson CW, Quintero-Del-Rio AI, Ballesteros MD, Punaro MG, Karp DR, Wallace DJ, Weisman M, Merrill JT, Rivera R, Petri MA, Albert DA, Espinoza LR, Utset TO, Shaver TS, Arthur E, Anaya JM, Bruner GR, Harley JB, The Lupus Family Registry and Repository, Rheumatology (Oxford). 2010;
281. Wallace DJ, Advances in drug therapy for systemic lupus erythematosus, BMC Medicine 2010; 8:77, 1-19.
282. Ishimori, M.L, Martin, R., Berman, D.S., Goykhman, P., Shaw, L.J., Shufelt, C., Slomka, P.J., Thomson, L.E.J., Schapira, J., Yang, Y., Wallace, D.J., Weisman, M.H., Bairey Merz, N. Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. J Am Coll Cardiol Img 2011;4(1):27-33.
283.Mundwiler ML, Maranian P, Brown DH, Silverman JM, Wallace D, Khanna D, Louie J, Furst DE, Weisman MH., The utility of
284. Ippolito A, Wallace DJ, Gladman D, Fortin P, Urowitz M, Werth V, Costner M, Gordon C, Alarcón G, Ramsey-Goldman R, Maddison P, Clarke A, Bernatsky S, Manzi S, Bae SC, Merrill J, Ginzler E, Hanly J, Nived O, Sturfelt G, Sanchez-Guerrero J, Bruce I, Aranow C, Isenberg D, Zoma A, Magder L, Buyon J, Kalunian K, Dooley M, Steinsson K, Vollenhoven R, Stoll T, Weisman M, Petri M., Autoantibodies in systemic lupus erythematotosus: Comparison of historical and current assessment of seropositivity, Lupus 2011; 20: 250-255.
285.Hanly JG, Urowitz MB, Jackson D, Bae SC, Gordon C, Wallace DJ, Clarke A, Bernatsky S, Vasudevan A, Isenberg D, Rahman A, Sanchez-Guerrero J, Romero-Diaz J, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Steinsson K, Khamashta M, Alarcón GS, Fessler B, Petri M, Manzi S, Nived O, Sturfelt G, Ramsey-Goldman R, Dooley MA, Aranow C, Van Vollenhoven R, Ramos-Casals M, Zoma A, Kalunian K, Farewell V, Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus, Ann Rheum Dis 2011; 70: 1726-1732.
286. Firooz N, Albert DA, Wallace DJ, Ishimori M, Berel D, Weisman MH, High sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus, Lupus 2011;20: 588-597.
287. Wallace DJ, Book Review: Understanding Hughes’ Syndrome. Case studies for patients, J Rheum 2011; 38:787.
288. Hanly JG, Urowitz MB, Jackson D, Bae SC, Gordon C, Wallace DJ, Clarke A, Bernatsky S, Vasudvan A, Isenberg D, Rahman A, Sanchez-Guerrero J, Romero-Diaz J, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Steinsson K, Khamashta M, Alarcon GS, Fessler B, Petri M, Manzi S, Nived O, Sturfelt G, Ramsey-Goldman R, Dooley MA, Aranow C, van Vollenhoven R, Ramos-Casals M, Zoma A, Kalunian K, Farwell V, SF-36 summary and subscale scores are relaiable outcomes of neuropsychiatric events in systemic lupus erythematosus, Ann Rheum Dis 2011: 70: 961-967.
289. Mc Mahon M, Skaggs BJ, Sahakian L, Grossman J, FitzGerald J, Ragavendra N, Charles-Schoeman C, Chernishof M, Gorn A, Witztum JL, Wong WK, Weisman M, Wallace DJ, La Cava A, Hahn BH, High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus, and are associated with inflammatory oxidixed lipids, Ann Rheum Dis doi:10.1136/ard 2010.142737 2011: 70: 1619-1624.
290. Vinet E, Clarke AE, Gordon C, Urowitz M, Hanly JG, Pineau CA, Isenberg D, Rahman A, Wallace D, Alarcon GS, Bruce I, Petri M, Dooley MA, Kalunian K, Maddison P, Aranow C, von Vollenhoven R, Bernatsky S, Decreased live births in women with systemic lupus erythematosus, Arthritis Care Research 2011; 63: 1068-1072.
291. Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B, Safety profile and clinical activity of sifalumumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomized study, Annals Rhem Dis ; 2011; 70: 1905-1913.
292. Bagheri S, Wallace DJ, Prescribing trends for targeted therapies in rheumatoid arthritis among rheumatologists in Southern California (2008-2010), Arthritis Rheum 2011; 63: 3641.
293. Moldovan I, Katsaros E, Carr FN, Cooray D, Torralba K, Shinada S, Ishimori ML, Jolly M, Wallace DJ, Weisman MH, Nicassio PM, The patient reported outcomes in Lupus (PATROL) study: role of depression in health-related quality of life in a southern California lupus cohort, Lupus 2011; 20: 1285-1292.
294. Ramage AE, Fox PT, Brey RL, Narayana S, Cykowski MD, Naqibuddin M, Sampedro M, Holliday SL, Franklin C, Wallace DJ, Weisman MH, Petri M, Neuroimaging of white matter inflammation in newly diagnosed systemic lupus erythematosus, Arthritis Rheum 2011; 63: 3048-3057.
295. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, Sanchez-guererro J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Freimuth W, van Vollenhoven R, A Phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, Arthritis Rheum 2011; 63: 3918-3930.
296. Jolly M, Pickard AS, Sequeira W, Wallace DJ, Solem CT, Mikolaitis RA, Fogg L, Weisman MH, Block JA, Cash TF, A brief assessment tool for body image in systemic lupus erythematosus, Body Image. 2011 Dec 7.
297. Dillon SP, Kurien BT, Li S, Bruner GR, Harley JB, Gaffney PM, Wallace DJ, Weisman MH, Scofield RH, Sex chromosome aneuploidies among men with systemic lupus erythematosus, J Autoimmun 2011;
298. Ramage AE, Fox PT, Brey RL, Narayana S, Cykowski MD, Naqibuddin M, Sampedro M, Holliday SL, Franklin C, Wallace DJ, Weisman MH, Petri M, Neuroimaging of white matter inflammation in newly diagnosed systemic lupus erythematosus, Arthritis Rheum 2011; 63: 3048-3057.
299. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, Sanchez-Guererro J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Freimuth W, van Vollenhoven R, A Phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, Arthritis Rheum 2011; 63: 3918-3930.
300. Jolly M, Pickard AS, Sequeira W, Wallace DJ, Solem CT, Mikolaitis RA, Fogg L, Weisman MH, Block JA, Cash TF, A brief assessment tool for body image in systemic lupus erythematosus, Body Image. 2012; 9: 279-284.
301. Dillon SP, Kurien BT, Li S, Bruner GR, Harley JB, Gaffney PM, Wallace DJ, Weisman MH, Scofield RH, Sex chromosome aneuploidies among men with systemic lupus erythematosus, J Autoimmun 2011;
302. Urowitz MB, Gladman DD, Ibanez D, Fortin PR, Bae SC, Gordon C, Clarke A, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Sanchez-Guererro, Wallace DJ, Ginzler E, Alarson GS, Merrill JT, Bruce IN, Sturfelt G, Nived D, Steinsson K, Khamashta M, Petri M, Manzi S, Ramsey-Goldman R, Dooley MA, van Vollenhoven R, Ramos M, Stoll T, Zoma A, Kalunian K, Aranow C, Evolution of disease burden over five years in a multicenter inception lupus erythematosus cohort, Arthritis Care Res 2012; 64: 132-137.
303. Wallace DJ, A guide to successfully treating patients with SLE, Medscape Rheumatology (SF 75820.1)
304. Goykhman P, Mehta PK, Minissian M, Thompson LEJ, Berman DS, Ishimori M, Wallace DJ, Weisman MH, Shufelt CL, Bairey Merz N, Subendocardial ischemia and systemic lupus erythematosus detected by cardiac magnetic resonance imaging, J Rheumatol 2012; 39: 448-450.
305. van Vollenhoven RF, Jacobsen S, Wallace D, Hanly JG, Petri M, Isenberg DA, Clarke AE, Pineau CA, Bernatsky S, Simard JF, Bae S-C, Ramos-Casals M, Diaz-Ligares C, Ruiz-Irastorza G, Martinez-Berriotxoa A, Garcia-Hernandez FJ, Castilo-Palma MJ, Saez L, Callejas JL, Rascon J, de Ramon E, Ayala-Gutierrez MM, Camps M, Mild M, Inanc M, Artim-Eisen B, Ramsay-Goldman R, Peschken CA, Squartrito D, Emmi L, Kovacs L, Doria A, Skekanecz Z, Ferraccioli G, Gremese E, Sato EI, Biologics use in SLE in 23 centers—data from the international registry for biologics in SLE, Annals Rheum Dis 2012; 71:
306. Hanly JA, Urowitz MB, Su L, Gordon C, Bae S-C, Sanchez-Guererro J, Romero-Diaz J, Wallace DJ, Clarke AE, Ginzler EM, Merrill JT, Isenberg DA, Rahman A, Petri M, Fortin PR, Gladman DD, Bruce IN, Steinsson K, Dooley MA, Khamashta MA, Alarcon GS, Fessler BJ, Ramsey-Goldman R, Manzi S, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Theriault C, Thompson K, Farewell V, Seizure disorders in systemic lupus erythematosus: Results from an international, prospective, inception cohort, Annals Rheum Dis 2012: 71: 1502-1509.
307. Jolly M, Pickard AS, Block JA, Kumar RB, Mikolaitis RA, Wilke CT, Rodby RA, Fogg L, Sequeira W, Utset TO, Cash TE, Moldovan J, Kalastaros E, Nicassio P, Ishimori ML, Kosinsky M, Merrill JT, Weisman MH, Wallace DJ, Disease-specific patient reported outcome tools for systemic lupus erythematosus, Seminars Arth Rheum 2012; 42: 56-65.
308. Hahn BH, Mc Machon MA, Wilkinson A, Wallace WD, Daikh D, Fitzgerald JD, Karpouzas GA, Merrill JA, Wallace DJ, Yazdany Y, Ramsay-Goldman R, Singh K, Khalighi M, Choi SI, Googia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM, American College of Rheumatology Guidelines for Screening, Treatment and Management of Lupus Nephritis, Arthritis Care Res 2012; 64: 797-808.
309. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsay-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kallunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, Vanvollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, Mc Gwin G Jr, Magder Ls, Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus, Arthritis Rheum 2012; 64: 2677-2686.
310. Wang FF, Zhu LA, Zou YQ, Zheng H, Wilson A, Yang CD, Shen N, Wallace DJ, Weisman MH, Chen SL, Lu LJ, New insights into the role and mechanism of macrophage migration inhibitiory factor in steroid-resistant patients with systemic lupus erythematosus, Arthritis Res Ther 2012; May 14: R103.
311. Merrill JT, Ginzler EM, Wallace DJ, Mc Kay JD, Lisse JR, Aranow C, Wellborne FR, Burnette M, Condemi J, Zhong ZH, Pindeda L, Klein, Freimuth WW, Long-term safety of belimumab plus standard therapy in patients with systemic lupus erythematosus, Arthritis Rheum 2012
312. Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, Mc Cune WY, Tegzova D, Mc Kay JD, Avila-Armengol HE, Utset TO, Zhong ZJ, Freimuth WW, Migone TS, Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal and tetanus vaccines in patiens with systemic lupus erythematosus in the BlISS-76 trial, J Rheumatol 2012; 39:1632-1640.
313. Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR, New insights into mechanisms of therapeutic effects of antimalarial agents in SLE, Nat Rev Rheumatol 2012; 8: 522-533.
314. Mc Bride JM, Jiang J, Abbas A, Morimoto A, Li J, Maciuca R, Townsend M, Wallace DJ, Kennedy WP, Drappa J, Safety and pharmacodynamics results of rontilzumab in a phase I, placebo-controlled, double-blind, dose-escalation study in systemic lupus erythematosus, Arthritis Rheum 2012: 64:3666-3676
315. Parker B, Urowitz MB, Gladman DD, Lunt M, Bae S-C, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcon GS, Fessler BJ, Fortin PR, Hanly JG, Petri M, Steinsson K, Dooley MA, Manzi S, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, McKay M, Ramos-Casals M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza F, Lim S, Kamen DL, Peschken CA, Inanc M, Bruce IN, Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort, Annals Rheum Dis 2012:
316. Lu R, Robertson JM, Bruner BF, Guthridge JM, Nease BR, Nath SK, Kelly JA, Moser Sivlis KL, Chakavarty EF, Kamen DL, Gilkeson GS, Wallace DJ, Scofield RH, Karley JB, James JA, Multiple autoantibodies display association with lymphopenia, proteinuria, and cellular casts in a large, ethnically diverse SLE patient cohort, Autoimmune diseases, 2012;
317. Venuturupalli S, Gudsoorkar V, Wallace D, Reconsidering antimalarials in systemic lupus erythematosus: Developments of translational interest, J Rheumatology 2012; 39: 1769-1771
318. Merrill JT, Ginzler EM, Wallace DJ, Mc Kay JD, Lisse JR, Aranow C, Wellborne FR, Burnette M, Condemi J, Zhong ZJ, Pineda L, Klein J, Freimuth WW, Long term safey profile of belimumab plus standard therapy in patients with systemic lupus erythmatosus, Arthritis Rheum 2012; 64: 3364-3373
319. Wu B, Wilson A, Wang FF, Wang SI, Wallace DJ, Weisman MH, Lu LJ, Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in China, PLoS One 2012; 7 (10): e47373, doid: 10.1371/journal.pone.0047373
320. Wang SL, Wang FF, Chen SL, Shen N, Xue F, Ye P, Bao CD, Gu YY, Wilson A, Wallace DJ, Weisman MH, Li LJ, Expression, localization and clinical application of exogenous Smith proteins D1 in gene transfected HEp-2 cells, Int J Rheum Dis 2012; 1-7.
321. Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, Levy RA, van Vollenhoven RF, Cooper S, Zhong ZJ, Freimuth W, Cervera R, Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus, Lupus 2012:
322. Parker B, Urowitz MB, Gladman DD, Lunt M, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Hanly JG, Petri M, Steinsson K, Dooley MA, Manzi S, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Bruce IN, Clinical associations of the metabolic syndrome in systemic lupus erythematotus: data from an international inception cohort, Ann Rheum Dis. 2012 Sep 22. [Epub ahead of print]
323. Wallace D, Navarra S, Petri M, Gallacher A, Thomas M, Furie R, Levy R, van Vollenhoven R, Cooper S, Zhong Z, Freimuth W, Cervera R, Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus, Lupus. 2012 Dec 4. [Epub ahead of print]
324. Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, Kalgallen B, Bongardt S, Barry A, Kelley L, Gordon L, Efficacy and safety of epratuzumab in aptients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomized, double-blind, placebo-controlled multicentre study, Ann Rheum Dis 2013; in press.
325. Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, Neuwelt CM, Robbie G, White WI, Higgs BW, Yao Y, Wang L, Ethgen D, Greth W, Sifalimumab, a human anti-interferon-a monoclonal antibody, in systemic lupus erythematosus: A phase I randomized controlled, dose-escalation study, Arthritis Rheum. 2013 65: 1011-1021 Feb 11. doi: 10.1002/art.37824
326. DJ Wallace; C Gordon; VStrand; K Hobbs; M Petri; K Kalunian; F Houssiau; P P. Tak; D A. Isenberg; L Kelley; BKilgallen; A N. Barry; W A. Wegener; D M. Goldenberg, Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up Rheumatology 2013; doi: 10.1093/rheumatology/ket129. 1313-1322
327. Jolly M, Toloza S, Block J, Mikolaitis R, Kosinski M, Wallace D, Durran-Barragan S, Bertoli A, Blavezic I, Lillall L, Cooray D, Moldovan I, Kastaros E, Weisman M, Torralba KM, Alcaron G, Spanish Lupus PRO: Cross cultural validation study in lupus; Lupus 2013: 22: 431-436.
328. Wallace DJ, Goldenberg D, Epratuzumab for systemic lupus erythematosus, Lupus. 2013;22(4):400-5. doi: 10.1177/0961203312469692.
329. Ishimori ML, Anderson L, Weisman MH, Mehta PK, Bairey Merz CN, Wallace DJ, Microvascular angina: An underappreciated cause of SLE chest pain, J Rhumatol 2013; 40: 746-747.
330. Wallace DJ, Quality guidelines for systemic lupus erythematosus: Slow but steady progress, J Rheumatol 2103; 40: 542-543.
331. Wallace DJ, Ten developments in the use of biological for systemic lupus erythematosus, Curr Rheumatol Rep 2013; 15:337
332. Rossi EA, Goldenberg DM, Michel R, Rossi DL, Wallace DJ, Chang C-H, Trogocytosis of multiple B-cell surface markers by CD-22-targeting with epratuzumab, Blood 2013; 122:3020-3029. Blood -2012-published ahead of print July 2, 2013, doi:10.1182/blood-2012-12-473744
334. Moldovan I, Cooray D, Farr F, Katsaros E, Torralba K, Shinada S, Ishimori M, Jolly M, Wilson A, Wallace D, Weisman M, Nicassio P, Pain and depression predict self-reported fatigue/energy in lupus, Lupus 2013; 22: 684-689.
335.Tessier Cloutier B, Clarke AE, Ramsey-Goldman R, Wang Y, Foulkes W, Gordon C, Hansen JE, Yelin E, Urowitz MB, Gladman D, Fortin PR, Wallace DJ, Petri M, Manzi S, Ginzler EM, Labrecque J, Edworthy S, Dooley MA, Senécal JL, Peschken CA, Bae SC, Isenberg D, Rahman A, Ruiz-Irastorza G, Hanly JG, Jacobsen S, Nived O, Witte T, Criswell LA, Barr SG, Dreyer L, Sturfelt G, Bernatsky S, Breast cancer in systemic lupus erythematosus, Oncology. 2013 Jul 25;85(2):117-121.
336. Grossman JM, Hahn BH, Mc Mahon MA, FitzGerald JD, Merrill JT, Yazdany J, Wallace DJ, Ramsey-Goldman R, Managing lupus nephritis in pregnant women: comment on the article by Hahn et al: Reply, Arthritis Care Res 2013; 65: 1392.
337. Wang SL, Wang FF, Chen SL, Shen N, Xue F, Ye P, Bao CD, Gu YY, Yu CZ, Wilson A, Wallace DJ, Weisman MH, Lu JL, Expression, localization and clinical application of exogenous Smith proteins D1 in gene transfected HEp-2 cells, Int J Rheum Dis 2013; 16: 303-309.
338. Mc Mahon M, Skaggs B, Grossman J, Sahakian L, Fitzgerald L, Wong WK, Laurenco E, Ragavendra N, Charles-Schoeman C, Gorn A, Karpouzas G, Taylor M, Watson K, Weisman M, Wallace DJ, Hahn BH, A panel of biomarkers is associated with increased risk for the presence and progression of atherosclerosis in women with systemic lupus erythematosus, Arthritis Rheum 2013; Sept 24 doi: 10.1992/art38204 (E pub ahead of print)
339. Lu M, Bernatsky S, Ramsy-Goldman R, Petri M, Manzi S, Urowitz MB, Gladman MB, Fortin FR, Ginzler EM, Yelin E, Bae SC, Wallace DJ, Jacobsen S, Dooley MA, Peschken CA, Alarcon GS, Nived O, Gottesman L, Criswell LA, Sturfelt G, Dreyer L, Lee JL, Clarke AE, Non-lymphoma hematological malignancies in systemic lupus erythematosus, Oncology 2013; 85: 235-240.
340.Hanly JG, Urowitz MB, O’Keefe AG, Gorson C, Bae SC, Sanchez-Guerrerro J, Romero-Diaz J, Clarke AE, Bernatsky S, Wallace DJ, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Petri M, Fortin PR, gladman DD, Fessler BJ. Alarcon GS, Bruce IN, Dooley MA, Steinsson K, Khamashta MA, Ramsey-Goldman R, Manzi S, Sturfelt GK, Nived O, Zoma AA, van Volenhoven RF, Ramos-Casals M, Aranow C, Mackey M, Ruiz-Irastorza G, Kalunian KC, Lim SS, Kamen DL, Peschken CA, Jacobsen S, Theriault C< Thompson K, Farewell V, Headache in systemic lupus erythematosus: results from a prospective, International inception cohort study, Arthritis Rheum 2013; 65: 2887-2297.
341. Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, Mc Cune WJ, Zhong ZJ, Freimuth WW, Petri MA, Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus, J Rheumatol 2013; Nov 1 (Epub ahead of print)
342. Strand V, Petri M, Kalunian K, Gordon C, Wallace DJ, Hobbs K, Kelley L, Kilgallen B, Wegener WA, Goldenberg DM, Epratuzumab for patients with moderate to severe flaring SLE: health related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006, Rheumatology (Oxford); 2013; Nov 22 (E pub ahead of print)
Abstracts:
1. Wallace, D., "RNA tumor viruses and aging," Clin. Res., 22:198A, 1974.
2. Wallace, D., Fan, P., Gatti, R, Goldfinger, D., Klinenberg, J., and Bluestone, R, "Effects of lymphoplasmapheresis on immunologic status," Arthritis Rheum 22:670, 1979.
3. Wallace, D., Goldfinger, D., Gatti, R, Fan, P., Klinenberg, J., and Bluestone, R, "Long term plasmapheresis and Iymphoplasmapheresis in the management of rheumatoid arthritis," Arthritis Rheum,22:670, 1979.
4. Wallace, D., Goldfinger, D., Brachman, M., Bluestone, R, and Klinenberg, J., "Therapeutic pheresis in the management of rheumatoid arthritis," Clin. Res., 28:77A, 1980.
5. Wallace, D., Podell, T., Forouzesh, S., Cox, M., Weiner, J., and Dubois, E., "Systemic lupus erythematosus: A retrospective study of 443 patients followed in private practice with emphasis on survival,"Clin. Res., 28:77A, 1980.
6. Wallace, D., Goldfinger, D., Bluestone, R, and Klinenberg, J.R, "Therapeutic pheresis in the management of rheumatoid arthritis," Arthritis Rheum 23:759, 1980.
7. Podell, T., Wallace, D., Forouzesh, S., Cox, M., Weiner, J., Klinenberg, J., and Dubois, E., "SLE: A retrospective study of 443 patients followed in a private practice with emphasis on survival," Arthritis Rheum, 23: 732, 1980.
8. Brachman, M.B., Wallace, D., Tanasescu, D., Ramanna, L., and Waxman, A., "Rheumatoid arthritis: Can quantitative joint scanning be used to evaluate the response to therapy?" Clin. Nuclear Med., 5:S38-29, 1980.
9. Wallace, D., Goldfinger, D., Thompson-Breton, R, Martin, V., Lowe, C., and Klinenberg, J., "A double blind controlled study of Iymphoplasmapheresis in rheumatoid arthritis," Arthritis Rheum, 24:S125, 1981.
10. Wallace. D., Podell, T., and Dubois, E., "Nitrogen mustard in lupus nephritis," Arthritis, 24: 70S, 1981.
11. Podell, T., Wallace, D., Forouzesh, S., Cox, M., Weiner, J., and Dubois, E., "Experience with 230 lupus nephritis patients: 1950-1980," Arthritis Rheum, 24: 121S, 1981.
12. Brachman, M.B., Wallace, D.J., Garcia, E., Klinenberg, J., Brown, D. E., Tanasescu, D.E., Ramanna, L., and Waxman, A-D., "Quantitative joint scanning in rheumatoid arthritis," Clin. Nuclear Med. 6: 455, 1981.
13. Wallace, D., Goldfinger, D., Brachman, M., and Klinenberg, J., "A double-blind controlled study of lymphoplasmapheresis in rheumatoid arthritis," Arthritis Rheum, 25:3S, 1982.
14. Wallace, D., Goldfinger, D., and Klinenberg, J., "Therapeutic plasmapheresis in systemic lupus with nephrotic syndrome," Arthritis Rheum, 25: S81, 1982.
15. Wallace, D., Goldfinger, D., Klinenberg, J., Barnett, E., and Curd, J., "Immunologic regulation in selective plasmapheresis in rheumatoid arthritis," Arthritis Rheum,26:S44, 1983.
16. Wallace, D., "Plasmapheresis vs lymphoplasmapheresis: Immunologic difference," J Clin. Apheresis, 2:141, 1984.
17. Wallace D., Goldfinger, D., and Klinenberg, J.R, "Plasmapheresis in lupus nephritis: A controlled study, Preliminary results," Arthritis Rheum, 28:S46, 1985.
18. Wallace D. J., Brachman, M., Feldman, G., Reichman, R, and Klinenberg, J.R, "Quantitative computeized joint scanning in rheumatoid arthritis: An accurate, reproducible method of quantitating synovitis," Arthritis Rheum, 29: S81. 1986.
19. Wallace, D. J., Goldfinger, D., and Klinenberg, J.R, "Plasmapheresis in lupus nephritis: A controlled study—preliminary results," Plasma Therapy, 7:418, 1986.
20. Wallace, D. J., Peter, J.B., Wiedmann, C. R, Knight, P.J., and Klinenberg, J.R, "Antibodies to non-cardiolipin antibodies in SLE: Clinical associations," Arthritis Rheum, 30:S26, 1987 (Suppl 1).
21. Wallace, D.J., Goldfinger, D., Goodman, D., Fichman, M., and Klinenberg, J.R, "A controlled study on the use of plasmapheresis in steroid immunosuppressive resistant SLE patients with nephrotic svndrome," Arthritis Rheum, 30:S26, 1987 (Suppl 1).
22. Wallace, D. J., Wiedmann, C., Peter, J., Knight P., and Klinenberg, J.R, "Anticardiolipin isotypes in SLE,"Arthritis Rheum, 30:S29, 1987 (Suppl 1).
23. Wigfall, D.R, Wallace, D.J., Sakai, RS., and Jordan, S.C., "In vitro interleukin-2 receptor generation by PBL isolated from SLE patients," Pediat. Res., 21:A486, 1987.
24. Wallace, D.J., Wiedmann, C.E., Peter, J.B., Knight, P.K., and Klinenberg, J.R, "Antiphospholipid antibody isotypes in SLE," Arthritis Rheum, 30:S5S, 1987.
25. Wallace, D.J., Goldfinger, D., Goodman, D., and Fichman, M., "Predictive value of outcome variables in immunosuppressive resistant lupus nephritis," Arthritis Rheum 30:S70, 1987.
26. Wigfall, D.R, Wallace, D.J., Sakai, RS., and Jordan, S.C., "In vitro interleukin-2 receptor expression by PBL isolated from SLE patients," Kidney Int. 33: 331, 1988.
27. Peter, J.B., Lee, C.T., Wallace, D.J., "Studies of immune regulation in primary fibromyalgia syndrome,"Arthritis Rheum, 31 :R18, 1988.
28. Wigfall, D.R, Wallace, D.J., Sakai, RJ., Jordan, S.C., "Interleukin-2 receptor expression in peripheral blood lymphocytes in SLE patients, relationship to clinical activity," Arthritis Rheum, 32:R22, 1988.
29. Wallace D.J., Goldfinger, D., Dubois, E.L., Klinenberg, J.R, "Refractory lupus nephritis: A controlled study on the use of plasmapheresis in 59 patients," Artificial Organs 12:286, 1988.
30. Wigfall, D.R, Wallace, D.J., Sakai, RS., Jordan S.C., "B-cell interleukin-2 (IL-2) receptor expression in systemic lupus erythematosus (SLE)," Arthritis Rheum 31:S106, 1988.
31. Wallace, D.J., Margolin, K., "Acute-onset fibromyalgia as a complication of interleukin-2 therapy,"Arthritis Rheum 31: S24, 1988.
32. Peter, J.B., Wallace, D.J., "Abnormal immune regulation in fibromyalgia," Arthritis Rheum 31: S24, 1988.
33. Wallace, D.J., Bowman, R, Wormley, S.B., Peter, J.B., "Are there immunoregulatory abnormalities in the primary fibromyalgia (fibrositis) syndrome?" Arthritis Rheum 32:S69, 1989.
34. Chong, P.J., Matzner, W.L., Wallace, D.J., Klinenberg, J.R, Jordan, S.C., "Protein kinase-C pathway reglation of immunoglobulin synthesis in peripheral blood mononuclear cells of patients with SLE,"Arthritis Rheum 32: S92, 1989.
35. Pistiner, M., Wallace, D.J., Klinenberg, J.R, "A survey of 536 patients with lupus erythematosus,"Arthritis Rheum 33:R5, 1990.
36. Wallace, D.J., Metzger, AL., "Antihyperlipidemic actions of hydroxychloroquine (Plaqueril)," Arthritis Rheum 33:R7, 1990.
37. Wallace, D.J., "Genitourinary manifestations of fibromyalgia: an increased association with the female urethral syndrome," Arthritis Rheum 33:R8, 1990.
38. Linker-Israeli M, Deans RJ, Wallace DJ, Jordan S, Quismorio FP, Klinenberg JR, Ozeri-Chen T, "Up-regulation of spontaneous IgG by endogenous cytokines in systemic lupus erythematosus," FASEB J4:A2104, 1990.
39. Wallace DJ, Pistiner M, Klinenberg JR, "464 patients with idiopathic SLE: Clinical and laboratory findings," Arthritis Rheum 33:S130, 1990.
40. Wallace DJ, Pistiner M, Klinenberg JR, "464 patients with idiopathic SLE: Natural course, treatment and causes of death," Arthritis Rheum 33: S130,1990.
41. Wallace DJ, Metzger AL, Stecher V, Kern P, "Cholesterol lowering effect of hydroxychloroquine in rheumatic disease patients. Reversal of deleterious effects of steroids on lipids," Arthritis Rheum 33: S165, 1990.
42. Linker-Israeli M, Wallace DJ, Ozeri-Chen T, Klinenberg JR, "Soluble CD4 and CD 8 in SLE sera: Possible new markers for disease activity and enphritis," Arthritis Rheum 34:R15, 1991.
43. Linker-Israeli M, Wallace DJ, Prehn J, Oseri-Chen T, Klinenberg JR, "Elevated levels of endogenous IL 6 in systemic lupus erythematosus (SLE): A putative role in pathogenesis," Arthritis Rheum 34:R15, 1991.
44. Linker-Israeli M, Wallace DJ, Jordan SC, Klinenberg JR, "Demonstration of IL-1, IL-6 and IFN garnma in SLE kidney biopsies," Arthritis Rheum 34:R20, 1991.
45. Silverman SL, Wallace DJ, "Calcitonin helps a subset of patients with fibromyalgia," Arthritis Rheum34:R21, 1991.
46. Wallace, DJ, Pistiner M, Nessim S, Metzger AL, Klinenberg JR, "Chronic cutaneous (Discoid) lupus (DLE): Clinical and laboratory parameters in 67 patients followed in a private practice (1980-1989),"Arthritis Rheum 34:S130, 1991.
47. Linker-Israeli M, Wallace DJ, Prehn J, Ozeri-Chan T, Klinenberg JR, "Elevated levels of endogenous IL-6 in systemic lupus erythematosus (SLE): A putative role in pathogenesis," Arthritis Rheum 34:S141, 1991.
48. Lahita RG, Rivkin E, Wallace DJ, Cavanagh L, "Low LDL cholesterol and apolipoprotein A1 levels in patients with SLE and IgG cardiolipin antibodies: A possible etiologic factor in atherosclerosis,"Arthritis Rheum 34:S42, 1991.
49. Hyun S, Linker-Israeli M, Ozeri-Chen T, Wallace DJ, Klinenberg JR, "Do soluble accessory molecules play a role in autoimmunity?" FASEB J 6: 1980, 1992.
50. Wallace DJ, "A new role for hydroxychloroquine in the 1990s?," Lupus 1:98 (S1), 1992.
51. Neumann K, Wallace D, Azen C, Goodman D, Fichman M, Klinenberg J, "Influence of treatment and biopsy variables on outcome of 150 lupus nephritis patients seen in a private practice between 1950 and 1980," Arthritis Rheum 35:S357, 1992.
52. Linker-Israeli M, Hyun S, Ozeri-Chen T, Wallace DJ, Klinenberg JR, "Soluble CD8 molecules in systemic lupus erythematosus," Arthritis Rheum 35:S138, 1992.
53. Linker-Israeli M, Prehn J, Wallace DJ, Li L, Toyoda H, Klinenberg JR, "Novel polymorphisms of the IL-6 gene in systemic lupus erythematosus," Arthritis Rheum 35:S175, 1992.
54. Wallace DJ, Metzger AL, "Antimalarials decrease the risk of thromboembolic events in anticardiolipin positive lupus patients," Arthritis Rheum 35:S110, 1992.
55. Wallace DJ, Linker-Israeli M, Stecher V, Klinenberg JR, "The effect of hydoxycholorquine (HC) on soluble accessory molecules and cytokines in systemic lupus erythematosus (SLE)," Arthritis Rheum 36:R6,1993 (supp).
56. Neumann K, Wallace DJ, Klinenberg JR, "Influence of clinical variables, biopsy and treatment on the outcome of 150 patients with lupus nephritis seen at a single center in the 1980s," Arthritis Rheum 36:S229, 1993.
57. Shen G, Li L, Wallace DJ, Lin H-C, "Combined measurements of serum hyaluronic acid and IgM RF levels increase the sensitivity for the diagnosis of rheumatoid arthritis without sacrificins~ the specificity," Arthritis Rheum 36:S125, 1993.
58. Liven L, Shen G, Wallace DJ, "A rapid and specific enzyme immunoassay to measure serum hyaluronic acid concentration," Arthritis Rheum 36:S126, 1993.
59. Wallace DJ, Lin H-C, Peter JB, "The 'does she or doesn't have lupus' consultation: Improving diagnostic acumen," Arthritis Rheum 36:S185, 1993.
60. Allosachie I, Lin H-C, Shoenfeld Y, Wallace DJ, "Evaluation of neuronal antibody reactivity in neuropsychiatric systemic lupus by flow cytometry," Arthritis Rheum 36:S185, 1993.
61. Wallace DJ, Linker-Israeli M, Hyun S, Stecher V, Klinenberg JR, "The effect of hydroxychloroquine (HC) therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus," Arthritis Rheum 36:S231, 1993.
62. Linker-Israeli M, Prehn J, Wallace DJ, Li L, Klinenberg JR, "Study of an IL-6 gene XBAI restriction fragment associated with systemic lupus erythematosus," Arthritis Rheum 36:S 111, 1993.
63. Linker-Israeli M, Prehn J, Li L, Wallace DJ, Klinenberg JR, "IL-6 gene polymorphisms in SLE (systemic lupus erythematosus)," J Immunol 150 A40, 1993.
64. Linker-Israeli M, Prehn J, Wallace DJ, Klinenberg JR, "Cytokine genes of lupus patients: Do they differ from normal?," Arthritis Rheum 37:S168, 1994.
65. Stecher VJ, Wallace DJ, Metzger AL, "Antihyperlipidemic actions of hydroxychloroquine (Plaquenil),"Rev Bras Rheumatol 34:S88 (suppl), 1994.
66. Shen GQ, Lin H-C, Wallace DJ, Shoenfeld Y, Lai N, Peter JB, "Detection of (H2A-H2B)-DNA histone-complex antibodies in autoimmune-diseases and drug-induced lupus," J Am S Nephrol 5:769, 1994.
67. Linker-Israeli M, Hyun S, Ozeri-Chen T, Wallace D, Klinenberg J, "Elevated in vivo and in vitro secretion of CD8-a molecules in patients with systemic lupus erythematosus," Lupus 4:48, 1995 (suppl 2).
68. Linker-Israeli M, Prehn J, Toyoda H, Wallace D, "The interleukin-6 gene; Studies in patients with systemic lupus erythematosus (SLE)," Lupus 4:7, 1995 (suppl 2).
69. Linker-Israeli M, Wallace D, Elstner E, Koefiler P, Klinenberg J, "Vitamin D3 inhibits immunoglobulin production by peripheral blood mononuclear cells (PBMC) of systemic lupus erythematosus (SLE) patients," Lupus 4:63, 1995 (suppl 2).
70. Wallace DJ, Pepkowitz S, Goldfinger D, "Pulse synchronization plasmapheresis for proliferative lupus nephritis with nephrotic syndrome: A randomized trial progress report," J Clin Apheresis 10:55, 1995.
71. Schwartz EF, Wallace DJ, Klinenberg JR, "Clinical and laboratory features of 20 patients with scleroderma and silicone breast implants," Arthritis Rheum 38: RS, 1995 (suppl).
72. Basbug E, Wallace DJ, Nessim S, Klinenberg JR, "Clinical and laboratory features of 24 patients with systemic lupus erythematosus and silicone breast implants," Arthritis Rheum 38:R8, 1995 (suppl).
73. Basbug E, Schwartz E, Wallace DJ, Nessim S, Klinenberg JR, "Clinical and laboratory features of 30 patients with systemic lupus erythematosus and silicone breast implants," Arthritis Rheum 1995;38:S265.
74. Wallace DJ, Cozen LJ, "Avascular necrosis in SLE: Lack of association with antiphospholipid antibodies and other clinical correlates," Arthritis Rheum 1996; 39:R4.
75. Linker-Israeli M, Wallace DJ, Prehn J, Michael D, Yang H, Klinenberg JR, "Skewed allele distribution of the IL-6 gene associated minisatellite in patients with SLE," J Experimental Med 1996; 44:A276.
76. Linker-Israeli M, Wallace DJ, Prehn J, Michael D, Yang H, Nand R, Klinenberg JR, "Aberrant distribution of the IL-6 gene minisatellite alleles in SLE patients: Population and multiplex family studies,"Arthritis Rheum 1996; 39:S128.
77. Tsao BP, Cantor RM, Kalunian KC, Chen C-J, Singh R, Wallace DJ, Kitridou RC, Chen SI, Shen N, SongYW, Isenberg DA, Yu C-I, Hahn BH, Rotter JL, "Evidence for linkage of a candidate chromosome 1region to systemic lupus erythematosus (SLE)," Arthritis Rheum 1996; 39:S217.
78. Linker-Israeli M, Ebling F, Wallace DJ, Nand R, Singh RR, Lin P, Klinenberg JR, Hahn BH, "T cells of SLE patients recognize VH determinants of anti ds DNA autoantibodies," Arthritis Rheum 1996; 39:S267.
79. Hallegua D, Wallace DJ, Metzger AL, Klinenberg JR, "Cyclosporine for membranous lupus nephritis",Arthritis Rheum 1997; 40 S57.
80. Wallace D, Goldfinger D, Pepkowitz S, "A prospective, controlled trial of pulse synchronization cyclophosphamide (CTX)/apheresis for proliferative lupus nephritis", Arthritis Rheum 1997; 40: S58.
81. Tsao BP, Cantor RM, Badsha H. Grossman JM, Kalunian KC, Hartung K, Arnett FC, Wallace DJ, Hahn BH, Rotter JI, "A susceptibility gene for SLE maps to a 5 cM region of chromosome lq", Arthritis Rlteum 1997; 40 S315.
82. Moser KL, Yu H. Asunde N. Koelsch G. Salmon JE, Wallace D, Ginzler E, Wolf RE, Bruner G. Neas BR,Harley JB, "Evidence for racial differences in genetic linkage to multiple loci spanning chromosome lq in human systemic lupus", Arthritis Rheum 1997; 40: S315.
83. Wallace DJ Post S, "An epidemiologic survey of Moorpark, California", Lupus 1998; 7: 23, Supp 1.
84. Wallace DJ, Goldfinger D, Pepkowitz S, Fichman M, Metzger AL," A randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative nephritis", Lupus 1998; 7: 79, supp 1.
85. Moser KL, Neas BR, Bruner G, Salmon J, Harley JB, Wallace D, Petri M, Mc Kown K, Carson C, Albert D, "Scanning the genome for human SLE genes: Design and candidate regions", Lupus 7: 13, 1998, Supp 1
86. Honda M, Nand R, Mandyam R, Mengesha E, Wallace DJ, Metzger A, Bharler, Klinenberg JR, Morris R, Linker-Israeli M, "IL-6, IL-10 and IL-4 expression and cross talk in patients with systemic lupus erythmeatosus", Arthritis Rheum 1998; 41: S39.
87. Shai R, Quismorio FP Jr, Li L, Kwon OJ, Morrison J, Wallace DJ, Neuwelt CM, Gauderman WJ, Jacob CO, "Multigenic control of disease in multiplex families with systemic lupus erythematosus", Arthritis Rheum 1998; 41:S80.
88. Pachinian N, Wallace DJ, Klinenberg JR, "Mycophenolate mofetil for systemic lupus erythematosus", Arthritis Rheum 1998; 41: S110.
89. Neumann K, Golde G, Wallace DJ, Metzger AL, "Osteoporosis--less than expected in scleroderma?", Arthritis Rheum 1998; 41:S216.
90. Salonen E-M, Wallace DJ, Metzger AL, Avaniss-Aghajani E, "Anti-telomere antibodies are highly specific for systemic lupus erythematosus (SLE)", Arthritis Rheum 1998; 41: S247.
91. Hallegua D, Bonert V, Mathur R, Silverman S, Wallace DJ, Klinenberg JR, "Prevalence of fibromyalgia (FM) in growth hormone deficient (GH) adults", Arthritis Rheum 1998; 41:S256.
92. Linker-Israeli M, Wallace DJ, Michael D, Prehn J, Nand P, Taylor KD, Paul-Labrador M, Honda M, Fishel- Ghodsian N, Fraser PA, Klinenberg JR, "Novel alleles of the IL-6 gene minisatellite are associated with systemic lupus erythematosus (SLE) and with differential IL-6 expression", Arthritis Rheum 1998; 41:S282.
93. Weinreb A, Grossman JM, Theophilov N, Zhao Y, Wallace DJ, Hahn BH, Tsao BP, "Family- based and case-control association studies of the interleukin-1 receptor antagonist (IL-1RA) ILRN*2 allele in North-American caucasian and han-Chinese populations with systemic lupus erythematosus (SLE) and glomerulonephritis", Arthritis Rheum 1998; $1: S285.
94. Grossman JM, Teophilov N, Kalunian KC, Wallace DJ, Arnett FC, Hartung K, Goldstein R, Lin HY, Hahn BH, Tsao BP, "Comparison of clinical manifestations of lupus patients in simplex and multiplex families", Arthritis Rheum 1998; 41:S329.
95. Hallegua D, Wallace DJ, Metzger AL, Klinenberg JR, "Association of goat milk exposure with autoantibodies", Arthrits Rheum 1998; 41:S331.
96. Moser KL, Neas BR, Salmon JE, Yu H, McGuire C, Asundi N, Gruner GR, Fox J, Kelly J, Henshall S, Bacino D, Dietz M, Hogue R, Koelsch G, Nightingale L, Abdou N, Albert D, Carson C, Ginzler E, McKowen K, Petri M, Ramsey-Goldman R, Treadwall E, Wallace D, Wilson J, Wolf R, Sahver T, James JA, Harley JB, "Genome scan of human systemic lupus erythematosus (SLE) identifies multiple loci influenced by racial origin", Arthritis Rheum 1998; 41:S283.
97. Tsao BP, Cantor RM, Grossman JM, Theophilov N, Wallace DJ, Arnett FC, Hartung K, Goldstein R, Kalunian KC, Hahn BH, Rotter JL, "ADPRT alleles from the chromosome 1q41-q42 linked region are associated with SLE", Arthritis Rheum 1998; 41: S80.
98. Linker-Israeli M, Wallace DJ, Michael D, Nand R, Honda M, Klinenberg JR, IL-6 minisatellite alleles are associated with SLE and with up-regulated IL-6 expression, FASEB J 1998; 12: 3521.
99. Honda M, Wallace DJ, Metzger A, Morris R, Behariar B, Klinenberg JR, Linker-Israeli M, Contrasting effects of IL-10 and IL-4 on IL-6 content of SLE PBMC subsets, FASEB J 1998: 12:3524.
100. Pimentel M, Hallegua D, Wallace D, Bonorris G, Chow E, Tabibzadeh S, Lin HC, Eradication of small intestinal bacterial overgrowth decreases symptoms in fibromyalgia, Arthritis Rheum 1999: 42:S343.
101. Linker-Israeli M, Wallace DJ, Mengesha E, Taylor K, Fishel-Ghodissian N, Klinenberg JR, SLE-associated alleles of the IL-6 3'flanking region modulate IL-6 expression, Arthritis Rheum 1999; 42: S309.
102. Albano S, Hallegua D, Wallace DJ, Klinenberg JR, Lin HC, Small intestinal bacterial overgrowth in systemic lupus erythematosus (SLE), Arthritis Rheum 1999; 42: S305.
103. Grossman JM, Hahn BH, Kalunian KC, Wallace DJ, Arnett FC, Rubin RL, Tsao BP, IgG anti-chromatin antibodies are associated with lupus nephritis, Arthritis Rheum 1999; 42: S215.
104. Weinreb A, Grossman JM, Cantor RM, Theophil N, Wallace DJ, Hahn BH, Tsao BP, Association of the interleukin-1 receptor antagonist IL-1RN*1 allele with systemic lupus erythematosus (SLE) clinical phenotypes. Am J Hum Genet 1999; 65: 2277.
105. Linker-Isareli M, Wallace DJ, Mengesha E, Taylor KE, Fischelg N, Mueller C, SLE-associated alleles of the IL-6 3’ flanking region contribute to IL-6 gene regulation. FASEB J, 2000; 14: 1206.
106. Pimentel M, Chow EJ, Bonorris G, Hallegua D, Wallace D, Lin HC, Eradication of small-intestinal bacterial overgrowth decreases the gastrointestinal symptoms in fibromyalgia, Gastroenterology 2000; 118: 2143.
107. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman SL, Silver D, Weisman MH, Cytokines play an etiopathogenetic role in fibromyalgia: A pilot study, Arthritis Rheum 2000; 43: S212.
108. Lander S, Wallace S, Weisman MH, Is celecoxib safe in SLE with or without sulfa allergy? A pilot study, Arthritis Rheum 2000; 43: S242.
109. Tsao BP, Grossman JM, Arnett FC, Chak S, Wallace DJ, Ginzler DM, Goldstein R, Kalunian KC, Hahn BH, Cantor RM, Investigation of SLE-linked regions identified by genome scans: Support for 1q24, 16q13 and 20p12, Arthritis Rheum 2000; 43: S278.
110. Linker-Israeli M, Honda M, Wallace DJ, Albano S, Mengesha E, Nichols S, Klinenberg JR, Metzger A, Morris R, Loss of telomeric DNA and fewer proliferative cycles, contrasted by continuous in vitro cycling of non-senescent, CD28-CD8+ T cells in patients with systemic lupus erythematosus, Arthritis Rheum 2000; 43: S273.
111. Remer CF, Weisman MH, Wallace DJ, Benefits of leflunomide (LEF) in systemic lupus erythematosus, Lupus 2001; 10: S10.
112. Wallace DJ, Telomere antibodies and telomere biology in autoimmunity, The Ryumachi 2001; 41:209.
113. Wallace DJ, Do cytokines play a pathogenetic role in fibromyalgia? A hypothesis and pilot study, Journal of Musculoskeletal Pain 2001; 9: 80 (supp5).
114. Grossman JM, Kim SK, Wallace DJ, Chen CJ, Lau CS, Ginzler DM, Goldstein R, Shen N, Kalunian KC, Arnett FC, Hahn BH, Interaction of loci at 1Q23 and IBD.1 may contribute to lupus susceptibility, Arthritis Rheum 2001; 44: S248.
115. Tsao BP, Grossman JM, Riemekasten G, Kasli J, Wallace DJ, Chen CJ, Lau CS, Ginzler EM, Goldstein RM, Arnett FC, Kalunian KC, Hahn BH, Familialty of clinical features of SLE in affected sib pairs, Arthritis Rheum 2001; 44: S248.
116. Strand V, Aranow C, Cardiel M, Furie R, Sherrer Y, Tumlin J, Wallace DJ, Crawford B, Improvement in health related quality of life in SLE patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo, Arthritis Rheum 2002; 46: S119.
117. Antoni CE, Kavanaugh A, Kirkham B, Burmeistr G, Manger B, Tituncu Z, Schneider U, Ebner W, Wassenberg S, Furst D, Molitor J, Weisman M, Wallace D, Keystone E, Kalden JR, Smolen J, The Infliximab multinational psoriatic arthritis controlled trial (IMPACT): Substantial efficacy of synovitis and psoriatic lesions with or without concomitant DMARD therapy, Ann Rheum Dis 2003; 62: 90.
118. Wu H, Cantor RM, Grossman JM, Rumbin AA, Shen A, Lau CS, Wallace DJ, Arnett FC, Badsha HM, Chng HH, Hahn BH, Tsao BP, Markers in a 1-Mb interval within 1q23.2 are associated with systemic lupus susceptibility, Arthritis Rheum 2003; 47: S256..
119. Antoni C, Kavanaugh A, Kirkham B, Burmeister G, Manger B, Schneider U, Tutuncu Z, Ebner W, Wassenberg S, Furst D, Molitor J, Keystone E, Gladman D, Weisman M, Wallace D, Kalden J, Smolen J, The one year results of the infliximab multinational psoriatic arthritis controlled trial (IMPACT), Arthritis 2003; 47: S265-266.
120. Lannik MD, Salter-Cid L, Miller AC, Furie RA, Horizon A, Weisman MH, Wallace DJ, Merrill JT, Cockerill K, Domain specificity of autoantibodies to beta2-glycoprotein 1 in patients with antiphospholipid syndrome enrolled in a phase ½ trial with LJP, Arthritis Rheum 2003; 47: S356.
121. Horizon A, Weisman MH, Wallace DJ, Merill JT, Linnik MD, Cockerill K, Furie RA, Results of a randomized, placebo, controlled, double-blind phase ½ clinical trial (RCT) to assess the safety and tolerability of LJP 1082 in patients with antiphospholipid syndrome, Arthritis Rheum 2003; 47: 364-365.
122. Horizon AA, Yu X, Hwang KK, Fitzgerald J, Wallace DJ, Metzger AL, Weisman MH, The application of the CL154C peptide-mimetic to study disease—relevant antiphospholipid antibodies in patients with APS and SLE, Arthritis Rheum 2003; 47: 3638-3639.
123. Linnik MD, Joh T, Strand V, Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Hura C, SLE patients with sustained reductions in anti-DNA antibodies have a reduced risk of renal flare and major SLE flare, Arthritis Rheum 2003; 47:S582.
124. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Hura C, Strand V, Foster V, Hu J, Helibrunn KR, Linnik MD, Clinical efficacy results from a RCT of LJP 394 in SLE patients with history of renal disease, Arthritis Rheum 2003; 47: S582-S583.
125. Wallace DJ, Cardiel MH, Tumlin JA, Furie RA, Hura C, Strand V, Wang S-L, Yushamanova I, Heilbrunn KR, Safety results from a randomized, controlled trial (RCT) of LJP 394 in systemic lupus erythematosus (SLE) patients with a history of renal disease, Arthritis Rheum 2003; 47: S583.
126. Ginzler EM, Aranow C, Buyon J, Dooley MA, Merill JT, Petri M, Allep G, Cilekson G, Wallace D, Weisman M, A multicenter study of mycophenolate mofetil (MMF) vs intravenous cyclosphosphamide (IVC) as induction therapy for severe lupus nephritis (LN): Preliminary results, Arthritis Rheum 2003; 47: S647.
127. Wu H, Cantor RM, Shen N, Arnett FC, Grossman JM, Lau CS, Badsha HM, Rumbin AA, Wallace DJ, Ching HH, Linkage and association of systemic-lupus-erythematosus (SLE) on 1q23,2, Am J Hu Gen 2003; 73: 1950.
128. Wallace DJ, Cardiel MH, Tumlin JA, Furie J, Hura C, Strand V, Wang S, Yushmanova I, Heilbrunn KR, Safet;y results from a RCT of LJP 394 in SLE patients with a history of renal disease, Am J Soc Nephrol 2003.
129. Bombardieri S, CardielMA, Tumlin JA, Furie RA, Wallace DJ, Hura C, Schneider M, Hieppe F, Strand V, Joh T, Foster T, Yushmanova I, Keilbrunn KR, Summary of safety results from studies of LJP 394 in SLE patients, Annals Rheum Dis 2004 63: 216 supp1.
130. Wallace DJ, Weaver A, Stein B, Campbell D, Huston J, Goldman J, Xia HA, Louie J, Etanercept of infliximab in combination with methotrexate (MTX) in the treatment of rheumatoid arthritis—results from the Radius registry, Annals Rheum Dis 2004 63: 251, supp1.
131. Antoni CE, Kavanaugh A, Kirkham, Burmeister G, Manger B, Schneider U, Tutuncu Z, Ebner W, Wassenberg S, Furst D, Molitor J, Keystone E, Gladman D, Weisman M, Wallace D, Weier R, Kalden JR, Smolen J, The infliximab multinational psoriatic arthritis controlled trial (Impact 1): The concomitant use of DMARDS does not influence the efficacy and safety of infliximab over a one year period, Annals Rheum Dis 2004; 63: 411, supp 1.
132. Chiou C, Weisman M, Sherbourne C, Reyes R, Dylan M, Ofman J, Wallace DJ, Miszutani W, Suarex-Almazor ME, Meauring preference weights for health states with rheumatoid arthritis, Annals Rheum Dis 2004; 63: 534, supp 1.
133. Mc Mahon M, Grossman J, Fitzgrald J, Ebling F, Dahlin-Lee E, Thong B, Kalunian K, Wallace DJ, Badsha H, Navab M, Fogelman AM, Hahn BH, Atherosclerosis in SLE may relate to abnormal protective capacity of HDL, Arthritis Rheum 2004; 5: S192.
134. Brey RL, Fox PT, Narayana S, Martinez MJ, Naqibuddin M, Holliday SL, Wallace DJ, Weisman MH, Brain imaging findings in an SLE inception cohort: Brain CONNECTIONS, Arthritis Rheum 2004; 50: S194.
135. Paulus HE, Weaver A, Wallace DJ, Whitmore JB, Leff JA, The CORRONA patient registry for patients with rheumatic diseases, Arthritis Rheum 2004; 50: S376.
136. Naqibuddin M, Wallace DJ, Weisman MH, Holliday SL, Wing NF, Brey RL, Petri M, Cognitive functioning in recently diagnosed systemic lupus erythematosus, Arthritis Rheum 2004; 50: S195.
137. Keilbrunn KR, Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Hura C, Strand V, Joh T, The effect of LJP 394 and concomitant immunosuppressive agents on levels of anti ds DNA antibodies in SLE patients, Arthritis Rheum 2004; 50: S406.
138. Wu H, Cantor RM, Grossman JA, Park E, Rumbn AA, Wallace DJ, Hahn BH, Tsao B, Toll-like receptor 9 gene polymorphisms protective for SLE, Arthritis Rheum 2004; 50: S459.
139. Lee YH, Wu H, Cantor RM, Grossman JM, Rumbin AA, Park E, Shen N, Chen CJ, Hadsha HM, Thong BYH, Chong HH, Wallace DJ, Hahn BH, Tsao BP, Evidence for SLE susceptibility gene(s) at 1q32, Arthritis Rheum 2004; 50: 607-608.
140. Antoni Ca, Kavanaugh A,Birkham B, Tutuncu Z, Burmeister GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace D, Weisman MH, Kalden JR, Smolen J, Two year data: Infliximab maintains clinical response in psoriatic arthritis patients: an analysis of the year 2 data from the infliximab multinational psoriatic arthritis controlled trial (IMPACT), Annals Rheum Dis 2005; 64: 82.
141. Furst D, Yocum D, Weisman M, Troum O, Bray V, Wallace D, Gaylis N, Ritter J, Yeilding N, Gilmer K, Infliximab provides additional clinical and radiographical benefits in RA patients who have an inadequate response to etanercept, Annals Rheum Dis 2005; 64: 427.
142. Binder SR, Homberger HA, Moder KG, Wener MH, Weisman MH, Wallace DJ, Multi-Site evaluation of the BioPoex ™ ANA Screen Kit, Clinical Chemistry 2005;
143. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu ZN, Burmeister G, Schneider U, Furst DE, Moliter J, Keystone EC, Gladman D, Manger M, Wassenberg S, Weier R, Wallace D, Weisman M, Kalden JR, Smolen JS, 2 year data: Infliximab maintains clinical response in psoriatic arthritis patients—data from the infliximab multinational psoriatic arthritis controlled trial (IMPACT), Arthritis Rheum 2005; 52: S209
144. Hanly JG, Urowitz MB, Sanchez-Guerrero S, Bae SC, Clarke A, Gordon C, Isenberg D, Alarcon G, Wallace DJ, Petri M, Dooley MA, Gladman D, Fortin P, Merrill JT, Steinsson I, Bruce I, Aranow C, Zoma A, Van Vollenhoven R, Sturfelt G, Nived O, Ramsey-Goldman R, Khamashta M, Neuropsychiatric events at diagnosis of systemic lupus erythematosus, Arthritis Rheum 2005; 52: S379
145. Naqibuddin M, Wallace DJ, Weisman MH, Brey RL, Sampedro M, Carson KA, Holliday SL, Petri M, Depression is associated with poorer cognitive function in newly diagnosed systemic lupus erythematosus patients, Arthritis Rheum 2005; 52: S379-S380
146. Naqibuddin M, Wallace DJ, Weisman MH, Brey RL, Sampedro M, Carson KA, Holliday SL, Petri M, Change in cognitive function in newly diagnosed systemic lupus erythematosus patients, Arthritis Rheum 2005: 52: S380
147. Urowitz MB, Sanchez-Guerrero J, Gladman DD, Fortin PR, Clarke A, Bae SC, Gordon C, Isenberg D, Hanly J, Merrill J, Ginzler E, Alarcon G, Wallace DJ, Petri M, Steinsson K, Dooley MA, Manzi S, Bruce, Maddison P, Sturfelt G, Nived O, Zoma A, Aranow C, Ramsey-Goldman R, van Vollenhoven R, Khamashta M, Stoll T, Systemic Lupus International Collaborating Clinics (SLICC) inception cohort registry to study risk factors for atherosclerosis (SLICC RAS): First follow up report, Arthritis Rheum 2005; 52: S608.
148. Naqibuddin M, Sampedro M, Wallace DJ, Weisman MH, Brey RL, Holliday SL, Carson KA, Anti-NR2 and anti ds DNA in newly diagnosed systemic lupus erythematosus: Analysis of cognitive function, brain MRI and PET, Arthritis Rheum 2005; 52: S621-S622.
149. Mc Mahon M, Grossman J, Fitzgerald J, Dahlin-Lee E, Ebling F, Thong B, Badsha H, Wallace DJ, Kalunian K, Hahn BH, Pro-inflammatory HDL as a biomarker for atherosclerosis in SLE and RA, Arthritis Rheum 2005; 52: S697-698.
150. Weisman M, Furst D, Park G, Kremer J, Smith K, Smith-Riggs M, Meyer G, Barham R, Caldwell J, Wallace D, Hettinger K, Dervieux T, Risk genotypes in folate-dependent enzymes profile rheumatoid arthritis patients with side effects to methotrexate therapy, Arthritis Rheum 2005; 52: S722-723.
151. Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Clarke A, Gordon C, Isenberg D, Alarcon G, Wallace DJ, Petri MA, Dooley MA, Gladman D, Fortin P, Merrill JT, Manzi S, Steinsson K, Bruce I, Aranow C, Zoma A, Van Vollenhoven R, Sturfelt G, Nived O, Ramsey-Goldman R, Khamashta M, Attribution of neuropsychiatric events at diagnosis of systemic lupus erythematosus, Arthritis Rheum 2005; 52: S727.
152. Gordon C, Wallace DJ, Kalunian KC, Shinada S, Forbess L, Braunstein GD, Weisman MH, Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus, Arthritis Rheum 2005; 52: S741.
153. Ferbas J, Wallace DJ, Weisman MH, Belouski SS, Kesslak JP, Vincent M, Ma J, Zack D, Hendricks L, Chung J, A systemic analysis of circulating B cell populations in healthy and SLE subjects, Annals Rheum Dis 2006; 65: 584, s.11
154. Rojas J, Visvanathan S, Weisman M, Troum O, Bray V, Wallace D, Gaylis N, Ritter J, Yocum D, Hegedus R, Gilmer KE, Furst DE, Open, randomized study of rheumatoid arthritis patients switched from etanercept to infliximab compared with those who remained on etanercept: Changes in serum inflammatory, bone, and cartilage markers correlated with efficacy, Annals Rheum Dis 2006; 65: 464, s. 11
155. Petri M, Wallace DJ, Stohl W, McKay J, Stern S, Furie R, McCain A, Ginzler E, Chatham W, Hall L, Migone T, Pineda L, Freimuth W, Chevrier M, SLE patients with active production of antinuclear autoantibodies (ANA) have distinct patterns of lupus activity and peripheral B cell biomarkers compared to ANA negative patients, Annals Rheum Dis 2006; 65: 356, s.11
156. Wallace DJ, Lisse J, Stohl W, McKay J, Boling E, Merrill JT, Furie R, Petri M, Ginzler E, Chatham W, Fernandez V, Zhong J, Chevrier M, Freimuth W, Belimumab (BMAB), a fully human monoclonal antibody to B-lymphocyte stimulator (BlyS), shows bioactivity and reduces systemic lupus erythematosus disease activity, Annals Rheum Dis 2006; 65: 62-63, s.11
157. Burge DJ, Shu C, Martin RW, Littlejohn TW, Wallace DJ, Taborn J, Palmer WR, Kivitz A, TRU-015, a small modular immunopharmaceutical (SMIP-TM) drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis, Arthritis Rheum 2006; 53: S230
158. Ostergaard M, Wiell C, Sierakowski S, Wallace D, HuMax-CD20, a novel fully human monoclonal IgG1 antibody in the treatment of rheumatoid arthritis, Arthritis Rheum 2006; 53: S832
159. Urowitz MB, Gladman DD, Ibanez D, Fortin PR, Sanchez-Guererro J, Bae S, Clarke A, Cordon C, Hanly J, Isenberg D, Wallace D, Ginzler E, Merrill J, Alarcon G, Steinsson K, Petri M, Dooley M, Bruce I, Manzi S, Ramsey-Goldman R, Nived O, Sturfelt G, Maddison P, Khamashta M, Font J, Zoma A, Aranow C, van Vollenhoven R, Kalunian K, Stoll T, Systemic lupus international collaborating clinics (SLICC) inception cohort registry to study risk factors for atherosclerosis: Report on the first 582 patients, Arthritis Rheum 2006; 53: S281
160. Urowitz M, Gladman D, Fortin P, Ibanez D, Sanchez-Guerrero J, Bae SC, Clarke A, Gordon C, Hanly J, Isenberg D, Wallace D, Ginzler E, Merrill J, Alarcon G, Steinsson K, Petri M, Dooley MA, Bruce I, Manzi S, Ramsey-Goldman R, Nived O, Sturfelt G, Maddison P, Khamashta M, Font J, Zoma A, Aranow C, van Vollenhoven R, Kalunian K, Stoll T, Systemic lupus international collaborating clinics inception cohort registry to study risk factors for atherosclerosis: Metabolic syndrome, prevalence and associated features, Arthritis Rheum 2006; 53: S282
161. Petri M, Kasitanon N, Magder LS, Bae SC, Hanly JG, Isenberg D, Nived O, Sturfelt G, van Volenhoven R, Wallace DJ, Alarcon G, Adu J, Avila-Casado, Bernatsky S, Bruce I, Clarke A, Contreras G, Fine DM, Gladman D, Gordon C, Kalunian K, Madaio MP, Rovin BH, Sanchez-Guererro J, Steinsson K, Systemic lupus international collaborating clinics (SLICC) renal activity/response exercise (RARE): Comparison of agreement in renal response, Arthritis Rheum 2006; 53: S444
162. Petri M, Kasitanon N, Magder LS, Bae SC, Hanly JG, Isenberg D, Nived O, Sturfelt G, van Volenhoven R, Wallace DJ, Alarcon G, Adu J, Avila-Casado, Bernatsky S, Bruce I, Clarke A, Contreras G, Fine DM, Gladman D, Gordon C, Kalunian K, Madaio MP, Rovin BH, Sanchez-Guererro J, Steinsson K, Systemic lupus international collaborating clinics (SLICC) renal activity/response exercise (RARE): Developing a renal activity index and a renal response index, Arthritis Rheum 2006; 53: S444
163. Petri M, Hewitt A, Wallace DJ, Celecoxib does not increase hypercoagulability in serum nor decrease urinary 2,3-dinor-6-keto-PGF1 alpha in SLE, Arthritis Rheum 2006; 53: S446
164. . Urowitz M, Gladman D, Fortin P, Ibanez D, Sanchez-Guerrero J, Bae SC, Clarke A, Gordon C, Hanly J, Isenberg D, Wallace D, Ginzler E, Merrill J, Alarcon G, Steinsson K, Petri M, Dooley MA, Bruce I, Manzi S, Ramsey-Goldman R, Nived O, Sturfelt G, Maddison P, Khamashta M, Font J, Zoma A, Aranow C, van Vollenhoven R, Kalunian K, Stoll T, Systemic lupus international collaborating clinics (SLICC) inception cohort registry to study risk factors for atherosclerosis: accumulation of atherosclerotic risk factors over 3 years, Arthritis Rheum 2006; 53: S521
165. Brey RL, Naqubuddin M, Holliday, SL, Padilla PA, Fox PT, Narayana S, Franklin C, Samerdro M, Wallace DJ, Weisman MH, Petri M, Matrix metalloproteinase-9 level, brain imaging findings and cognitive dysfunction in an SLE inception cohort: Brain CONNECTIONS, Arthritis Rheum 2006; 53: S552
166. Driver CB, Forbess CJ, Pourrabbani S, Wallace DJ, Waxman AD, Liou D, Minoshima S, Weisman MH, Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus, Arthritis Rheum 2006; 53: S620
167. Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae S-C, Gordon C, Wallace DJ, Isenberg D, Alarcon G, Clarke A, Bernatsky S, Merrill JT, Petri M, Dooley MA, Gladman D, Fortin PR, Steinsson K, Bruce I, Manzi S, Khamashta M, Zoma A, Aranow C, Ginzler E, Van Volenhoven R, Font J, Sturfelt, Nived O, Ramsey-Goldman R, Kalunian K, Douglas J, Thompson K, Farewell V, Clinical significance of neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus, Arthritis Rheum 2006; 53: S274
168. Hanvivadhanakul P, Johnson B, Wu H, Grossman JM, Cantor RM, Hebert LA, Rovin BH, Birmingham DJ, Yung Yu c, Wallace DJ, Goodship THJ, Hahn BH, Feng X, Tsao BP, Association between 2 functional single polymorphisms (SNPs) in complement factor H (CFH) and SLE, Arthritis Rheum 2006; 53: S297
169. Wu H, Boackie S, Hanvivadhanakul P, Ulgiati D, Grossman J, Lee Y, Shen N, Abraham L, Mercer T, Park E, Herbert L, Rovin B, Birmingham D, Chang C, Chen C, Mc Curdy D, Badsha H, Thong B, Ching H, Arnett F, Wallace D, Yu CY, Hahn BH, Cantor R, Tsao B, Association of a common haplotype of complement receptor 2 (CR2) with increased risk of SLE, Arthritis Rheum 2006; 53: S291
170. Ishimori ML, Metzger AL, Wallace DJ, Morris RI, Sama J, Weisman MH, Screening for autoantibodies: the significance of ANA titer and its relationship to other antibodies, Arthritis Rheum 2006; 53: S441-442
171. Nazibuddin M, Carson KA, Sampedro MM, Wallace DJ, Weisman MH, Brey RL, Holliday SL, Narayana S, Fox PT, Franklin C, Padilla PA, Petri M, Brain imaging (MRI and FDG-PET) and cognitive function in newly diagnosed SLE, Arthritis Rheum 2006; 53: S623
172. Stohl W, Wallace DJ, Merrill JT, Chatham W, Gruhn W, Aranow C, Burnette M, Pogue B, Mc Cune W, Petrone D, Zhong J, Migone TS, Freimuth, Chevrier M, Changes in circulating B-cell counts, autoantibody levels and immunoglobulins that associate with therapeutic responsiveness in SLE to BLyS protein antagonism by belimumab, Arthritis Rheum 2006; 53: S780
173. Wallace DJ, Lisse J, Stohl W, McKay J, Boling E, Merrill JT, Furie R, Petri M, Ginzler E, Chatham W, Fernandez V, Zhong J, Chevrier M, Freimuth W, Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks, Arthritis Rheum 2006; 53: S790
174. Shoenwetter M, Aguilar D, Dubois RW, Hector R, Russak SM, Ress RM, Wallace DJ, Eisenberg D, Weisman MH, Content development for a new SLE quality of life questionnaire: Use of open and closed-ended patient inputs to identify important themes in daily functioning among SLE patients, Arthritis Rheum 2006:; 54: 404804049.
175. Shoenwetter M, Aguilar D, Dubois RW, Hector R, Russak SM, Ress RM, Wallace DJ, Eisenberg D, Robinson D Jr, Calimlim BM, Weisman MH, Content development for a new SLE quality of life questionnaire: Use of open and closed-ended patient inputs to identify important themes perceived to be most important among SLE patients, Arthritis Rheum 2006:; 54: 4100-4101 .
176. Dall’Era M, Chakravarty E, Genovese M, Wallace D, Kavanaugh A, Kalunian K, Dhar P, Pena-Rossi C, Wofsy D, Trial of atacicept in patients with systemic lupus erythematosus, Arthritis Rheum 2006; 54: 4042-4043.
177. Wallace DJ, Preventive strategies without using lupus medicine and newer concepts for older lupus medications, Lupus 2007; 16: 39 (supp)
178. Furie R, Wallace D, Lisse J, Stohl W, Merrill J, Petri M, Ginzler E, Aranow C, Weinstein A, Strand V, Fernandez V, Zhong J, Freimuth W, Novel combined response endpoint shows that belimumab (fully human monoclonal anatibody to B lymphocyte stimulator improves or stabilizes SLE disease activity in a Phase II trial, Lupus 2007; 16: 43-44 (supp)
179. Wu H, Grossman JM, Cantor RM, Herbert LA, Rovin BH, Birmingham DJ, Wallace DJ, Yu CY, Hahn BH, Tsao BP, Evidence for SLE susceptibility gene(s) at 1q23-24, Lupus 2007; 16: 63 (supp) Ishimori M, Schoenwetter M, Aguilar D, Dubois RW, Hector R, Nicassion P, Russak SM, Ress RM, 180. Wallace DJ, Eisenberg D, Robinson D Jr, Getsy JA, Weisman MH, Differences between patient and clinician perceptions of physical and psychosocial issues in systemic lupus erythematosus, Lupus 2007; 16: 107 (supp)
180. Hanly JG, Urowitz MB, Sanchez-Guererro J, Bae SC, Gordon C, Wallace DJ, Isenberg D, Alarcon G, Clarke A, Bernatsky S, Merrill JT, Petri M, Dooley MA, Gladman D, Fortin P, Steinsson E, Bruce I, Manzi S, Khamashta M, Zoma A, Aranow C, Ginzler E, Van Vollenhoven R, Font J, Sturfelt G, Nived O, Ramsay-Goldman R, Kalunian K, Douglas J, Thompson K, Farewell V, Clinical significance of neuropsychiatric (NP) events at the time of diagnosis of systemic lupus erythematosus (SLE), Lupus 2007; 16: 116-117 (supp)
181. Wu H, Yu Y, Hanvivadhanakul P, Johnson BB, Qian XX, Feng X, Grossman JM, Cantor RM, Hebert LA, Rovin BH, Birmingham DJ, Chen CJ, Badsha HM, Bernard YH, Ching HH, Wallace DJ, Hahn BH, Goodship THJ, Shen N, Tsao BP, Association between the Y402H polymorphism of complement factor H and lupus nephritis is identified and confirmed in Chinese families, Lupus 2007; 16: 153 (supp)
182. Wallace D, Levin R, Matheson R, Merrill R, White B, Early safety results of MEDI-545, an anti-interferon-alpha-monoclonal antibody, in patients with systemic lupus erythematous in the MI-CP126 trial, Lupus 1007 16: 233 (supp)
183. Ginzler E, Furie R, Wallace D, Strand V, Lisse J, Stohl W, Merrill J, Petri M, Aranow C, Weinstein A, Fernandez V, Zhong J, Freimuth W, Novel combined response endpoint shows that belimumab (fully human monoclonal antibody to B-lymphocyte stimulator (BLYS) improves or stabilizes SLE activity in a phase II trial, Ann Rheum Dis 2007; 62. 0P0018
184. Nestrorov I, Pena Rossi C, Manafo A, Papasouiltiotos O, Rogge M, Dall’Era M, Wofsy D, Chakravarty E, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Nasanov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, Wallace D, Pharmacokinetics and biololgical activity of atacicept after intravenous and subcutaneous administration to SLE patients, Ann Rheum Dis 2007; 0P0021
185. Wallace D, Gotto J, Bipolar illness with complaints of chronic musculoskeletal pain is a form of pseudofibromyalgia. J Musculoskeletal Pain 2007; 15: Supp: 59.
186. Burge D, Martin R, Wallace D, Littlejohn T, Bookbinder S, Bannink J, Shu C, Safety and pharmacodynamics of repeat administration of TRU-015, a CD20-directed SMIP therapeutic, in subjects with rheumatoid arthritis, Arthritis Rheum 2007; 56: S168-169.
187. Urowitz M, Gladman DD, Ibanez D, Fortin PR, Sanchez-Guerrero J, Bae S-C, Gordon CP, Clarke AE, Hanly JG, Wallace DJ, Isenberg DA, Merrill JT, Ginzler EM, Alarcon GS, Steinsson K, Petri MA, Khamashta MA, Bruce I, Dooley MA, Manzi S, Ramsey-Goldman R, Sturfelt GK, Nived O, Zoma AA, Maddison PJ, Font J, van Vollenhoven R, Aranow C, Kalunian KC, Stoll T, Wofsy D, Buyon JP, Disease outcomes in the first 4 years of SLE: Results from the SLICC inception cohort, Arthritis Rheum 2007; 56: S454-455
188. Urowitz M, Gladman DD, Ibanez D, Fortin PR, Sanchez-Guerrero J, Bae S-C, Gordon CP, Clarke AE, Hanly JG, Wallace DJ, Isenberg DA, Merrill JT, Ginzler EM, Alarcon GS, Steinsson K, Petri MA, Khamashta MA, Bruce I, Dooley MA, Manzi S, Ramsey-Goldman R, Sturfelt GK, Nived O, Zoma AA, Maddison PJ, Font J, van Vollenhoven R, Aranow C, Kalunian KC, Stoll T, Wofsy D, Buyon JP, Accumulation of atherosclerotic risk factors over 3 years by ethnicity in an International Inception Cohort, Arthritis Rheum 2007; 56:S455.
189. Merrill JR, Wallace DJ, Stohl W, Furie R, Ginzler E, Stern S, Lisse J, Lee E, Mc Cain A, Pineda L, Ronniger J, Freimuth W, Safety profile of belimumab (fully human monoclonal antibody to BlyS) in patients with systemic lupus erythematosus (SLE) treated during a placebo-controlled trial and in a long-term continuation study, Arthritis Rheum 2007; 56: S210
190. Mundwiler ML, Brown DL, Silverman JM, Furst DE, Khanna D, Leibling M, Louie JS, Wallace DJ, Weisman MH, What is the utility of the MRI in predicting radiographic erosions in the rheumatoid foot, Arthritis Rheum 2007; 56:S276-277
191. Petri M, Wallace DJ, Weisman M, Gladman D, Fortin P, Urowitz M, Werth V, Costner M, Gordon C, Alarcon GS, Ramsey-Goldman R, Maddison P, Clarke A, Manzi S, Bae S-C, Merrill JT, Ginzler E, Hanly J, Nived O, Sturfelt G, Sanchez-Guerrero J, Bruce I, Aranow C, Isenberg D, Zoma A, The association between reference laboratory values and the classification of SLE, Arthritis Rheum 2007; 56: S218.
192. Mc Mahon MA, Grossman J, Skaggs B, Li M, Fitzgerald J, Charles C, Ragavendra R, Wallace D, Weisman M, Chen W, Hahn BH, Accelerated atherosclerosis in women with SLE and pro-inflammatory HDL may in part be explained by reduced Apo3 activity, Arthritis Rheum 2007; 56: S216-217.
193. Ishimori ML, Schoenwetter M, Aguilar D, Dubois RW, Hector R, Niccasio P, Russak S, Ress RM, Wallace DJ, Eisenberg D, Robinson D Jr, Getsy JA, Patients and clinical perceptions of importance differ on physical and psychosocial issues in systemic lupus erythematosus (SLE), Arthritis Rheum 2007; 56: S457.
194. Posalski J, Ishimori ML, Wallace DJ, Weisman MH, Mycophenolate mofetil in SLE: Results from treatment of 75 patients in a community practice, Arthritis Rheum 2007; 56: 4290-4291.
195. Wallace DJ, Petri M, Olsen N, Kyriou K, Dennis G, Yao Y, Jallal B, Coyle A, Zeng L, White B, MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus, Arthritis Rheum 2007; 56: S526.
196. Petri M, Furie R, Ginzler E, Wallace DJ, Stohl W, Strand V, Weinstein A, Mc Kay J, Zhong J, Fernandez V, Freimuth W, Novel combined response endpoint and systemic lupus erythematosus (SLE) flare index (SFI) demonstrate belimumab (Fully human monoclonal antibody to BLyS) improves or stabilizes SLE disease activity and reduces flare rate over 2.5 years, Arthritis Rheum 2007; 56: S527.
197. Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC, Isenberg D, Dooley MA, Clarke AE, Bernatsky S, Gladman D, Fortin PR, Manzi S, Steinsson K, Bruce I, Ginzler E, Aranow C, Wallace DJ, Ramsey-Goldman R, Van Vollenhoven R, Sturfelt F, Nived O, Sanchez-Guererro J, Alarcon GS, Petri M, Khamashta M, Zoma A, Font J, Kalulnian K, Qi DQ, Merrill JT, Autoantibodies and neuropsychiatric events at diagnosis of systemic lupus erythematosus, Arthritis Rheum 2007; 56: S749.
198. Petri M, Narayana S, Naqibuddin M, Sampedro M, Brey RL, Holliday SL, Kochunov P, Franklin C, Wallace DJ, Weisman MH, Fox PT, White matter inflammation revealed by FDG-PET as a marker of SLE disease activity, Arthritis Rheum 2007; 56: S797.
199. Naqibuddin M, Sampedro M, Carson KA, Wallace DJ, Weisman MH, Brey RL, Holliday SL, Petri M, Cognitive function changes in newly diagnosed systemic lupus erythematosus, Arthritis Rheum 2007; 56: S823.
200. Urowitz M, Gladman DD, Ibanez D, Fortin PR, Sanchez-Guerrero J, Bae S-C, Gordon CP, Clarke AE, Hanly JG, Wallace DJ, Isenberg DA, Merrill JT, Ginzler EM, Alarcon GS, Steinsson K, Petri MA, Khamashta MA, Bruce I, Dooley MA, Manzi S, Ramsey-Goldman R, Sturfelt GK, Nived O, Zoma AA, Maddison PJ, Font J, van Vollenhoven R, Aranow C, Kalunian KC, Stoll T, Wofsy D, Buyon JP, Arteriosclerotic vascular events in a multinational inception cohort of SLE: Description and attribution, Arthritis Rheum 2007; 55: S454-455.
201.Burge D, Martin R, Wallace DJ, Bookbinder S, Kirsch T, Bass D, Littlejohn T, Repeated therapy with TRU-015 is well tolerated and results in consistent pharmacodynamic effects in rheumatoid arthritis patients, Annals Rheum Dis 2008; 67 supp 2; 128.
202. Merrill J, Lantis K, Wallace DJ, Shanahan J, Utset T, Neuwelt C, Wallace D, Gordon C, Oates J, Isenberg D, Zhang D, Brunetta P, Design and baseline characteristics of patients in a randomized double-blind, placebo-controlled Phase II/III study (Explorer) to evaluate the efficacy and safety of rituximab in patients with moderate to severely active systemic lupus erythematosus (SLE), Annals Rheum Dis 2008; 67 supp 2: 347
203. Petri M, Barry A, Kelley L, Strand V, Wallace DJ, Houssiau F, Hobbs K, Tak PP, Wegener W, Randomized controlled trials of epratuzumab (Anti CD22 MAB targeting B cells) reveal clinically meaningful reductions in corticosteroid (CS) use with favorable safety profile in moderate and severe flaring SLE patients, Annals Rheum Dis 2008; 67 supp 2; 53
204. Ginzler E, Wallace DJ, Freimuth W, Hough D, Dooley M, Martin D, Zhong J, Wolfe S, Mc Cune J, Merrill J, Furie R, Mc Kay J, Chatham W,Belimumab (fully human monoclonal antibody to BlyS) reduced steroid dose in systemic lupus erythematosus (SLE) patients during 3 years of therapy, Annals Rheum Dis 2008; 67 supp 2; 217
205. Merrill J, Wallace D, Mc Cain A, Lisse J, Lee E, Mc Kay J, Ginzler E, Pineda L, Wellborne F, Freimuth W, Ronniger J, Mishra N, Long-term safety profile of belimumab (fully human monoclonal antibody to BlyS) in patient with systemic lupus erythematosus (SLE), Annals Rheum Dis 2008; 217
206. Petri M, Furie R, Ginzler EM, Wallace DJ, Weisman MH, Stohl W, Mc Kay J, Strand V, Clarke A, Burnetter MC, Wellborne F, Dooley M, Mc Cune J, Latnis K, Zhong J, Penda L, Freimuth, Belumumab (fully human monoclonal antibody to BlyS) improved or stabilized systemic lupus erythematosus (SLE) disease activity over 2.5 years of therapy, Lupus 2008; 17: 453.
207. Ginzler EM, Chatham W, Stohl W, Wallace DJ, Merrill JT, Petri M, Furie R, Aranow C, Mc Cune J, Mc Cain A, Weinstein A, Diskin K, Zhong J, Pineda J, Freimuth W, Correlation of biomarker changes with clinical improvement over 2.5 years of belimumab (fully human monoclonal antibody to BlyS) therapy in systemic lupus erythematosus patients, Lupus 2008; 17: 457.
208. Wallace DJ, Merrill JT, Stohl W, Furie R, Ginzler EM, Petri M, Wolfe SM, Mc Kay J, Dooley M, Pineda L, Ronniger J, Freimuth W, Long term safety profile of belimumab (fully human monoclonal antibody to BlyS) in patients with systemic lupus erythematosus (SLE), Lupus 2008; 17: 483.
209. Wallace D, Hobbs K, Houssiau f, Strand V, Tak P, Wegener W, Kelley L, Barry A, Randomized controlled trials of epratuzumab (anti CD22 MAB targeting B cells) reveal clinically meaningful reductions in corticosteroid (CS) use with favorable safety profile in moderate and severe flaring SLE patients, Ann Rheum Dis 2008; 67 supp 2; 212.
210.Burge D, Martin RW, Bookbinder S, Littlejohn T, Wallace D, Kirsch T, Bass D, Shu C, TRU-015 adminsitered every 24 weeks for 2 years is well tolerated and maintains consistent pharmacodynamic effects in rheumatoid arthritis patients, Arthritis Rheum 2008; 58: S 374
211. Urowitz MB, Gladman DD, Ibanez D, Sanchez-Guererro J, Bae SC, Gordon C, Fortin PR, Clarke, Hanly JG, Wallace D, et al, Accumulation of atherosclerotic risk factors and lupus disease risk factors in the first 5 years of SLE: Results from the SLICC inception cohort, Arthritis Rheum 2008; 430
212. Urowitz MB, Gladman DD, Ibanez d, Sanchez-Guererro J, Bae SC, Gordon C, Fortin PR, Clarke A, Hanly JG, Wallace D, et al, Predictors of atherosclerotic vascular events (AVE) in a multnational inception cohort of SLE: a time to event analysis, Arthritis Rheum 2008; 58: S 431
213. Hanly JG, Urowitz MB, Su L, Sanchez-Guererro J, Bae SC, Gordon C, Wallace DJ, Short-term outcome of neuropsychiatric events in SLE patients upon enrollment into an international inception cohort study, Arthritis Rheum 2008; 58: S 460
214. Mc Mahon M, Grossman JM, Sahakian L, Skaggs BJ, FitzGerald DJ, Charles-Schoeman C, Ragavendra N, Wallace DJ, Weisman M, Witzum J, Hahn BH, PiHDL is a stronger predictor for atherosclerosis than other high-risk inflammatory lipids, and is associated with a 17-fold risk of subclinical atherosclerosis in SLE, Arthritis Rheum 2008; 58: S 571
215. Urowitz MB, Gladman DD, Ibanez D, Sanchez-Guererro J, Bae SC, Gordon C, Fortin PR, Clarke A, Hanly JG, Wallace D, et al, Arhterosclerotic vascular events in a multinational inception cohort of SLE: description and attribution over an 8 year period, Arthritis Rheum 2008; 58: S 664
216. Au K, Sahakian L, Skaggs B, Grossman J, Fitzgerald J, Wallace D, Hahn B, Lipid biomarkers may be associated with osteoporosis in systemic lupus erythematosus, Arthritis Rheum 2008; 58: S 665
217. Mc Kay J, Merrill JT, Wallace DJ, Furie R, Stohl W, Latinis K, Wellborne F, Wolfe Sm Angelly T, Chen A, Pineda L, Hough D, Long-term safety profile of belimumab (Fully human monoclonal antibody to BlyS) in patients with systemic lupus erythematosus (SLE), Arthritis Rheum 2008; 58: S 1064
218. Stohl W, Merrill JT, Looney RJ, Buyon J, Wallace DJ, Weisman M, Ginzler EM, et al, Phase Ia single- and phase Ib multiple-dose studies of AMG 623 (an anti-BAFF peptibody) in systemic lupus erythematosus, (SLE), Arthritis Rheum 2008; 58: S 1065
219. Utowitz M, Gladman DD, Ibanez D, Bae SC, Gordon C, Fortin PR, Clarke A, Hanly JG, Wallace D, et al, Changes in Quality of Life in the first 5 years of disese in a multicentre cohort of patients with systemic lupus erythematosus (SLE), Arthritis Rheum 2008; 58: S 1072
220. Petri M, Hobbs K, Gordon C, Strand V, Wallace DJ, Kelly L, Wegener W, Barry A, Clinical meaningful improvements with epratuzumab (Anti-CD22 mAB targeting B cells) in patients with moderate/severe SLE flares: Results from 2 randomized controlled trials, Arthritis Rheum 2008; 58: S 1084
221. Wallace DJ, Hobbs K, Houssiau F, Strand V, Tak PP, Wegner WA, Kelly L, Barry A, Epratuzumab (anti-CD22 mAB targeting B-cells) provides clnically meaningful reductions in corticosteroid (CS) use with a favorable safety profile in patients with moderate/severe flaring SLE: Results from randomized controlled trials (RCTs), Arthritis Rheum 2008; 58: S 1087
222. Chatham W, Furie R, Petri M, Ginzler EM, Wallace DJ, Stohl W, Strand V, Weinstein A, Zhong J, Hough D, Freimuth W, Belimumab (Fully human monoclonal antibody to BlyS) improved or stabilized systemic lupus erythematosus (SLE) disease activity over 3 years of therapy, Arthritis Rheum 2008; 58: S 1088
223. Petri M, Naqibuddin M, Wallace DJ, Weisman MH, Holliday SL, Sampedro MM, Carson K, Padilla P, Brey RL, Cognitive function over time in SLE: The Brain CONNECTIONS inception cohort, Arthritis Rheum 2008; 58: S 1094
224. Petri M, Sturfeldt G, Nived O, Wallace DJ, Weisman M, Gladman D, et al, The relationship of anti-C1q to the ACR Classification Criteria for SLE, Arthritis Rheum 2008; 58: S 1256
225. Jolly M, Pickard AS, Fogg L, Wilke CT, Lin HW, Mikolaitis RA, Sequeira W, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG, Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): Results from the randomized, double-blind phase II/III study EXPLORER, Arthritis Rheum 2008; 58:
226. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace D, Bae SC, Sigal L, Becker J-C, Kelly S, Raghupathi K, Peng Y, Kinaszczuk M, Nash P, The efficacy and safety of abatacept in SLE: Results of a 12 month-exploratory study, Arthritis Rheum 2008; 58:
227. Merrill JT, Furie R, Wallace DJ, Mc Kay J, Ginzler EM, Wellborne F, Aranow C, Burnette M, Mishra N, Pineda L, Zhong J, Hough D, Freimuth W, 4 year experience of belimumab, a fully human monoclonal antibody, in the treatment of systemic lupus erythematosus, Ann Rheum Dis 2009; 68: THU245
228. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ, Bae SC, Sigal LH, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszuk M, Nash P, Activity of abatacept in SLE: Results of a 12 month phas II exploratory study, Ann Rheum Dis 2009; 68: OP0009.
229. Merrill J, Shanahan J, Neuwelt C, Latinis K., Hsieh HJ, Isener D, Brunetta P, Gordon C, Wallace D, Zhang D, Oates J, Utset T, Rituximab in extra-renal SLE patients showed no significant difference compared to placebo at 52 weeks in the randomized, double-blind phase Phase II/III Explorer, Ann Rheum Dis 2009; 68: THU0230.
230.Merrill JT, Wallace DJ, Latinis KM, Utset TO, Furie R, Neuwelt CM, Looney RJ, Hsieh H, Wagner B, Brunetta P, Treatment of systemic lupus erythematosus (SLE) with rituximab: 78-week safety daa from the Phase II/III EXPLORER Trial, Arthritis Rheum 2009; 60: S103-104
231. Mc Mahon M, Sahakian LJ, Grossman JM, Skaggs BJ, FitzGerald JD, Charles-Schoeman C, Ragavendra N, Gorn AH, Karpouzis GA, Volkman ER, Weisman M, Wallace D, Hahn BH, PiHDL is associated with a 19-fold increased risk of progression of subclinical atherosclerosis in SLE, Arthritis Rheum 2009; 50: S108-109
232. Petri M, Furie R, Merrill J, Wallace DJ, Ginzler EM, Stohl W, Chatham W, Mc Cune J, Weinstein A, Pineda L, Zhong ZJ, Klein J, Hough D, Freimuth W, Four-year experience of belimumab, a BlyS specific inhibitor, in systemic lupus erythematosus (SLE), Arthritis Rheum 2009; S515-516
233. Vinet E, Clarke AE, Gordon C, Urowitz MB, Pineau CA, Isenberg DA, Rahman A, Wallace DJ, Alarcon GS, Bruce IN, Petri MA, Dooley MA, Aranow C, van Vollenhoven RF, Decreased live births in women with SLE, Arth Rheum 2009; 60: S584
234. Volkmann ER, Grossman JM, Sahakian LJ, Skaggs BJ, FitzGeraald JD, Ragavendra N, Charles-Schoeman C, Chen W, Gorn AH, Karpouzis GA, Weisman MA, Wallace DJ, Hahn BH, Mc Mahon MA, Low physical activity is associated with proinflammaory dhigh-density lipoprotein and increased subclinical atherosclerosis in wome with systemic lupus erythematosus, Arthritis Rheum 2009; S 590
235. Cervera J, Ishimori ML, Cooray D, Jolly M, Katsaros E, Moldovan I, Shinada S, Torralba KD, Wallace DJ, Block JA, Weisman MH, Nicassio P, Predictors of SF36 scores in a new lupus cohort in Southern California, Arthritis Rheum 2009; 60: S 721
236. Gordon C, Merrill JT, Wallace DJ, Hsieh H, Brunetta P, BILAG versus SELENA-SLEDAI scoring in systemic lupus erythematosus (SLE) patients in EXPLORER, Arthritis Rheum 2009; S774
237. Jolly M, Ishimori M, Moldovan I, Katsaros EP, Torralba KD, Cooray D, Shinada S, Block JA, Wallace DJ, Weisman MH, Nicassio P, What does patient-reported Systemic Lupus Activity Questionnaire (SLAQ) measure? Arthritis Rheum 2009; S775
238. Goykhman P, Thompson LEF, Yang Y, Shaw LJ, Berman DS, Gill E, Ishimori ML, Martin R, Wallace DJ, Schapira JM, Shufelt CL, Weisman MH, Bairey Merz CN, The utility of adenosine stress-rest cardiac magnetic resonance imaging in evaluating cardiac function and perfusion in women with systemic lupus erythematosus, J Am College Cardiology 2010; 55: A127E1190 (supp 1).
239. Furie RA, Merrill J, Wallace D, Ginzler E, Stohl W, Chatham W, Mc Cune J, Weinstein A, Petri M, Pineda L, Zhong ZJ, Klein J, Freimuth W, Four-year experience with belimumab, a BLyS specific inhibitor, in patients with systemic lupus erythematosus (SLE) LBS02/99 study, J Clin Rheumatol 2010; 16: S58-S59.
240. Furie RA, Gladman D, d’Cruz D, Zamani O, Wallace D, von Vollenhoven R, Tegzova D, Merrill JT, Schwarting A, Clarke AE, Doria AE, Sanchez-Guererro J, Chatham WW, Manzi S, Ginzler E, Mc Kay J, Stohl W, Zhong ZJ, Hough D, Cooper SM, Freimuth W, Petri M, Belimumab, a BLyS specific inhibitor, reduced disease activity and severe flares with seropositive SLE: BLISS-76 study, Lupus 2010 19S: 13.
241. Wallace DJ, Kalunian K, Petri M, Strand V, Kilgallen B, Barry A, Gordon A, Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): Results from the EMBLEM, a phase IIb study, Lupus 2010: 19S, 14.
242. Gordon C, Wallace DJ, Petri M, Houssiau F, Pike M, Kilgallen B, Barry A, Kalunian K, BILAG measured improvement in moderately and severey affected body systems in patients with systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIb study, Lupus 2010: 19S, 14.
243. Mc Bride J, Wallace DJ, Morimoto AY, Zhenling Y, Abbas A, Romeo M, Jiang J, Drappa J, Safety and pharmacodyamic response with administration of single and repeat doses of rontiluzmab in a phase I, placebo, controlled, double-blind, dose escalaion study in SLE, Lupus 2010; 19S:15.
244. Jolly M, Pickard AS, Mc Elhone K, The SL, Mikoliatis RA, Rodby R, Sequeira W, Utset TO, Nicassio P, Ishimori M, Wallace DJ, Weisman MH, Block JA, Disease specific patient reported outcome benchmarks for US lupus patients: Lupus PRO and Lupus QoL-US, Lupus 2010; 19S: 134.
245. Jolly M, Pickard AS, Mikolatis r, Wilke CF, Rodby R, Fogg R, Sequiera W, Utset TO, Cash TF, Moldovan Im Katasoros E, Nicassio P, Ishmori M, Wallace DJ, Block JA, The Lupus PRO: a disease specific patient reported outcome measure for systemic lupus erythematosus in the USA, Lupus 2010; 19S: 134.
246. Hanly JG, Urowitz MB, Jackson D, Bae SC, Gordon C, Wallace D, Clarke A, Bernatsky S, Basudevan A, Isenberg D, Rahman A, Sanchez-Guererro J, Romero-Diaz J, Alarcon GS, Merrill JT, Fortin P, Gladman D, Bruce I, Steinsson K, Khamashta M, Petri M, Sturfelt G, Nived O, Ramsey-Goldman Rm Dooley MA, Aranow C, van Vollenhoven R, Ramos-Casals M, Zoma A, Kalunian K, Farewell V, Change in SF-36 summary and sub-scale scores in SLE patients who have clinical improvemen and deterioration in neuropsychiatric (NP) events; Lupus 2010; 19S: 139.
247. Petri M, Wallace D, Furie R, Merrill JT, Ginzler E, Stohl W, Chatham WW, Mc Cune J, Weinstein A, Klein J, ZJ Zhong, Freimuth W, Five-year experience with belimumab, a BlyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE), Lupus 2010; 19S: 153.
248. Urowitz MB, Gladman DD, Ibanez D, Gordon C, Bae SC, Clarke A, Bernatsky S, Hanly J, Isenberg D, Rahman A, Sanchez-Guererro J, Fortin PR, Wallace D, Vasudevan A, Merrill J, Alarcon GS, Bruce IN, Sturfelt F, Nived O, Steinsson K, Khamashta MA, Petri M, Manzi S, Dooley MA, Ramsey-Goldman R, Aranow C, van Vollenhoven R, Ramos-Casals M, Stoll T, Kalunian K, Zoma A, Maddison P, ACR criteria at inception and accumulation over 5 years in SLE, Lupus 2010; 19S: 142-3.
249. Urowitz MB, Gladman DD, Ibanez D, Gordon C, Bae SC, Clarke A, Bernatsky S, Hanly J, Isenberg D, Rahman A, Sanchez-Guererro J, Fortin PR, Wallace D, Vasudevan A, Merrill J, Alarcon GS, Bruce IN, Sturfelt F, Nived O, Steinsson K, Khamashta MA, Petri M, Manzi S, Dooley MA, Ramsey-Goldman R, Aranow C, van Vollenhoven R, Ramos-Casals M, Stoll T, Kalunian K, Zoma A, Maddison P, Clinical-serologic discordance in a multicentre, international cohort of patients with SLE, Lupus 2010; 19S: 143.
250. Urowitz MB, Gladman DD, Ibanez D, Gordon C, Bae SC, Clarke A, Bernatsky S, Hanly J, Isenberg D, Rahman A, Sanchez-Guererro J, Fortin PR, Wallace D, Vasudevan A, Merrill J, Alarcon GS, Bruce IN, Sturfelt F, Nived O, Steinsson K, Khamashta MA, Petri M, Manzi S, Dooley MA, Ramsey-Goldman R, Aranow C, van Vollenhoven R, Ramos-Casals M, Stoll T, Kalunian K, Zoma A, Maddison P, Damage due to glucocorticoids in an SLE inception cohort, Lupus 2010; 19S: 144.
251. Urowitz MB, Gladman DD, Ibanez D, Gordon C, Bae SC, Clarke A, Bernatsky S, Hanly J, Isenberg D, Rahman A, Sanchez-Guererro J, Fortin PR, Wallace D, Vasudevan A, Merrill J, Alarcon GS, Bruce IN, Sturfelt F, Nived O, Steinsson K, Khamashta MA, Petri M, Manzi S, Dooley MA, Ramsey-Goldman R, Aranow C, van Vollenhoven R, Ramos-Casals M, Stoll T, Kalunian K, Zoma A, Maddison P, Bruce I, Prevalence and persistence of metabolic syndrome in a multicentre international inception cohort of patients with SLE, Lupus 2010; 19S, 144.
252. Chatham W, Weinstein A, Petri M, Merrill JT, Furie R, Wallace DJ, Ginzler EM, Stohl W, Mc Cune J, Pineda L, Zhong ZJ, Klein J, Hough D, Freimuth W, Five years of treatment with belimumab, a BlyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE): Long-term safety and efficacy analyses, Annals Rheum Dis (Supp 3) 2010; 69: 147-148.
253.Van Vollenhoven RF, Zamani O, Wallace D, Tegzova D, Merrill JT, Chatham WW, Schwarting A, Hiepe F, Doria A, Sanchez-Guererro J, Jeka S, Dyczek A, Furie R, Petri M, d’Cruz D, Fojtik Z, Pineda L, Zhong ZJ, Hough D, Freimuth W, Cervera R, Belimumab, a BlyS-specific inhibitor reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study, Annals Rheum Dis 2010; 69 (Supp 3), 74-75.
254. Kalunian K, Wallace D, Petri M, Houssiau F, Pike M, Kilgallen B, Barry A, Gordon C, BILAG-measured improvement in moderately and severely affected body systems with systemic lupus erythematosus (SLE) by epratuzumab: Results from EMBLEM, a Phase IIB study, Annals Rheum Dis 2010: 69 (Supp 3), 553.
255. Wallace D, Kalunian K, Petri M, Strand V, Kilgallen B, Barry A, Gordon C, Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): Results from EMBLEM, a Phase IIb study, Annals Rheum Dis 2010; 69 (Supp 3): 558
256. Ting MHX, Donn RP, Lunt M, Urowitz MB, Gladman DD, Ibanez D, Gordon C, Bae SC, Clarke A, Bernasky S, Hanly J, Isenberg D, Rahman A, Sanchez-Guererro J, Romero-Dia J, Fortin PR, Wallace D, Ginzler E, Vasudevan A, Merrill J, Alarcon GS, Fessler B, Sturfelt G, Nived O, Steinsson K, Khamashta M, Petri M, Manzi S, Dooley M, Ramsey-Goldman R, Aranow C, Van Volenhoven R, Ramos M, Stoll T, Kalunian, Zoma A, Maddison P, Bruce IN, Antimalarials may attenuate the risk of metabolic syndrome in SLE: Results from an International Inception Cohort Registry, Arthritis Rheum 2010, 62:S187
257. Urowitz MB, Gladman DD, Ibanez D, Gordon CP, Bae S-C, Clarke AE, Bernatsky SR, Sanchez-Gererro, Hanly JG, Isenberg DA, Rahman A, Fortin PR, Wallace DJ, Ginzler EM, Merrill JT, Alarcon GS, Fessler BJ, Bruce IN, Sturfelt GK, Nived O, Steinsson K, Khamashta MA, Petri MA, Ramsey-Goldman R, Manzi S, Dooley MA, Van Vollenhoven RV, Aranow CB, Stoll T, Ramos M, Kalunian KC, Zoma AA, Ruiz-Irastorza G, Maddison PJ, Kamen DL, Lim SS, Peschken CA, Atherosclerotic vascular events in a multinational inception cohort of SLE: Description and attribution over an 8 year period, Arthritis Rheum 2010; 62:S188
258. Van Volenhoven FR, Gallacher A, Navarra S, Ginzler EM, Dooley MA, Cervera R, Li EK, Levy RA, Guzman R, Zhong ZJ, Cooper S, Pineda L, Hough D, Wallace DJ, Belimumab, a BlyS-specific inhibitor, reduced corticosteroid use in patients with active SLE: Results from the Phase 3 BLISS-52 and -76 studies, Arthritis Rheum 2010; 62:S189
259. Kalunian KC, Wallace DJ, Petri MA, Houssiau FA, Pike MC, Kilgallen B, Kelley L, Gordon CA, BILAG-measured improvement in moderately and severely affected body systems in patients with systemic lupus erythematosus (SLE) by epratuzumab: Results from EMBLEM, a Phase III study, Arthritis Rheum 2010; 62:S190
260. Van Vollenhoven R, Jacobsen S, Wallace DJ, Hanly JG, Petri MA, Isenberg DA, Clarke AE, Simard JF, Pineau CA, Bernatsky SR, Biologics use in SLE in 7 centers---Data from the International Registry for Biologics in SLE (IBRIS), Arthritis Rheum 2010; 62:S191
261. Chatham WW, Wallace DJ, Stohl W, Latinis K, Manzi S, Mc Cune J, Tegzova D, McKay J, Avila-Armengol, Utset TO, Zhong ZJ, Hough D, Freimuth W, Migone TS, Effect of belimumab, a B-lymphocyte stimulator-specific inhibitor, on functional antibodies to pneumococcal, tetanus and influenza vaccines, Arthritis Rheum 2010; 62:S192
262. Mc Mahon MA, Grossman JM, Sahakian L, Skaggs B, FitzGerald JD, Charles-Schoeman C, Gorn AH, Weisman MH, Wallace DJ, Hahn BH, PiHDL and high plasma leptin levels are predictors of longitudinal progression of subclinical atherosclerosis in SLE, Arthritis Rheum 2010; 62: S197-198.
263. Urowitz MB, Gladman DD, Ibanez D, Bruce IN Gordon CP, Bae S-C, Clarke AE, Bernatsky SR, Sanchez-Guererro, Hanly JG, Isenberg DA, Rahman A, Fortin PR, Wallace DJ, Ginzler EM, Merrill JT, Alarcon GS, Fessler BJ, Bruce IN, Sturfelt GK, Nived O, Steinsson K, Khamashta MA, Petri MA, Ramsey-Goldman R, Manzi S, Dooley MA, Van Vollenhoven RV, Aranow CB, Stoll T, Ramos M, Kalunian KC, Zoma AA, Ruiz-Irastorza G, Maddison PJ, Kamen DL, Lim SS, Peschken CA, Prevalence and persistence of metabolic syndrome in a multicentre international inception cohort of patients with SLE, Arthritis Rheum 2010, S200.
264. Wallace DJ, Navarra S, Gallacher A, Guzman R, Thomas M, Furie RA, Zamani O, Levy RA, van Vollenhoven R, Cooper S, Zhong ZJ, Freimuth W, Pineda L, Cervera R, Safety profile of belimumab, a BlyS-specific inhibitor in patients with active systemic lupus erythematosus (SLE): Pooled data from phase 2 and 3 studies, Arthritis Rheum 2010; 62: S491.
265. Wallace DJ, Kalunian KC, Petri MA, Strand V, Kilgallen B, Kelley L, Gordon CP, Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): Results from EMBLEM, a Phase IIb study, Arthritis Rheum 2010; 62: S605.
266. Furie RA, Zamani O, Wallace DJ, Tegzova D, Petri M, Merrill JT, Chatham WW, Stohl W, Schwarting A, Cooper S, Zhong ZJ, Freimuth W, Hough DR, van Vollenhoven R, Belimumab, a BlyS-specific inhibitor, reduced disease activity and severe flares in seropositive SLE patients: BLISS-76 study results through week 76, Arthritis Rheum 2010; 62:S606.
267. Merrill JT, Wallace DJ, Furie RA, Petri MA, Stohl W, Chatham WW, Mc Cune J, Weinstein A, McKay J, Zhong ZJ, Pineda L, Klein J, Freimuth W, Ginzler EM, Five-year experience with belimumab, a BlyS-specific inhibitor, in patients with SLE, Arthritis Rheum 2010; 62: S608.
268. Urowitz MB, Gladman DD, Ibanez D, Bruce IN Gordon CP, Bae S-C, Clarke AE, Bernatsky SR, Sanchez-Guererro, Hanly JG, Isenberg DA, Rahman A, Fortin PR, Wallace DJ, Ginzler EM, Merrill JT, Alarcon GS, Fessler BJ, Bruce IN, Sturfelt GK, Nived O, Steinsson K, Khamashta MA, Petri MA, Ramsey-Goldman R, Manzi S, Dooley MA, Van Vollenhoven RV, Aranow CB, Stoll T, Ramos M, Kalunian KC, Zoma AA, Ruiz-Irastorza G, Maddison PJ, Kamen DL, Lim SS, Peschken CA, Arthritis Rheum 2010; 62: S941
269. Hanly JG, Urowitz MB, Su L, Gladman DD, Bae S-C, Gordon C, Clarke AE, Bernatsky SR, Sanchez-Guererro, Hanly JG, Isenberg DA, Rahman A, Fortin PR, Wallace DJ, Ginzler EM, Alarcon GS, Fessler BJ, Bruce IN, Sturfelt GK, Nived O, Steinsson K, Khamashta MA, Petri MA, Ramsey-Goldman R, Manzi S, Dooley MA, Van Vollenhoven RV, Aranow CB, Stoll T, Ramos M, Kalunian KC, Zoma AA, Ruiz-Irastorza G, Maddison PJ, Kamen DL, Lim SS, Peschken CA, Farewell, Thompson K, Theriault C, Merrill J, Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus, Arthritis Rheum 2010; 62: S943.
270. Urowitz MB, Gladman DD, Ibanez D, Gordon CP, Bae S-C, Clarke AE, Bernatsky SR, Sanchez-Gererro, Hanly JG, Isenberg DA, Rahman A, Fortin PR, Wallace DJ, Ginzler EM, Merrill JT, Alarcon GS, Fessler BJ, Bruce IN, Sturfelt GK, Nived O, Steinsson K, Khamashta MA, Petri MA, Ramsey-Goldman R, Manzi S, Dooley MA, Van Vollenhoven RV, Aranow CB, Stoll T, Ramos M, Kalunian KC, Zoma AA, Ruiz-Irastorza G, Maddison PJ, Kamen DL, Lim SS, Peschken CA, SLE and atherosclerotic risk factors by ethnicity and geographic distribution at inception in an international cohort of SLE, Arthritis Rheum 2010; 62: S784-785.
271. van Vollenhoven RF, Zamani O, Wallace D, Tegzova D, Petri M, Merrill JR, Chatham W, Stohl W, Schwarting A, Cooper S, Zhong ZJ, Freimuth W, Hough D, Furie R, Belimumab reduced disease activity in patients with SLE: BLISS-76, Lupus 2011; 20: 349,.
272. Gordon C, Petri M, Kalunian K, Strand V, Houssiau F, Pike M, Kilgallen B, Kelley L, Wallace DJ, Epratuzumab demonstrates clinically meaningful improvements in patients with moderate-to-severe systemic lupus erythematosus: Results from Emblem, Lupus 2011; 20: 301.
273. Furie R, Merrill JT, Wallace DJ, Stohl W, Chatham W, Mc Cune W, Weinstein A, Mc Kay J, Ginzler EM, Zhong ZJ, Pineda L, Klein J, Freimuth W, Petri M, Five-year experience with belimumab in SLE, Lupus 2011; 20: 425.
274. van vollenhoven R, Gallacher A, Navarra S, Ginzler EM, Dooley MA, Cervera R, Li EK, Levy RA, Guzman R, Zhong ZJ, Cooper S, Pindea L, Hough D, Wallace D, Belimumab reduced corticosteroid use in patients with SLE: Results from the phase 3 BLISS-52 and BLISS-76 studies, Lupus 2011; 20: 425.
275. Wallace DJ, Chatham W, Stohl W, Latinis K, Manzi S, Mc Cune WJ, Tegzova D, Mc Kay J, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough D, Freimuth W, Migone TS, Effect of belimumab on functional antibodies in pneumococcal, tetanus, and influenza vaccines, Lupus 2011; 20: 425-426.
276. Van Vollenhoven R, Schneider M, Wallace D, Gallacher A, Roth D, Ji B, Kleodis C, Freimuth W, Hough D, Efficacy of belimumab in patients with systemic lupus erythematosus: Focus on patients with low complement and positive anti ds DNA antibodies—Results from Bliss 52/Bliss76, Ann Rheum Dis 2011; 70 (S3): 124.
277.Petri M, Wallace D, Spindler A, Chindalore V, Wang L, Greth W, Sifalimumab, a fully human anti-inferferon-alpha monoclonal antibody, in subjects with systemic lupus erythematosus (SLE): Results of a Phase IB ramdonized, placebo-controlled, dose-escalation intravenous study, Ann Rheum Dis 2011; 70 (S3); 125.
278.Petri M, Furie R, Merrill J, Wallace D, Stohl W, Chatham W, Weinstein A, McKay J, Ginzler E, Zhong Z, Pineda L, Klein J, Freimuth W, Six-year experience with belimumab in patients with SLE; Ann Rheum Dis 2011; 70 (S3): 314
279.Urowitz M, Isenberg D, Wallace DJ, Prelude—Edratide Phase-II study outcome—from predefined analyses to more recent assessment approaches, Ann Rheum Dis 2011; 70 (S3); 315.
280.Wallace D, Navarra S, Houssiau F, Gallacher A, Guzman R, Thomas M, Furie R, Zamani O, Levy R, van vollenhoven R, Cooper S, Zhong z, Freimuth W, Hough D, Cervera R, Safety profile of belimumab in patients with active systemic lupus erythematosus: Pooled Phase 2/3 data, Ann Rheum Dis 2011; 70 (S3); 318
281.Van Vollenhovem R, Jacobsen S, Wallace D, Hanly J, Petri M, Isenberg D, Clarke A, Pineau C, Bernatsky S, Simard J, Simon M, Bae S-C, Ramos-Casals M, Diaz-Lagres C, Ruiz-Irastorza G, Martinez-Berriotxoa A, Garcia-Hernandez F, Gonzalez-Leon R, Castillo-Palma, de Ramon E, Saez L, Luis Callejas C, Rascon J, Inanc M, Artim-Esen B, Ramsay-Goldman R, Peschken C, Biologics use in SLE in 18 centers—Data from the International Registry for Biologics, Annals Rheum Dis 2011; 70 (S3):322.
282.Jolly M, Kosinski M, Garris CP, Jhingan PM, Mikolatis RA, Dennis G, Wallace DJ, Clarke A, Parke A, Dooley MA, Strand V, Alarcon GS, Validation of the lupus impact tracker: A tool for patients to assess and monitor the impact of SLE; Annals Rheum Dis 2011; 70 (S3): 322.
283.Jolly M, Kosinski M, Garris CP, Jhingan PM, Mikolatis RA, Dennis G, Wallace DJ, Clarke A, Parke A, Dooley MA, Strand V, Alarcon GS, Development of the lupus impact tracker: A tool for patients and physicians to assess and monitor the impact of SLE; Annals Rheum Dis 2011; 70 (S3): 501.
284. S Bernatsky, Ramsey-Goldman R, Foulkes W, Gordon C, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin P, Petri M, Yelin E, Wallace DJ, Edworthy S, Barr S, Jacobsen S, Bae S, Peschken C, Kalunian K, Istenberg D, Rahman A, Aranow C, Dooley M, Steinsson K, NIved O, Sturfelt G, Alarcon GS, Kamen D, Kanly J, Ensworth S, Pope J, Senecal J, Zummer M, Clarke AE, Breast, ovarian and endometrial malignancies in systemic lupus, Annals Rheum Dis 2011; 70 (S3): 506.
285. Orbai AM, Fang H, Merrill JR, Alarson GS, Gordon C, Fortin PR, Bruce IN, Isenberg DA, Wallace DJ, Nived O, Sturfelt GK, Ramsay-Goldman R, Bae S-C, J-G, Sanchez-Guererro J, Clarke AE, Aranow C, Manzi Sm Urowitz MB, Gladman DG, Kalunian KC, Costner MI, Magder LS,Anti beta-2 glycoprotein I IgA in systemic lupus erythematosus, Arthritis Rheum 2011; 63: S2
286. Orbai AM, , Fang H, Merrill JR, Alarson GS, Gordon C, Fortin PR, Bruce IN, Isenberg DA, Wallace DJ, Nived O, Sturfelt GK, Ramsay-Goldman R, Bae S-C, J-G, Sanchez-Guererro J, Clarke AE, Aranow C, Manzi Sm Urowitz MB, Gladman DG, Kalunian KC, Costner MI, Magder LS, Prevalence of direct Coombs test in systemic lupus erythematosus: Clinical and Immunologic associations, Arthritis Rheum 2011; S541
287. Munroe ME, Guthridge JM, Kamen DL, Norris JM, Moser KL, Niewold TB, Gilkeson GS, Karp DR, Weisman MH, Ishimori ML, Wallace DJ, Harley JB, James JA, Altered soluble mediators of inflammation at baseline in individuals who subsequently transition to systemic lupus erythematosus: Early studieds from the Lupus Autoimmunity in Relatives (LAUREL) study, Arthritis Rheum 2011; 63: S650
288. Carr FN, Nicassio PM, Cooray D, Moldovan I, Katsoros EP, Torralba KD, Shinada S, Jolly M, Ishimori ML, Wilson AL, Wallace DJ, Weisman MH, The role of pain and depression in self-reported fatigue, Arthritis Rheum 2011; 63: S938
289. Jolly M, Block JA, Mikolatis RA, Wallace D, Duran-Barragan S, Bertoli S, Toloza S, Blazevic I, Vila LM, Cooray D, Katsaros EP, Torralba K, Weisman MH, Alarcon GS, Spanish Lupus PRO; Cross cultural validation study for lupus, Arthritis Rheum 2011; 63: S725
290. Wallace DJ, Safety profile of belimumab, a B-lymphocyte stimulator-specific inhibitor, in Phase 2 and 3 clinical trials of patients with active systemic lupus erythematosus, Arthritis Rheum 2011; 63:S220
291. Mc Mahon M, Lorenco E, Grossman JM, Sahakian L, FitzGerald J, Ragvendra N, Charles-Schoeman C, Gorn AH, Weisman MH, Wallace D, Hahn BH, Skaggs B, Plasma tumor necrosis factor-like inducer of apoptosis (sTWEAK) levels are associated with carotid plaque progression in women with SLE, Arthritis Rheum 2011; 63: S310
292. van Vollenhoven R, Jacobsen S, Wallace D, Hanly JG, Petri M, Isenberg DA, Clarke AE, Pineau CA, Bernatsky S. Simard JF, Bae S-C, Ramos-Casals M, Diaz-Ligares C, Ruiz-Irastorza G, Martinez-Berriotxoa A, Garcia-Hernandez FJ, Gonzalez-Leon R, Castillo-Palma MJ, Saez L, Callejas JL, Rascon J, de Ramon E, Ayala-Guttierez M, Camps M, Mild M, Inanc M, Artim-Esen B, Ramsay-Goldman R, Peschken Ca, Suartrito D, Emmi L, Kovacs L, Doria D, Skekanec Z, Ferraccioli G, Gremese E, Sato EI, Biologics use in 23 centers—Data from the International Registry for Biologics in SLE (IRBIS), Arthritis Rheum 2011; 63: S235
293. Hanly JG, Urowitz MB, Su L, Gordon C, Bae S-C, Sanchez-Guererro J, Romero-Diz J, Wallace D, Clarke AE, Bernatsky S, Ginzler EM, Merrill JR, Isenberg DA, Rahman A, Gladman DD, Petri M, Fortin PR, Bruce IN, Steinisson K, Dooley MA, Khamashta MA, Alarcon GS, Fessler NJ, Ramsey-Goldman R, Manzi S, Zoma AA, Sturfelt GK, Aranow C, Ramos M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim SS, Kamen DL, Peschken CA, Inanc M, Predictors of seizures in systemic lupus erythematosus, Arthritis Rheum 2011; 63: 226
294. Hanly JG, Urowitz MB, Su L, Gordon C, Bae S-C, Sanchez-Guererro J, Romero-Diz J, Wallace D, Clarke AE, Bernatsky S, Ginzler EM, Merrill JR, Isenberg DA, Rahman A, Gladman DD, Petri M, Fortin PR, Bruce IN, Steinisson K, Dooley MA, Khamashta MA, Alarcon GS, Fessler NJ, Ramsey-Goldman R, Manzi S, Zoma AA, Sturfelt GK, Aranow C, Ramos M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim SS, Kamen DL, Peschken CA, Inanc M, A prospective study of seizures in systemic lupus erythematosus, Arthritis Rheum 2011; 63L S226-S227
295. Merrill JT, Furie RA, Wallace DJ, Stohl W, Chatham WW, Weinstein A, Mc Kay J, GInzler DM, Zhong ZJ, Pineda L, Klein J, Freimuth W, Petri M, Sustained disease improvement and safety profile over the 1500 patient-year experience (6 years) with belimumab in patients with systemic lupus erythematosus, Arthritis Rheum 2011; 63: S222-S223
296. Wallace D, Strand V, Furie R, Petri M, Kalunian K, Pike M, Kelley L, Gordon C, Evaluation of treatment success in systemic lupus erythematosus clinical trials: Development of the BILAG based composite lupus assessment endpoint, Arthritis Rheum 2011; 63: S885-886
297. Petri M, Orbai A-M, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg DA, Wallace DJ, Nived O, Sturfelt GK, Ramsey-Goldman R, Bae Sang-Choi, Janly JG, Sanchez-Gurerrero, Clarke AE, Aranow C, Manzi S, Urowitz MB, Magder L, Derivation and validation of the SLICC classification for systemic lupus erythematosus, Arthritis Rheum 2011; 63: S669
298. Orbai AM, Sturfelt GK, Nived O, Fang H, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg DA, Wallace DJ, Ramsey-Goldman R, Bae S-C, Hanly JG, Sanchez-Guerrero J, Clarke AE, Aranow C, Manzi S, Urowitz MB, Petri M, Anti –C1q antibody in systemic lupus erythematosus, Arthritis Rheum 2011; S538
299. Doria A, Sanchez-Guerrero J, Tegzova D, Ginzler EM, Zhong ZJ, Dennis G, Wallace DJ, Early clinical improvement in SLE patients treated with belimumab,Annals Rheum Dis 2012; 71 (S3), 535.
300. Zimmer R, Wallace DJ, Muller S, Randomized, double-blind, placebo-controlled studies of P140 peptide in mannitol (Lupozor) and trehalose (Forigerimod) in patients with SLE, Arthritis Rheum 2012; 64: S1110
301. Hobbs K, Wallace DJ, Strand V, Kalunian K, Kilgallen B, Bongardt S, Wegener WA, Goldenberg DM, Safety and efficacy of epratuzumab in open-label extension study (SL006), Arthritis Rheum 2012; 64: S276-277
302. Strand V, Hobbs K, Wallace DJ, Kalunian K, Kilgallen B, Nikal E, Wegener WA, Goldenberg DM, Epratuzumab-treated systemic lupus erythematosus patients report improvements in health-related quality of life: Final results from an open-label extension study (SL006), Arthritis Rheum 2012; 64: S953-954
303. Merrill JT, Furie RA, Wallace DJ, Stohl W, Chatham WW, Weinstein A, McKay JD, Ginzler EM, Zhong W, Freimuth WW, Petri MA, Sustained disease improvement and safety profile over 1745 patient-year (7 years) with belimumab in systemic lupus erythematosus patients, Arthritis Rheum 2012; 64: S1110-S1111
304. Shum KM, Askanase A, Buyon JP, Belmont HM, Franks AG, Furie R, Kamen DL, Manzi S, Petri M, Ramsey-Goldman R, Tseng CE, van Vollenhoven RF, Wallace D, Favorable response to belimumab at 3 months, Arthritis Rheum 2012; 64: S610
305. Mc Mahon M, Grossman JM, Skaggs B, Lourenco E, Lee C, Sahakian L, FitzGerald J, Charles-Schoeman C, Gorn AH, Karpouzas G, Weisman MH, Wallace DJ, Chen W, Hahn BH, Inflammatory biomarkers of atherosclerosis and oxidative stress are associated with disease flare in SLE, Arthritis Rheum 2012; 64: S272-273
306. Churchill M, Flores-Suarez LF, Wallace D, Phillips K, Martin RW, Cardiel M, Kane J, Bautista E, Salinger DH, Stevens E, Russell CB, Martin D, A Phase Ib multiple, ascending dose study evaluating safety, pharmacokinetics, and early clinical response to brolalumab, a human anti interleukin-17 receptor antibody in rheumatoid arthritis, Arthritis Rheum 2012; 64: S555
307. Bernatsky S, A E. Clarke, K Costenbader, M B. Urowitz, D. Gladman, P R. Fortin, M Petri, S Manzi, D.A. Isenberg, A Rahman, D Wallace, C Gordon, C Peschke, MA Dooley, E.M. Ginzler, C Aranow, S M. Edworthy, O Nived, S Jacobsen, G Ruiz-Irastorza, E Yelin, S G. Barr, I Blanco, C H. Feldman, R. Ramsey-Goldman Lymphoma risk in systemic lupus: Effects of disease activity versus treatment, Arthritis Rheum 2012; 64: S1087
308. Munroe ME, J M. Norris, J M. Guthridge, DL. Kamen, K Moser Sivils, T B. Niewold, G S. Gilkeson5, M H. Weisman, M L. Ishimori, D J. Wallace, D R. Karp, J B. Harley, J A. James, Altlered soluble mediators in individuals with incomplete lupus in the Lupus Autoimmunity in Relatives (LAUREL) study, Arhtirits Rheum 2012; 64: S290
309. M Jolly, M Kosinski, S Toloza J Block, R Mikolaitis, S Durán-Barragan, A M. Bertoli, I Blazevic, L M. Vila, D Cooray, E P. Katsaros, K. Torralba, I Moldovan, AKay, BGoker, S Haznedaroglu, ME. Tezcan, JBourré-Tessier, S Bernatsky, A E. Clarke, M H. Weisman, S V. Navarra, D J. Wallace16 Graciela S. Alarcon,; Equivalence of various language versions of lupus specific patient reported outcomes measure (Lupus PRO), Arthritis Rheum 2012; 64: S607-608
310. Clarke AE, Bernatsky S, Costenbader KH, Urowitz MB, Gladman DD, Fortin PR, Petri M, Manzi S, Isenberg DA, Rahman A, Wallace D, Gordon C, Peschken C, Dooley MA, Ginzler EM, Aranow C, Edowrthy SM, Nived O, Jacobsen S, Ruiz-Irastorza, Yelin E, Barr SG, Criswell, Sturfelt G, Dreyer L, Blanco I, Gottesman L, Feldman CH, Ramsey-Goldman R, Lymphoma risk in systemic lupus: effects of treatment versus disease activity, Arthritis Research & Therapy 2012: 14: S3, A16.
311. Ishimori M, Gal NJ, Rogatko A, Berman DS, Wilson A, Wallace DJ, Merz NB, Weisman MH, Prevalence of angina in patients with systemic lupus erythematosus, Arthritis Research & Therapy, 2012; 14: (S3); A62.
312. M Lu, Ramsey-Goldman R, Bernatsky S, Petri M, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler E, Yelin E, Bae S-C, Wallace DJ, Jacobsen S, Dooley MA, Peschken CA, Alarcon GS, Nived O, Gottesman L, Criswell L, Sturfelt G, Dreyer L, Lee JL, Clarke AE, Nonlymphoma hematological malignancies in systemic lupus erythematosus, Arthritis Research & Therapy 2012; 14: S3, A64.
313. Reddy A, Buyon JP, Franks AG, Furie R, Kamen DL, Manzi S, Petri M, Ramsey-Goldman R, Tseng CE, van Vollenhoven FR, Wallace DJ, Askanase A, Favorable clinical response to belimumab at three months, Ann Rheum Dis 2013; 72: THU0271.
314. van Volenhoven R, Mild M, Jacobsen S, Wallace DJ, Hanly JG, Petri MA, Bernatsky SR, Bae SC, Ramos-Casals M, Garcia-Hernandez F, Ayala-Guiterrez MDM, Ramsey-Goldman R, Doria A, Mosca M, Two year follow up on biologics use in 13 centers: Data from the Intenrational Registry for Biologics in SLE (IRBIS), Ann Rheum Dis 2013; 72:THU0283.
315. Strand V, Leszczynski P, Keiserman M, Kilgallen B, Bongardt S, Wallace DJ, Gordon C, Immunologic response to long-term epratuzumab treatment in SL0008, an open-label long-term extension study in patients with moderate-to-severe systemic lupus erythematosus, Annals Rheum Dis 2013; 72: THU0286.
316. Gordon C, Clowse M, Houssiau F, Petri M, Kilgallen B, Kalunian K, Strand V, Bongardt S, Wallace DJ, Epratuzumab maintains improvements in disease activity for over two years in patients with moderate-to-severe systemic lupus erytheamtosus: Results from an open-label, long-term extensions study (SL0008), Annals Rheum Dis 2013; 72: THU0272.
317. Wallace DJ, Ordi-Ros J, Neuwelt M, Kalunian K, Kilgallen B, Bongardt S, Petri M, Pike M, Jeka S, Gordon C, Strand V, Epratuzumab: Susteained safety profile and effect on corticosteroid use on long-term treatment in pateitns with moderate-to-severe systemic lupus erythematosus: Results from an open-label, long-term extensions study (SL0008), Annals Rheum Dis 2013; 72: THU0277.
318. Goldenberg DM, Rossi EA, Michel R, Wallace DJ, Chang CH, Epratuzumab mediates BCR-antigen trogocytosis as potential mechanism of action in systemic lupus erythematosus (SLE), Annals Rheum Dis 2103; 72: OP0118.
319. Wallace DJ, Gillis BS, Gavin I, Karpenko O, A cytokine/chemokine multiplex assay that is sensitive and specific for fibromyalgia compared to controls, systemic lupus erythematosus and rheumatoid arthritis, Arthritis Rheum 2013; 65: abst 842
320. Jolly M, Aouhab Z, Toloza S, Bertoli A, Blazevik I, Vila L, Modovan I, Torralba KM, Kaya A, Goker B, Tezcan M, Haznedaroglu S, Bourre-Tessier J, Clarke AE, Wallace DJ, Weisman MH, Alarcon GS, Disease specific quality of life domains are impaired in patients with lupus nephritis, Arthritis Rheum 2013; 65: abst 610.
321. Clowse ME, Houssiau F, Petri M, Kilgallen B, Strand V, Bongardt S, Gordon C, Wallace DJ, Kalunian K, Epratuzumab maintains improvements in disease activity for over 2 years in patients with moderate-to-severe systemic lupus: Results from an open-label long-term extension study, Arthritis Rheum 2013; 65: abst 1738
322. Kalunian K, Clowse ME, Houssiau F, Petri M, Kigallen B, Gordon C, Strand V, Bongardt S, Wallace DJ, Stustained British Isles Assessment Group-measured improvement in moderate-to-severly affected body symptoms by epratuzumab: Results from an open-label extension study, Arthritis Rheum 2013; 65: abst 1739.
323. Askanase A, Reddy A, Buyon J, Franks A, Furie R, Kamen DL, Manzi S, Petri M, Ramsey-Goldman R, Tseng C-E, van Vollenhoven RF, Wallace DJ, Favorable clinical response to belimumab at three months, Arthritis Rheum 2013; 65: abst 1574.
324. Han K, Nagar S, Patel J, Oh A, Walalce DJ, Molta CT, Continuous variables of treatment interventions in patients diagnosed with systemic lupus erythematosus among commercially and Medicaid insured populations in the US, Arthritis Rheum 2013; 65: abst 1587.
325. Wallace DJ, Ordi-Ros J, Neuwelt CM, Kalunian K, Petri M, Slawomir J, van Vollenhoven R, Kigallen B, Bongardt S, Gordon C, Strand V, Overview of the safety of epratuzumab in systemic lupus erythematosus, Arthritis Rheum 2013; 65: abst 1606.
326. Munroe ME, Young KA, Norris JM, Guthridge JM, Kamen DL, Hiewold TB, Gilkeson GS, Weisman MH, Ishimori ML, Wallace DJ, Karp DR, Harley JB, James JA, Gender, race, and soluble mediatros distinguish blood relatives who develop incomplete lupus or classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) study, Arthritis Rheum 2013: 65: 1767.
327. Hanly JG, Urowitz MB, O’Keefe A, Gordon C, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Clarke AE, Bernatsky S, Wallace DJ, et al, “Lupus Headache”: Results from a prospective, international cohort study, Arthritis Rheum 2013: 65: 1592.
328. van Vollenhoven RF, Petri M, Wallace DJ, Roth D, Molta CT, Hammer H, Tang T, Thompson A, Corticosteroid use across 52 weeks of belimumab therapy in patients with systemic lupus erythematosus: Combined analysis from the BLISS trials, Arthritis Rheum 2013; 65: abst 1585.
329. van Vollenhoven RF, Mild M, Jacobsen S, Bernatsky S, Wallace DJ, Bae SC, Ramos-Casals M, Garcia-Hernandez FJ, Ramsey-Goldman R, Doria A, Mosca M, Petri MA, Ayala-Gutierrez M, Hanly JG, Two year follow-up on biologics use in 13 centers: Data from the international registry for biologics in systemic lupus erythematosus, Arthritis Rheum 2013; 65: abst 1607.